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ABSTRACT
In clinical trials of antibacterial drugs for treatment of acute exacerbation of chronic 
bronchitis (AECB), a high proportion of patients who have bacterial infection is 
essential. In 83 randomised clinical trials of antibacterial drugs in AECB or acute 
exacerbation of chronic obstructive pulmonary disease (AECOPD), published between 
1977 and 2007, the percentage of patients who were bacteriologically-positive ranged 
from 13.9% to 96.0%. There was no evidence that any particular combination of signs 
and symptoms was associated with a bacterial exacerbation. A study of patients with 
signs and symptoms of AECB was undertaken to identify entry criteria that would 
optimise the number of enrolled patients with bacteriologically-proven (culture-positive) 
exacerbations. This failed to demonstrate that patients with Type I exacerbations 
(increased sputum purulence, sputum volume, and dyspnoea) had a higher proportion of 
culture-positive sputum samples than patients with Type II exacerbations (two of these 
three symptoms). Fisher’s exact test produced a borderline result suggesting that 
patients with Type II exacerbations possibly had a higher chance of culture-positive 
sputum samples. From a range of demographic, symptomatic and laboratory 
investigations, the only factor which emerged as highly significant in distinguishing 
culture-positive from culture-negative patients was the semi-quantitative Gram stain 
analysis. Although this technique may offer a useful method of predicting bacterial 
infection in around 90% of patients, it may not be practical for all clinical trial settings. 
Nevertheless, identification of bacterial infection in patients with AECB or AECOPD 
remains an important target for the most cost-effective and scientifically robust clinical 
trials.
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1 ABBREVIATIONS
Abbreviation Definition
ai-AT Alpha 1-antitrypsin
ABECB Acute bacterial exacerbation of chronic bronchitis
AECB Acute exacerbation of chronic bronchitis
AECOPD Acute exacerbation of chronic obstructive pulmonary disease
ATS American Thoracic Society
CB Chronic bronchitis
CE Clinically-evaluable (population)
CF Cystic fibrosis
cfu Colony-forming units
CL Containment level (of laboratories)
COPD Chronic obstructive pulmonary disease
CRF Case report form
CRP C-reactive protein
EOT End of Therapy (visit)
FEVj Forced expiratory volume in 1 second
FVC Forced vital capacity
GP General practitioner
ICH-GCP International Conference on Harmonisation, Good Clinical Practice
IL-lp Interleukin-lp
IL-6 Interleukin-6
IL-8 Interleukin-8
ITT Intention-to-Treat (population)
LE Leucocyte esterase
LRT Lower respiratory tract
mL Millilitre
NE Neutrophil elastase
NPV Negative predictive value
PMN Polymorphonuclear neutrophils (or leucocytes)
PP Per protocol (population)
PPV Positive predictive value
SAA Serum amyloid A
SEC Squamous epithelial cell(s)
TOC Test of Cure (visit)
TNF-a Tumour necrosis factor-a
WBC White blood cell(s)
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2 INTRODUCTION
2.1 History of Chronic Bronchitis
In the British Isles, the diagnosis of bronchitis, and particularly of chronic bronchitis, 
has been a frequent one ever since the term was introduced into the medical literature in 
1808 by Dr Charles Badham [Badham, 1808]. From the early 1900s, doctors had 
considered that purulent exacerbations of chronic bronchitis might be caused by 
infection and in 1938, Mulder noted that it was often possible to isolate Haemophilus 
influenzae from the sputum of patients with ‘common acute and chronical purulent 
bronchitis’ [Mulder, 1938]. In fact, several bacterial species had been isolated from the 
sputum of patients with chronic bronchitis [Marshall, 1931; Southwell, 1946], however,
tVibecause of the lack of effective therapy in the first half of the 20 century, there was a 
feeling of futility and little motivation for specific research into the disorder [Stuart- 
Harris et al, 1953; McVay & Sprunt, 1953]. In 1950, a survey was made of the 
registered disabled persons in four areas of Great Britain; in all four areas chronic 
respiratory disease was an important cause of disability, and was the leading cause of 
disability in the north-west area and accounted for more unemployment than any other 
physical condition [Goodman et al, 1953]. The widespread introduction of antibiotics in 
the 1950s revived medical interest in chronic bronchitis, stimulated also by an increased 
incidence of the disease, a growing recognition of the economic impact, and a stable or 
declining frequency of other infections such as tuberculosis.
In 1953, May reported a significant association between the exacerbation of chronic 
bronchitis and the presence of bacteria in the sputum, especially of H  influenzae and 
Streptococcus pneumoniae [May, 1953]. In the same year Elmes published the results 
of a study of four antibiotics (penicillin, chloramphenicol, sulphadimidine and 
aureomycin) with potential to be used as prophylaxis during the winter months [Elmes 
et al, 1955]. The results showed no long term benefit for any of the four antibiotics 
used; they displayed too narrow a spectrum of activity for the range of pathogens 
observed, produced resistance in one or more species, or displayed little effect on the 
bacterial flora. A few years later a set of two studies over two winters, appeared to
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show a benefit of continuous antibiotic therapy during the winter months in the number 
and severity of exacerbations, however almost one-third of patients reported diarrhoea 
[Murdoch et al, 1959].
In the early 1950s, the link between cigarette smoking and chronic bronchitis had not 
been established. However, the observation that the mortality rates due to chronic 
bronchitis were three to four times higher in men than women of the same age prompted 
several possible explanations, one of which was the hypothesis that smoking may (at 
least partly) account for the higher mortality rates in men [Goodman et al, 1953]. Other 
explanations of this difference between the sexes offered by Goodman were: hormonal 
or other constitutional differences; the fact that far more men work outdoors in all 
weathers than women; the financial pressure on men to return to work as soon as 
possible following acute respiratory illness; the more physically demanding work that 
men tend to perform, requiring deeper breathing which might induce excessive 
stretching of the lung tissue that has not recovered after a recent infection. Interestingly, 
Goodman speculated that this sex difference might narrow over the coming 20 years due 
to the reduction in men’s physical workload (due to increasing mechanisation), and 
changes in the smoking habits of the sexes (more women smoking); this phenomenon 
has indeed been observed over the last few decades [Mannino et al, 2002].
2.2 Terminology
Bronchitis is a respiratory disease in which the mucous membrane in the bronchial 
passages of the lungs becomes inflamed. The irritated membrane swells due to 
inflammatory infiltrates and in doing so, it narrows or shuts off the bronchioles in the 
lungs, resulting in coughing spells and breathlessness because of the obstruction and 
consequent hypoxia. The cough is normally productive of thick phlegm which may be 
coloured yellow or green. Bronchitis comes in two forms: acute (lasting less than 6 
weeks) and chronic (a long-term disease in which there are underlying physiological 
changes and sudden worsenings occur regularly).
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Acute bronchitis is generally viral in origin, and is often preceded by an upper 
respiratory tract infection. In otherwise healthy children and adults, acute bronchitis, 
will normally resolve in 2-3 weeks without the need for an antibiotic. In elderly patients 
and people with concomitant diseases, a secondary bacterial infection may occur, which 
requires the addition of an antibiotic.
In chronic bronchitis (CB), there is a constant low level inflammation and swelling of 
the mucosal membranes that line of the airways. The inflammation stimulates 
production of mucus causing chronic mucus hypersecretion, which can cause further 
obstruction of the airways. Periodically, the level of inflammation increases because of 
viral or bacterial infection, or reaction to airborne pollution or an allergen; this results in 
a worsening of the condition, termed an acute exacerbation. Sufferers of chronic 
bronchitis tend to cough up significant quantities of sputum unlike those who do not 
suffer from chronic bronchitis. Sputum is a complex mixture of respiratory tract mucus, 
debris, inflammatory cells and exfoliated epithelial cells from upper and lower 
respiratory tracts.
Chronic bronchitis is defined as a chronic or recurrent productive cough, present on 
most days for a minimum of three months in the year and for not less than two 
successive years, in a patient in whom other causes of chronic cough have been 
excluded [Am Thome Soc, 1962]. It is a serious long-term disorder that requires regular 
medical treatment. CB is generally caused by a long-term, irritative assault to the lungs. 
The most common assault is that from cigarette smoke. In addition to its irritant 
properties, cigarette smoke causes temporary paralysis of the cilia lining the airways 
which sweep out debris, irritants and excess mucus. Over time, these cilia are damaged 
to the extent that they cannot function properly, leaving the lungs clogged with mucus. 
Obstruction of the airways, especially with mucus, increases the likelihood of bacterial 
lung infections (acute bacterial exacerbations). Although cigarette smoking is the main 
cause of chronic bronchitis, long-term exposure to other noxious chemicals or pollutants 
can also cause chronic bronchitis. Consequently, the vast majority of sufferers are over 
35 years of age [Ekberg-Aronsson et al, 2008]. The severity of the disease tends to 
increase with age, although stopping smoking and/or removing other irritants can reduce
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the progress of this disease significantly. However, recurrent exacerbations (bacterial or 
non-bacterial in nature) will tend to lead to a deterioration in lung function [Donaldson 
et al, 2002; Chodosh, 2005].
Chronic bronchitis is one form of the complex disease of COPD. It is useful to 
understand the relationship between chronic bronchitis and COPD as the terms may 
sometimes appear to be interchangeable. COPD is comprised primarily of two related 
diseases -  chronic bronchitis and emphysema. In both diseases, there is chronic 
obstruction of the flow of air through the airways and out of the lungs, and the 
obstruction generally is permanent and progressive over time. Asthma also is a 
pulmonary disease in which there is obstruction to the flow of air out of the lungs, but 
unlike chronic bronchitis and emphysema, the obstruction in asthma predominantly is 
reversible. Between ‘attacks’ of asthma the flow of air through the airways is generally 
good. In some patients with COPD the obstruction can be partially reversed by 
medications that enlarge or dilate the airways (bronchodilators) as with asthma. 
Conversely, some patients with asthma can develop permanent airway obstruction if 
chronic inflammation of the airways leads to scarring and narrowing of the airways.
This process is referred to as lung remodelling. These asthma patients with a fixed 
component of airway obstruction are also considered to have COPD. There is also 
frequent overlap among COPD patients: patients with emphysema may have some of 
the characteristics of chronic bronchitis; similarly, patients with chronic bronchitis also 
may have some of the characteristics of emphysema.
In its guidelines for the management of COPD, the British Thoracic Society stated that 
“COPD is a chronic, slowly progressive disorder characterised by airways obstruction 
(FEVi <80% predicted and FEVi/VC ratio <70%) which does not change markedly over 
several months” [BTS, 1997]. In this definition FEVi is the forced expiratory volume in 
1 second, and VC is the vital capacity (also called forced vital capacity or FVC), and is 
the total volume of air that can be forcibly exhaled after a full inspiration.
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2.3 Pathology of Chronic Bronchitis
Ciliated epithelial cells line the upper and lower (trachea to respiratory bronchioles) 
respiratory tracts. The cilia beat in a two-layered system of fluid, a watery layer lies 
below the layer of mucus. This mucociliary system forms the first line of defence of the 
respiratory tract against inhaled particles, including bacteria [Newhouse et al, 1976]. 
These inhaled particles stick on the mucus layer and are then transported towards the 
back of the throat by the coordinated movement of the cilia. The mucus that reaches the 
back of the throat is swept into the oesophagus and is swallowed; alternatively, it may 
be expectorated. Normally this system works extremely well and the amount and 
consistency of the mucus does not cause a problem.
Several pathological mechanisms predispose the bronchitic patient to increased mucus 
production and bacterial infection. Data from animal studies, post-mortem studies and 
epidemiology surveys suggest that these abnormalities are a result of prolonged 
exposure to cigarette smoke [Reid, 1988; Tager & Speizer, 1976]. Although tobacco 
use is the primary risk factor for the development of chronic bronchitis, other risk 
factors are involved.
In early chronic bronchitis, there is a hypertrophy of the submucosal glands in the walls 
of the large bronchi. This process results in the mucus hypersecretion that triggers the 
troublesome ‘smoker’s cough’ of the bronchitic patient. The glycoprotein and lipid 
composition of this mucus differs from normal bronchial secretions in that it is thick and 
tenacious, and resists airway clearance. Clinically, the patient often feels well except for 
a persistent daily cough that is productive of a clear or greyish-white sputum, which if 
examined is normally non-purulent and sterile. Little or no airways obstruction is 
present and infection plays a minor role at this stage. As the disease progresses, 
hypersecretion of mucus starts to involve the smaller airways. Another histological 
finding at this stage is a proliferation of goblet cells in the respiratory epithelium.
Goblet cells are normally found scattered relatively rarely throughout the epithelium of 
the large bronchi and produce mucin (a glycoprotein), which is the major component of 
mucus. The result of this proliferation in goblet cells is that mucociliary clearance is 
further impaired because of the loss of normal ciliated epithelium. In severe chronic
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bronchitis, goblet cells may account for the majority of respiratory epithelial cells, and 
can be found encroaching on the small airways.
Impaction of mucus in the lumen of the small airways along with the structural changes 
associated with submucosal gland hypertrophy, leads to progressive obstruction of the 
peripheral airways. Although a low-grade inflammation often exists, the sputum is not 
markedly purulent with only a moderate number of polymorphonuclear (PMN) 
leucocytes present. Tobacco smoke has also been shown to inhibit mucociliary 
function as demonstrated by impaired particle transport in vitro, ciliostasis (reduced 
motility of the bronchial cilia), decreased tracheal mucous velocity in animals, and 
reduced clearance of inhaled aerosols in humans [Warner, 1977]. In addition to 
cigarette smoke, viral infection also frequently damages ciliated epithelium, which then 
impairs mucociliary clearance [Stanley et al, 1986; Wilson et al, 1987]. In in vitro 
studies subtle defects in the local host immune system have been observed, particularly 
in patients who continue to smoke; these include impaired neutrophil phagocytosis, 
impaired bactericidal function, and decreased levels of sputum immunoglobulin A 
[Green et al, 1977, Chodosh, 1987]. Together, these mechanisms impair clearance of 
inhaled bacteria, and the large bronchi become colonised with the same bacteria that 
normally inhabit the oropharyx [Irwin et al, 1982].
If mucociliary clearance continues to be impaired, these bacteria may persist deep in 
bronchial epithelium even after antibiotic therapy. There is now the classic state of 
colonisation whereby organisms are replicating on or in host tissue, but tissue invasion 
does not take place and the host immune response is minimal. This baseline state of 
colonisation may periodically progress to active disease. Microscopically, there maybe 
evidence of bacterial proliferation and acute inflammation with PMN leucocytes. At 
this point, the patient will complain of worsened cough, sputum production, and 
dyspnoea.
More recently it has been recognised that patients with alpha 1-antitrypsin (aiAT) 
deficiency have increased inflammation of the larger airways, suggesting that a j^ r  has 
an important role in protecting these airways from the inflammatory effects of
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neutrophil elastase [Hill A et al, 2000]. Furthermore, purified neutrophil elastase has 
been shown to be a potent secretagogue for goblet cells in vitro, stimulating them to 
secret mucin [Nadel, 2000]. This suggests a link between the presence of neutrophils in 
the airways and mucus hypersecretion: the key symptom of chronic bronchitis.
2.4 Acute Exacerbations of Chronic Bronchitis
Acute exacerbations (often just referred to as exacerbations) are worsenings of the 
chronic bronchitis, which are frequently sudden in onset. They become a regular 
occurrence for chronic bronchitis patients, and they contrast with the slow progressive 
worsening of the condition that tends to occur over many years. An acute exacerbation 
of chronic bronchitis (AECB) may be caused by an acute bacterial or viral infection, 
environmental pollutants, or an allergic response. Acute infective exacerbations of 
chronic bronchitis are mucosal infections and in the majority of cases will resolve 
spontaneously [Wilson, 1992]. Acute exacerbations can cause distress to the patient, 
result in a reduced quality of life, require prolonged time away from work, and result in 
additional damage to the lungs. For these reasons most physicians will prescribe an 
antibiotic to a chronic bronchitis patient who has a significant exacerbation which is 
productive of purulent sputum, and therefore thought to be caused by a bacterial 
infection.
The current ‘vicious circle’ hypothesis attempts to explain the pathogenesis of an 
exacerbation of CB or COPD [Murphy & Sethi, 1992]. It has as the primary initiator, an 
environmental insult such as pollutants, smoking or a viral infection, which then allows 
an inflammatory cascade and bacterial numbers to increase. This hypothesis, assumes 
that the bacteria are opportunistic and that they are contributing to an already established 
process rather than initiating the process. It also suggests that each significant 
exacerbation results in further damage to the mucociliary clearance, leaving the airways 
even more vulnerable to infection. In this way a ‘vicious circle’ is set in place. This 
hypothesis was originally applied to the progression of bronchiectasis [Cole, 1986]; 
however, it can also explain the progression of COPD.
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Longitudinal studies estimate that each chronic bronchitis patient suffers approximately 
two to three exacerbations per year [Ball et al, 1995; Miravitlles et al, 2003; Schaberg et 
al, 2005; Langsetmo et al, 2008]. However many of these exacerbations are unreported; 
consequently, the reported number of exacerbations per year can be less than one 
[Langsetmo et al, 2008]. An exacerbation involves the development, or worsening, of 
one or more of the following signs and symptoms: volume of sputum produced, 
purulence of the sputum produced, dyspnoea, cough, wheeze, ausculatory findings such 
as rales (crackling sounds) or rhonchi (whistling/snoring sounds), cyanosis, and fever. 
Exacerbations are more frequent during the winter months of the year than during the 
summer months; however, among patients with severe chronic bronchitis and poor lung 
function, exacerbations can occur all year round.
2.4.1 Treatment of Acute Exacerbations of Chronic Bronchitis
Patients with chronic bronchitis are often prescribed medication on an ongoing basis to 
help to control their disease. Long-acting inhaled bronchodilators (beta2-agonists or 
anticholinergics) should be used to control symptoms and improve exercise capacity in 
patients who continue to experience problems despite the use of short-acting drugs. 
Inhaled corticosteroids may be added to long-acting bronchodilators to decrease 
exacerbation frequency in patients with an FEVi less than or equal to 50% predicted 
who have had two or more exacerbations requiring treatment with antibiotics or oral 
corticosteroids in a 12-month period [NICE, 2004]. These patients should also be 
offered annual influenza vaccination and a pneumococcal vaccine. If necessary, 
theophylline and/or oxygen therapy may be added [NICE, 2004].
During an exacerbation, the following therapy would routinely be prescribed: 
bronchodilator therapy (with an increase of dose or a change of agent if necessary); 
inhaled or oral corticosteroids; and oxygen therapy if FEVi <50% predicted. A 
mucolytic agent may be considered, and an oral antibiotic would normally be prescribed 
if the patient had purulent sputum, on the grounds that purulent sputum is associated 
with bacterial infection [NICE, 2004]. The choice of antibiotic will be discussed in 
Section 2.5.2. If the patient has severe chronic bronchitis, is frail and/or elderly, or lives
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alone without family support, admission to hospital is likely. Social reasons may also 
influence the decision to admit a patient to hospital.
2.5 The Role of Bacterial Infection
The role of bacteria as pathogens in acute exacerbations of chronic bronchitis (and acute 
exacerbations of COPD) is controversial and is still not fully understood despite many 
years of research. The problems that surround the role of bacteria in stable chronic 
bronchitis and their role causing acute exacerbations are numerous, and include: a) 
bacteria colonise the lower airways in chronic bronchitis patients, even in the absence of 
symptoms of an exacerbation; b) the information obtained from cultures of expectorated 
sputum is limited since the specimens may not reflect the complete picture of the flora 
of the lower airways, also, it may be contaminated with upper respiratory tract flora; c) 
patients with chronic bronchitis are a highly heterogeneous population, and as a result 
bacteria may vary from patient to patient and are likely to play different roles in 
different individuals; d) evidence indicates that bacteria play a role in only about 50% of 
infectious episodes; e) the three bacteria most strongly associated with infectious 
episodes (non-typeable H. influenzae, S. pneumoniae, and Moraxella catarrhalis) are 
exclusively human pathogens, limiting the use of animal models [Murphy et al, 2000].
Anthonisen and colleagues demonstrated a definite benefit of antibiotic therapy in 
patients who had at least two of the following three symptoms: increased dyspnoea, 
increased sputum volume, and increased sputum purulence [Anthonisen et al, 1987].
The benefits were most pronounced among patients who demonstrated all three of these 
‘cardinal’ (as termed by Anthonisen) symptoms. In addition, the patients who received 
antibiotic therapy had a significantly shorter duration of illness than those who received 
placebo. As expectorated sputum can easily be contaminated with organisms from the 
upper airways, studies carried out using protected specimen brash technique (which 
protect against contamination by upper respiratory tract flora), have established the 
presence of bacteria (>1,000 cfu/mL) in stable COPD disease in 25% of patients, but in 
52% of patients during an exacerbation [Monso et al, 1995]. In another study, increased 
airways inflammation was assessed by measuring levels of interleukin-8 (IL-8), tumour 
necrosis factor-a (TNF-a), and neutrophil elastase (NE) in patients with AECB who had
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non-typeable H  influenzae, Haemophilus parainfluenzae, or M. catarrhalis isolated as 
the sole pathogen. A control group of patients that were pathogen-negative were also 
assessed. The results showed that there was increased airways inflammation in patients 
who had H. influenzae or M. catarrhalis isolated from their sputum, and therefore 
support a causative role of these pathogens in AECB [Sethi et al, 2000]. A specific 
study of H. parainfluenzae found the organism to be present in 25% of patients with 
moderate to severe COPD and in vitro studies showed that H. parainfluenzae could 
cause extensive damage to epithelial cells and slowed ciliary beat frequency, suggesting 
that this organism might play a role in the pathogenesis of COPD [Hill et al, 2000].
By comparison, Hirschmann considered that any significant role of bacteria in 
exacerbations of COPD is unproven. He argued that large trials are consistent in 
showing that antibiotics are not helpful in mild exacerbations; in more severe episodes 
patients should receive systemic corticosteroids, and that with such therapy antibiotics 
provide no additional benefit [Hirschmann, 2002].
In a meta-analysis of nine placebo-controlled studies to evaluate the benefit of 
antibiotics in AECB, there was a small difference in favour of antibiotic therapy [Saint 
et al, 1995]. However, seven of the nine individual studies showed a benefit for 
antibiotic therapy, giving an advantage on the number of studies in favour of antibiotic 
therapy. Nevertheless, such a small difference may be viewed as disappointing and it 
has been suggested that in most cases there is no benefit of antibiotic therapy 
[Hirschmann, 2000]. Despite the uncertainty regarding the importance of bacteria in 
exacerbations, antibacterial therapy is widely recommended for exacerbations that are 
thought to be caused by bacteria (mainly indicated by purulent sputum).
2.5.1 The Bacteria of Acute Exacerbations of Chronic Bronchitis
Most studies show H. influenzae to be the major organism present in patients with acute 
exacerbations of chronic bronchitis [Ball & Make, 1998] and in the stable state [Monso 
et al, 1995]. H. parainfluenzae may also play an important role [Middleton et al, 2003], 
and Gram-negative opportunist organisms such as Escherichia coli and Klebsiella
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pneumoniae are increasingly identified in patients with advanced disease [Eller et al, 
1998; Miravitlles et al, 1999]. Eller’s study of more than 200 patients demonstrated a 
correlation between deteriorating lung function and increasing isolation of 
enterobacteria and Pseudomonas aeruginosa. These pathogens accounted for 63% of all 
bacteria isolated from patients with an FEVi of less than 35% predicted. This study also 
highlights a potential analogy with the colonisation of the lungs and the progression of 
pathogens that occurs in cystic fibrosis.
It is also recognised that the bacteria which are present during exacerbations are 
frequently the same as those found in the airways during the stable state [Monso et al, 
1995]. Indeed, another study using protected specimen brush technique demonstrated 
that 25% of stable patients had significant growth of potential pathogens in the lower 
airways [Pela et al, 1998]; the most commonly isolated organism from patients with 
exacerbations was S. pneumoniae. In addition, M. catarrhalis is also routinely isolated 
in patients with exacerbations of AECB [Sethi, 1999, Dever et al, 2002]. However, 
isolation of a new strain of H  influenzae, M. catarrhalis, or S. pneumoniae has also 
been associated with acute exacerbations [Sethi et al, 2002].
Atypical pathogens Chlamydia pneumoniae and Mycoplasma pneumoniae are 
implicated in AECB, but at a fairly low percentage (<5-15%) [Dever et al, 2002]. Many 
studies in AECB and acute exacerbations of COPD (AECOPD) over the previous 
decades have missed these atypical pathogens as they are normally confirmed by 
comparing antibody titres, are difficult to culture, and were not specifically looked for in 
most clinical trials. A more recent report found that no indication was found for the 
atypical organisms: Legionella spp, C. pneumoniae, and M. pneumoniae, in stable 
moderately severe COPD and in exacerbations [Diederen et al, 2007].
2.5.2 Choice of Antibiotic Therapy in Acute Exacerbation of Chronic 
Bronchitis
An antibiotic (or antibacterial drug) is defined as any compound which either kills or 
inhibits the growth of bacteria. These two terms are basically interchangeable; the term
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antibiotic classically describes a naturally occurring substance that has antibacterial 
activity; an antibacterial drug is any compound naturally occurring or synthetically 
derived which has antibacterial activity. In this thesis, the term antibiotic has been used 
in the broad sense to mean any antibacterial drug.
As previously described, the concept of the beneficial nature of prophylactic antibiotic 
therapy for the winter months to prevent exacerbations or reduce the number of 
exacerbations was first explored in the 1950s and remained an intriguing prospect for a 
number of researchers, and a number of other studies were performed with the aim 
proving this theory and identifying the best antibacterial agent(s). In a recent review of 
the well conducted studies, all performed before 1970, the conclusion was that although 
prophylactic antibiotic therapy can shorten the number of days of illness due to an 
exacerbation, they have no place in routine treatment because of the risk of antibiotic 
resistance developing, and the possibility of adverse effects [Staykova et al, 2007].
Except in very specific circumstances, antibiotics are only used in short courses of a 
maximum of 14 days, but more usually 5-7 days. The prescribing of an antibiotic is 
normally triggered by the start of an acute exacerbation that is thought to be caused by 
bacteria (productive of purulent sputum). A number of factors should be considered 
when selecting an antibiotic for treatment of AECB [revised from Schentag & Tillotson,
1997].
11 Antibiotic spectrum: As the pathogens that cause acute bacterial exacerbations of 
CB include both Gram-positive and Gram-negative organisms, the selected antibiotic 
must also have a broad spectrum of activity.
21 Antibiotic resistance: With the increase in antibiotic resistance worldwide, 
consideration needs to be given to the likelihood of resistance when selecting an 
antibiotic. Local resistance patterns are most useful; however, the risk factors of each 
patient should be considered. Factors that put a patient at higher risk of harbouring a 
resistant pathogen include: recent hospital stay, recent antibiotic treatment, living in 
community accommodation such as a care home.
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3) Mechanism of action: Antibiotics with bactericidal activity should be more effective 
in eradicating pathogens than those that have bacteriostatic activity, as pathogens that 
are only suppressed may give rise to a relapse, or develop resistance to the antibiotic. 
There is however no evidence which demonstrates conclusively that bactericidal 
antibiotics have better outcomes than bacteriostatic ones in the treatment of AECB.
4) Pharmacokinetics and pharmacodynamics: Penetration into respiratory secretions is 
one of the most important pharmacokinetic characteristics of antibiotics used to treat 
AECB. p-lactam antibiotics generally penetrate poorly into respiratory secretions with 
concentrations well below those found in serum, yet in clinical trials their efficacy tends 
to be equivalent to those drugs with better penetration.
5) Dosing regimens: The majority of patients are treated in the community and 
therefore oral antibiotics with once or twice daily dosing are preferable to aid 
compliance. In addition shorter duration of therapy may help compliance and reduce 
costs and adverse effects.
6) Side effects: The most common side effects of all antibiotics used to treat AECB are 
gastrointestinal, mainly diarrhoea, nausea, and vomiting. Rash, headache and taste 
disturbance may also occur, as well as a host of other less common adverse effects. 
Selecting an antibiotic with a favourable side effect profile is more likely to encourage 
compliance.
7) Cost: Direct comparison of the costs of antibiotic therapies is not straightforward. 
The cost of each tablet may be misleading if one antibiotic is effective at a dose of one 
tablet a day for five days, when the other has to taken three times a day for 10 days (5 
tablets versus 30 tablets). Other factors that affect cost are the cost of failure (cost of the 
second-line antibiotics), and the cost of treating side effects associated with antibiotic 
therapy.
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Many groups of antibiotics are used to treat AECB: penicillins (e.g. amoxicillin), 
cephalosporins (e.g. cefaclor), tetracyclines (e.g. oxytetracycline), macrolides (e.g. 
clarithromycin), folic acid inhibitors (e.g. trimethoprim), and fluoroquinolones (e.g. 
ciprofloxacin). There are significant national and local differences in the choice of first 
line oral antibiotic for patients with AECB of moderate severity, driven predominantly 
by national and local susceptibility patterns. However, because antibiotics are 
recommended for patients with purulent exacerbations and antibiotic resistance 
continues to be a problem, there is an ongoing need for new antibacterial agents to be 
developed and evaluated in clinical trials in AECB patients.
2.6 Frequency of Chronic Bronchitis and Impact on Healthcare 
Systems
The changing terminology in this area makes examination of chronic bronchitis difficult. 
Although some researchers still report data on chronic bronchitis, many groups and 
organisations (including the World Health Organisation) report on the broader definition 
of COPD. The data in this section therefore uses data on both definitions; this should 
not detract from the overall fact that chronic bronchitis is a significant burden to 
healthcare systems, is a major cause of death, and has considerable cost implications.
The WHO World Health Report o f2002 [WHO, 2002] recorded COPD as the fifth 
leading cause of death in the world. It has also been identified from a 5 year study, that 
mortality is significantly related to the frequency of severe exacerbations requiring 
hospital admission [Soler-Cataluna et al, 2005]. In addition, unlike some other leading 
causes of death such as cardiovascular disease, which are in decline [Pauwels & Rabe, 
2004], further increases in the prevalence of COPD and resultant mortality are 
anticipated over the next few decades [Murray & Lopez, 1997, Soriano et al, 2000].
In one study of the prevalence of COPD and one study of CB, which were conducted in 
several countries the prevalences were found to be similar. The prevalence of COPD 
among adults was found to be between 4% and 10% in countries where it has been 
rigorously measured [Halbert et al, 2003]. The overall prevalence of chronic bronchitis
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was found to be between 1% and 10% of the young adult population (20-44 years) 
across 16 developed countries [Cerveri et al, 2001]. In studies of specific populations 
within a country or city more specific and therefore varied prevalences were identified. 
A study of patients over 45 years of age in Manchester, 26% of patients were found to 
have chronic airways obstruction [Renwick & Connolly, 1996]. A study in France 
among people aged 25 years and over, found a prevalence of chronic bronchitis of 4.1%, 
but a prevalence of chronic cough and/or chronic expectoration of 11.7% [Huchon et al, 
2002].
These studies indicate how variable the prevalence of chronic bronchitis can be 
depending upon the specific population studied. Identifying data that relates the 
prevalence of chronic bronchitis directly to COPD is difficult; however, von Hertzen 
and colleagues achieved this in Finland and found that 11% of men and 5.2% of women 
aged 30 years or above had COPD (FEVi/FVC <70%), but almost twice as many had 
chronic bronchitis or emphysema when examined by a physician [von Hertzen et al, 
2000]. In addition, COPD (and chronic bronchitis) tend to be under diagnosed; a study 
in a GP practice in Lincolnshire found that there were 2.69 “true” cases of COPD for 
every diagnosed case in patients aged 60-74 years [Dickinson et al, 1999],
It has been estimated that at least 12 days are lost from work each year by each AECB 
patient in Germany, and the overall economic impact of CB amounts to €8.4 billion. 
[Lorenz et al, 2001]. In the USA, 14% of the adult population is affected by COPD, and 
the annual healthcare costs associated specifically with CB are calculated to be $11.7 
billion [Wilson et al, 2000]. In a separate study comparing CB patients aged under 65 
and over 65, it was calculated that the total treatment costs for AECB are $1.2 billion for 
patients aged 65 years and over, and $419 million for patients aged <65 years; the 
majority of these costs being related to hospitalization [Niederman et al, 1999]. The 
total economic impact of working days lost has not been estimated in the USA, but 
would clearly be significant. Whatever the true cost of CB in terms of healthcare costs 
and the economic impact, this disease has a huge impact to society.
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3 RATIONALE, OBJECTIVES, AND SUMMARY OF PROJECT 
DEVELOPMENT
3.1 Overall Objective
The overall objective of this project was to examine factors that might improve the 
identification of bacterial infection in patients with a history of chronic bronchitis who 
present in a GP or hospital setting with signs and symptoms of an acute exacerbation.
A successful outcome would mean that inclusion criteria in clinical trials of antibacterial 
drugs could be designed to target patients who have a high probability of being included 
in the microbiological populations (see Section 3.2). These microbiologically-evaluable 
populations are key in such studies, as these populations are used to evaluate the 
microbiological efficacy of each antibacterial drug (or combination of drugs) against 
each species of pathogenic bacteria isolated. The populations may also be used to 
evaluate the clinical efficacy of the study drugs.
3.2 Clinical Trial Populations for Analysis
Clinical studies in different therapeutic areas have slightly different requirements for 
their populations for analysis. This section outlines the standard populations in clinical 
studies of antibacterial drugs, and provides some comparison with clinical studies in 
other therapeutic areas. A summary of the populations for analysis in antibacterial 
studies is shown in Table 3-1
In some studies the Intention-to-Treat (ITT) population will be defined as all patients 
who were enrolled into the study, whether or not they received any study medication. 
However, in studies of antibacterial drugs, the ITT population is normally all 
randomised patients who received any study drug. This definition of the ITT population 
is also the population that is used for all the safety analyses.
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In non anti-infective clinical trials the next population is normally called the Modified 
ITT (MITT, sometimes written as mlTT), which will include patients that are confirmed 
as having the disease under study, and possibly who have received at least one dose of 
the medication or procedure under study. In studies of antibacterial drugs, this 
population is still sometimes called the modified ITT and sometimes called the 
microbiological ITT, which is what it is. The MITT population includes all the ITT 
patients who had one or more species of bacteria that are recognised pathogens in the 
infection under study isolated from an appropriate specimen taken at baseline. For 
example, in a study of AECB isolation of Streptococcus viridans from the sputum is 
unlikely to accepted as a pathogen (as this is normally a commensal of the oropharynx); 
however isolation of S. pneumoniae would be an accepted pathogen.
In antibacterial studies, the Clinically Evaluable (CE) population is the primary 
population for analysis and the one for which the sample size calculation should be 
made. The reason for this is because the objective of virtually all antibacterial studies is 
to demonstrate non-inferiority (or equivalence) and in non-inferiority studies, the CE 
population is more conservative than the ITT population (whereas the opposite is true 
when the objective of the study is to demonstrate superiority). The CE population 
includes all patients in the ITT population who meet pre-defined protocol criteria that 
will mean that clinical outcome of their infection is likely to be a result of the 
antibiotic(s) (or placebo) that they have received. An example of such a criterion is that 
the patient must not have received any concomitant antibacterial therapy, unless this was 
given for clinical failure.
The Microbiologically Evaluable (ME) population is a combination of the MITT and the 
CE populations. It will include all the patients who were eligible for the CE population 
who had one or more species of bacteria that are recognised pathogens in the infection 
under study isolated from an appropriate specimen taken at baseline.
The ITT and CE populations are used to assess the clinical outcomes; however, some 
studies will also evaluate the clinical response in the MITT and ME populations as well.
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Bacteriological outcomes however can only be assessed in the MITT and ME 
populations.
Table 3-1: Summaiy of Populations for Analysis in Antibacterial Studies
Population Abbrev. Definition
Intention-to-Treat ITT All randomised patients who receive any amount 
of study medication.
Modified or Microbiological 
Intention-to-Treat
MITT All ITT population patients with an accepted 
causative pathogen isolated at baseline.
Clinically Evaluable or 
Per Protocol
CE or 
PP
All patients in the ITT population who meet 
specific protocol criteria such that the clinical 
outcome of their infection could be inferred to 
reflect the effect of the study drug.
Microbiologically Evaluable ME All patients in the CE population who had an 
accepted causative pathogen isolated at baseline
3.3 Rationale for this Project
Over several years of working on clinical trials of antibacterial drugs in patients with 
AECB, I had observed the often low proportion (less than hall) of patients who had 
proven bacterial infection i.e. had a bacterial pathogen isolated from their baseline 
sputum sample. Consequently, a significant proportion of the patients in the CE 
population, did not have a proven bacterial infection, but were evaluable in terms of 
clinical response. These patients may or may not have had a bacterial infection, but 
those who did not have a bacterial infection were adversely affecting the scientific 
validity of the study; in effect diluting the true clinically evaluable population. I was 
concerned about the extent to which this could affect the results of a clinical trial, and 
the conclusions that would be drawn from these studies. It seemed that this could have 
influenced the move to equivalence (or non-inferiority) studies in this therapeutic area, 
because proving 10% superiority in a population where perhaps less than 50% of 
patients have a bacterial exacerbation, would be statistically very difficult [see Figure 
8-1]. Therefore, a method that could increase the percentage of microbiologically- 
evaluable patients in a clinical trial of antibacterial drugs in patients with AECB, would
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be a significant advantage to the pharmaceutical industry, and enable more cost- 
effective studies. In an era where many large pharmaceutical companies are no longer 
investing in research into new antibacterial drugs [Conly & Johnston, 2006; Tillotson, 
2008], a significant improvement in identifying bacterial infection in COPD patients 
could make this a more attractive investment opportunity.
A patient with AECB that is non-bacterial in origin does not need to be treated with 
antibacterial drugs. Such drugs will have no effect on the course of the exacerbation, 
and at a time when attempts are being made to limit the use of antibacterial drugs in 
order to reduce the spread of antibiotic resistance, treating patients who do not have a 
bacterial infection is potentially deleterious to the efficacy of the antibiotic used, and 
exposes the patients to the risk of adverse effects.
A few studies applied techniques that were designed to increase the likelihood of 
identifying bacterial exacerbations. The simplest method was to screen the sputum for 
microscopic purulence. This was defined as a sputum sample that contained >25 white 
blood cells and <10 squamous epithelial cells per low power field (xlO eyepiece and 
xlO objective lens) [Bartlett, 1974]. The rationale behind this definition was to identify 
samples that had come from deep in the lungs (few squamous epithelial cells), and had 
signs of infection by containing significant numbers of white blood cells. This 
procedure is now recommended by the FDA in its guidance document of 1998 [FDA,
1998]. The more complex method was to screen a Gram stained preparation of the 
sputum for the presence of bacterial cells. This method could not identify specific 
species of bacteria, but could identify particular morphological cells types, such as 
Gram-positive cocci or Gram-negative bacilli. However, much of the variation in 
clinical trials of antibacterial drugs in AECB patients was the inclusion criteria that 
different studies used to define an acute exacerbation.
In the 1980s, Anthonisen and co-workers [Anthonisen et al, 1987] defined three types of 
acute exacerbation based of the presence or absence of three cardinal features as shown 
in Table 3-2.
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Table 3-2: Anthonisen’s classification of acute exacerbations of COPD
Anthonisen classification Features Benefit of an antibiotic 
from this study*
Type I exacerbation -  increased sputum purulence,
-  increased sputum volume,
-  increased dyspnoea
Beneficial
Type II exacerbation Any 2 of the above 3 features Some benefit
Type HI exacerbation Any 1 of the above 3 features No clear benefit
* Anthonisen et al, 1987
Since the publication of these results, the majority of studies have applied these criteria, 
or a variation on these criteria. However, some studies included only patients with a 
Type I exacerbation, whereas others included patients with a Type I or a Type II 
exacerbation.
My hypothesis was, therefore, that patients with a Type I exacerbation were more likely 
to have a bacterial infection than those who had a Type II exacerbation; patients with 
Type III exacerbations would be excluded from the investigation as there was no 
evidence for the use of antibacterial therapy in these patients. This was the implication 
of the Anthonisen study, based on the significant benefit of antibiotic therapy over 
placebo in the Type I patients, which was less clear in Type II patients. However, since 
no bacteriology was performed in the Anthonisen study, it was impossible for this 
aspect to be proven.
In addition to this application for the improvement of clinical trials of antibacterial 
drugs, it has been recognised that antibacterial drugs tend to be over-prescribed for 
exacerbations of CB/COPD, and that there is a need to identify markers of bacterial 
infection, which will give a clearer indication for the use of these drugs [Smith et al,
1999].
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3.4 Summary of Project Development
This project started with a multicentre investigation into the best indicator of bacterial 
infection in patients who were diagnosed as having an acute exacerbation of chronic 
bronchitis. This investigation was designed as part of an MSc degree at the University 
of Surrey. The investigation started in 1999 and was completed in 2002. At the end of 
this project, I wanted to take the research further and made the decision not to submit 
the research for an MSc degree, but to move to a part-time MPhil/PhD course.
On acceptance to the part-time MPhil/PhD course a systematic review was undertaken 
as background to the project and to test the previously unsupported arguments of the 
completed investigation that:
i. the proportion of microbiologically-evaluable patients (patients in whom a 
recognised bacterial pathogen can be isolated from a sputum sample at baseline) 
in clinical trials of antibiotics in AECB patients is extremely variable, and
ii. in general, this proportion is disappointingly low; frequently less than 50%.
Consequently, clinical efficacy results (clinical cure, clinical failure etc.) may be based 
on a population in which less than half have a proven bacteriological infection.
The systematic review examined clinical trials of antibacterial drugs in AECB to 
examine the proportion of patients who were microbiologically-evaluable and what 
entry criteria were applied to selecting the patients for the study. Other aspects of these 
clinical studies were also examined (see Section 4).
3.4.1 History of Additional Investigation
An additional investigation was planned to examine the sensitivity and specificity of the 
presence of leucocyte esterase in the sputum as an indicator of bacterial infection. 
Leucocyte esterase is most familiar as one of the test patches on a urine dipstick. 
Leucocyte esterase is an enzyme that identifies the presence of polymorphonuclear 
neutrophils (PMNs), and is therefore a good suggestive marker of bacterial infection. 
The benefits of this technique to identify AECB patients who had bacterial infection
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were that it would be non-invasive, simple and quick to perform as it would require only 
a urine dipstick and a fresh sputum sample, and could therefore be performed in a GP 
surgery. If this procedure offered any advantage over assessing signs and symptoms, as 
a way of determining whether a patient had a bacterial exacerbation of AECB, it could 
be a useful tool not only in screening patients for clinical trials of antibacterial drugs for 
AECB, but also for the decision making process of whether a patient required 
antibacterial therapy.
A draft protocol was prepared for this additional investigation (Appendix 9.1).
However, as further background research was performed, it appeared that there were a 
number of issues that would make this planned investigation impractical to conduct, and 
that any benefit that was shown from such an investigation may not be able to be 
applied in GP surgeries as planned.
The issues that were identified were:
1) Standardisation of technique.
The original idea was to place the leucocyte esterase (LE) patch of a urine dipstick in 
contact with fresh sputum, collected from a patient in a sputum pot. However, the 
viscosity of sputum can vary significantly and how much a very viscous specimen 
would 6 wet’ the LE patch so that it could react with the test agents in the patch was 
unclear. It seemed that it would be necessary to run a series of tests on sputum and 
urine dipsticks to validate the methodology that would be used in the investigation. If 
normal saline had to be added to the specimen, it would then need to be homogenised in 
order to achieve a uniform sample. This would add to the complexity of the procedure 
and meant that it would not be practical for most GP surgeries as it was apparent that 
homogenisers would not be generally available in GP surgeries for this study and for the 
wider application of this technique.
2) Safety of handling raw sputum samples.
Health and safety regulations now mean that sputum samples which could contain a 
Hazard Group 3 organism (an organism that may cause severe human disease and 
presents a serious hazard to laboratory workers; it may present a risk of spread to the 
community but there is usually effective prophylaxis or treatment available), should not
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be handled except within a microbiological safety cabinet in a Containment Level 3 
(CL3) laboratory, and protective gloves and clothing should be worn [Health Protection 
Agency, 2008]. Hazard Group 3 organisms include Mycobacterium tuberculosis, other 
Mycobacterium species and Chlamydia psittaci. The majority of respiratory pathogens 
including H. influenzae, S. pneumoniae, and M. catarrhalis are in Hazard Group 2 (an 
organism that may cause human disease and which might be a hazard to laboratory 
workers but is unlikely to spread to the community). Although these organisms do not 
require a CL3 laboratory, they do require special precautions, and are not suitable to be 
handled in most GP surgeries. Although very few patients would be carrying Hazard 
Group 3 organisms, the risk is present and the general advice is that GPs should not in 
any way process sputum samples.
The difficulty surrounding being able to conduct this investigation safely in GP 
surgeries meant that it was impossible to proceed with this study. In addition, as the 
whole purpose of this research was to identify potential indicators of bacterial infection 
for application in clinical trials of antibacterial agents, the results of such a study would 
be irrelevant if they could not be applied directly to a clinical trial situation.
Alternative follow-up investigations were considered. However, the lack of 
identification within a reasonable time, of a valuable and feasible further investigation, 
which could be completed within a fixed timeframe, meant that further clinical study 
work was not possible.
3.5 Outcome
It was agreed that I would write up the work that I had already done (the systematic 
review and the clinical study) and along with further research into the current research 
into identifying bacterial exacerbations of chronic bronchitis and COPD, submit this as a 
thesis for an MPhil.
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4 SYSTEMATIC REVIEW OF CLINICAL TRIALS OF 
ANTIBACTERIAL DRUGS IN ACUTE EXACERBATIONS OF 
CHRONIC BRONCHITIS
4.1 Introduction
From the 1950s to the turn of the millennium more than 200 new antibacterial drugs were 
developed and marketed. Over this period, the way in which these new drugs were tested 
in clinical trials improved significantly. In the 1950’s clinical trials were often (to 
modem thinking) not scientifically robust: the doctors and patients frequently knew 
which drug was being given (not blinded), randomisation was often on the basis of 
alternate patients receiving study drug or comparator/placebo (a less than ideal system 
which is open to bias), the numbers of patients studied was small with no statistical 
sample size calculation and were often based on the number of patients seen in a fixed 
period of time e.g. 6 months. In addition, the vast majority of these studies were 
conducted in just one hospital, rather than several centres. This could sometimes result in 
widely varying conclusions between studies; in addition, the definitions of outcome were 
often vague.
In the 1980s Phase III and Phase IV clinical trial designs were statistically robust, in that 
the patient numbers were justified against the success rate anticipated, the power required 
and the equivalence (or superiority) level to be tested. However, in order to reduce 
patient numbers and therefore save time and money, the power was often set at only 80% 
or 85% [personal experience], thus giving a 15% to 20% chance that4true superiority’ or 
‘true equivalence’ would be missed, purely by chance. In addition, equivalence within 
15% was often applied in studies; a margin which, at its lower limit, could be argued is 
hardly equivalent at all.
By the mid 1990s, pivotal clinical trials (the Phase III studies that will be submitted to the 
Regulatory Agencies to gain a Marketing Authorisation for the product) required large 
studies that were statistically valid for the outcome that was to be tested. For studies of 
antibacterial drugs, clinical trials which were designed to prove equivalence between the 
test drug and the comparator drug were standard [Smith et al, 1998]. Equivalence within
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10% of the ‘gold standard’ therapy for that indication was the regulatory standard, and 
90% power was expected. Consequently, most two-arm antibacterial studies comprised 
500 -  800 patients (depending on the expected success rate). In addition, clinical studies 
were conducted to high standards as outlined in ICH-GCP (International Conference on 
Harmonisation, Good Clinical Practice). Throughout this period, clinical trials of 
antibiotics were conducted in patients with AECB. However, although the scientific 
robustness as described above had increased significantly, the proportion of patients who 
had a bacterial pathogen isolated at baseline did not appear to have changed, and 
remained highly variable. This may have been, in part, caused by the wide range of 
severity of the underlying chronic bronchitis or COPD e.g. GOLD criteria I -  IV [GOLD 
Report, 2007], which not only could influence the severity of the exacerbation, but also 
the likelihood of the exacerbation being of bacterial origin.
This systematic review of randomised, controlled, clinical trials of antibacterial agents 
(antibiotics) in the treatment of patients with an acute exacerbation of chronic bronchitis 
was, therefore, undertaken in order to attempt to understand the reasons why such 
variations in the proportions of bacteriologically-proven infections should exist, and 
examine which (if any) entry criteria improve the proportion of patients from whom a 
pathogen may be isolated.
4.2 Objective
The objective of this systematic review was to examine the differences in the rates of 
bacteriologically-positive sputum samples (i.e. sputum samples at study entry from 
which a recognised pathogen was isolated) in clinical trials of antibacterial drugs in 
patients with acute exacerbation of chronic bronchitis, and to investigate whether there 
was any association between the percentage of bacteriologically-positive patients and 
the following factors:
-  definition of chronic bronchitis
-  definition of an acute exacerbation
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-  microbiological screening of the sputum sample for white blood cells and 
squamous epithelial cells, +/- bacterial cells seen on Gram stain performed as an 
entry criterion
-  species of bacteria that were recognised as pathogens
-  date of the study
The protocol for this systematic review can be found in Appendix 9.2.
4.3 Selection of Papers
4.3.1 Databases Used
The following databases were used for this study:
a) Ovid Medline
b) Cochrane Library
4.3.2 Search Terms Applied 
Medline
The disease that we now call acute exacerbation of chronic bronchitis has had a variety 
of names and terms over the last 40 years. An examination of the terms used in Medline 
since 1966 showed that a number of different terms would need to be used in order to 
identify all papers on AECB since 1966.
The terms used in the Medline search were:
A) Disease definition
o bronchitis,
o lung diseases, obstructive,
o bronchitis, chronic
o pulmonary disease, chronic obstructive
o pulmonary emphysema
o acute exacerbation of chronic bronchitis
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B) Antibiotic therapy definition
o anti-infective agents (administration & dosage, therapeutic use)
A)and B)
Limit to: Human, Adult, English language, Randomised controlled clinical trial. 
Cochrane Library
The search of the Cochrane Library database was simpler than that of Medline as only 
one term was needed to identify all relevant papers.
Search term
o acute exacerbation chronic bronchitis
4.3.3 Entry Criteria for Papers
A number of inclusion and exclusion criteria were required so that only clinical studies 
with a certain level of scientific robustness would be included in the analysis.
43.3.1 Inclusion criteria
Papers that were eligible for this systematic review met the following criteria:
a) Clinical trials of one or more antibacterial agent in the treatment of patients with 
an acute exacerbation of chronic bronchitis or an acute exacerbation of COPD.
b) Randomised, controlled, clinical trials.
c) Published in English.
4.33.2 Exclusion criteria
The following types of papers were excluded from the analysis:
a) Letters.
b) Clinical trials that did not perform or report any bacteriology.
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c) Papers that did not give sufficient detail of the study design and/or the 
bacteriology.
d) Papers reporting interim data.
e) Clinical trials that only examined only one pathogen in AECB.
f) Papers that reported on a subset of a larger study (in such cases efforts were 
made to identify the publication of the full study).
g) Clinical trials that enrolled fewer than 100 patients.
This last exclusion criterion excluded a significant number of older studies, this aspect 
was highlighted in the Introduction (Section 4.1). However, with fewer than 100 
patients in a two-arm study each patient would account for a minimum of 2%. In a 
three-arm study that only recruited 60 patients (20 patients per arm), cure rates of 18,16 
and 15 patients, result in the possibly misleading percentage of cure rates of 90%, 80%, 
and 75% so that a three patient difference in success rate resulted in a 15% difference in 
cure rates. In the smaller bacteriological populations the differences would be more 
extreme. It was for this reason that the minimum of 100 patients was applied.
4.4 Information Collected
4.4.1 Overview of Data Collection
Each suitable paper (or potentially suitable paper) was obtained either from my own 
collection of papers and journals; from online access; from the library at the Royal 
Society of Medicine; or by ordering the paper from the British Library. Each paper was 
reviewed and the data from each suitable paper was collected on individual data 
collection forms (see Data Collection Form on page 39 and Appendix 9.2). At the end 
of data collection, the data from these forms was transferred to an Excel spreadsheet for 
analysis.
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4.4.2 Data Extracted from the Papers
Each paper identified was given a unique reference number and the following data was 
collected from each eligible paper:
1. Reference number.
2. 1st Author.
3. Journal.
4. Year; volume; and start page of paper.
5. Study drug.
6. Comparators).
7. Whether the standard definition of chronic bronchitis was applied in the study (daily 
production of sputum for 3 months of the year over at least 2 successive years).
8. Minimum and maximum age of patients.
9. The signs and symptoms of an acute exacerbation that were required for entry.
10. Whether there was any screening of the sputum prior to patient enrolment.
11. Whether there were any requirements that had to be met on the quality of the sputum 
e.g. WBCs; SECs.
12. Whether there was any statistical justification for the sample size.
If so, whether the a) enrolment target, b) evaluable patient target was reached.
13. The number of patients that were: a) enrolled, b) in the Intention-to-Treat (ITT) 
population, and c) in the Clinically Evaluable (CE) population.
14. Number of pathogens in the ITT population.
15. Number of bacteriologically-positive patients in the ITT population.
16. Proportion of bacteriologically-positive patients in the ITT population.
17. Number of pathogens in the CE population.
18. Number of bacteriologically-positive patients in the CE population.
19. Proportion of bacteriologically-positive patients in the CE population.
20. Clinical success rates in the ITT population.
21. Clinical success rates in the CE population.
22. The organisms that were recorded as pathogens.
23. Whether organisms that were resistant to the study drugs were excluded.
Page 38 of 213
Data Collection Form for Systematic Review
Study Details
Ref No.: EH - □ □ □ 1st Author:..................................................
Journal:.......................................... Year/Vol/pg:..............................................
Study drug:......................................... Comparators):..........................................
Population & Entry Criteria
Population: Std AECB? Yes EH No d  Age range: from f i n
if No, specify:.................................................. to EH EH OR no upper limit EH
Symptoms reqd for entry
Purul sputum: req.EH opt.EH; Dyspnoea: req.EH opt.EH; t  Sputum vol: req.EH opt.fH:
Cough: req.EH opt.EH; Wheezing/rales: req.EH opt.EH; Fever: req.EH opt.EH; FEVi: req.EH opt.EH 
Any 1 of optional EH Any 2 of optional EH Any 3 of optional EH Not specified EH Req. only EH 
Anything different to above:............................................................................................................
Sputum criteria for study entry Yes □  No □  N/K □
If Yes, WBCs >25: EH SECs <10: EH predominant cell types on Gram stain: EH
Sputum criteria for culture/to be included Bact Population Yes □  No □  N/K EH
If Yes, WBCs >25: EH SECs <10: EH predominant cell types on Gram stain: EH
Study Numbers
Total patients entered: 1 11 1 II 1 StatjustifofNo.? Yes 1 1 No[_J N/K I I
Recruit, target met? Yes LJ No LH N/K |_j Clin eval. target met? Yes EH No LH N/K LJ
No. in ITT: □ □ □ No. in PP: □ □ □
Bacteriological population
ITT - No. of paths: O D D  ITT - No. of Bact+ pats: O EH EH  ITT - % of Bact+ pats:
PP - No. of paths: EHEHEH PP - No. of Bact+ pats: O D D  PP - % of Bact+ pats:
ITT - Clinical Success (study drug vs comparator): EHEH-EH% vs EH EH-EH % vs EHEH-EH%
PP - Clinical Success (study drug vs comparator): EHEH-EH% vs EHEH-EH% vs EHEH-EH%
Path: SPNEn HINd MCAE] HPAEn SAUEH PAEEn E’bact □  others □  spp N/K EH R-orgs excl.EH
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4.5 Data Management, Analysis and Reporting
4.5.1 Database
An Excel spreadsheet was created to reflect the data collection form so that the 
information collected on the data collection forms could be easily transferred to the 
spreadsheet.
4.5.2 Analysis of Data
Studies varied in whether they reported bacteriology in the ITT and/or CE populations. 
Therefore, in order to capture the maximum number of good quality studies, studies 
were accepted for analysis provided that bacteriology was reported in at least one of 
these populations. The differences in the rates of bacteriologically-positive sputum 
samples (i.e. sputum samples at study entry from which a recognised pathogen was 
isolated) in clinical trials of antibacterial drugs in patients with acute exacerbation of 
chronic bronchitis was examined in both the ITT and CE populations and reported as a 
median and range.
The association between the percentage of bacteriologically-positive patients and the 
following factors were analysed:
-  definition of chronic bronchitis (ATS definition or alternative)
-  definition of an acute exacerbation (Anthonisen Type I and Type II 
exacerbations or alternative)
-  presence or absence of microbiological screening of the sputum sample for white 
blood cells and squamous epithelial cells, +/- bacterial cells seen on Gram stain 
performed as an entry criterion
-  the species of bacteria that were recognised as pathogens
-  date of the study (based on the year that the paper was published).
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4.6 Results
4.6.1 Overview of Papers from Search
The search of Medline generated 277 papers that fitted the general criteria, and the 
Cochrane Library search generated 265 papers. The Medline papers were then screened 
to check that they were randomised controlled clinical trials of antibiotics in patients 
with acute exacerbation of chronic bronchitis, and were published in English (inclusion 
criteria); the Cochrane papers were checked against the Medline list and all duplicates 
were deleted, the remaining papers were screened as described for the Medline papers. 
The results of the searches and checks are shown in Table 4-1.
Table 4-1: Results of the database searches
Database and search terms No. of references
Medline
A) Terms for disease definition 37,478
B) Terms for antibiotic therapy 301,063
A)and B) 2,918
Limit to: Human, Adult, English language, 277Randomised controlled clinical trial
After screening 132
Cochrane
Acute exacerbation chronic bronchitis 265
After screening 24
Overall Total from Database Searches 156
The Medline search resulted in 132 papers, and the Cochrane Library search resulted in 
24 papers that had not already been listed by Medline. The dates of the papers ranged 
from 1968 to 2004. In addition, during the identification, and collection of these 
references, my personal reading in this area provided a further five papers that had not 
been found on Medline or the Cochrane Library.
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4.6.2 Overview of Eligible Papers
Table 4-2 summarises the numbers of eligible and non-eligible papers that were 
identified in the search of Medline and the Cochrane Library.
Table 4-2: Summary of the database searches
Database
Eligible
Numbers of Papers 
Non-eligible Total
Medline 66 66 132
Cochrane 14 10 24
Personal 3 2 5
Total 83 78 161
A total of 161 papers were identified and reviewed. The inclusion criteria had already 
been applied in the screening of the papers, and this review therefore checked the 
inclusion criteria, but mainly checked the papers for the exclusion criteria. From this 
rigorous review 83 papers (52%) were found to be eligible for analysis in this systematic 
review. The reasons for non-eligibility of the remaining 78 papers are summarised in 
Table 4-3.
Table 4-3: Summary of the reasons for non-eligibility of papers
Reason for 
non-eligibility* Medline
Databases
Cochrane Personal Total
Insufficient or no bacteriology 27 5 1 33
Insufficient numbers 20 1 1 22
Insufficient detail 13 0 0 13
Mixed LRTIs 4 0 0 4
Interim data 2 0 0 2
Duplicate paper of study 0 2 0 2
Unsuitable design (eg. X-over 2 1 0 3
study, meta-analysis) 
Not a RCT 0 1 0 1
Prophylaxis study 1 0 0 1
S. pneumoniae only study 1 0 0 1
Not an antibiotic study 1 0 0 1
Letter 1 0 0 1
Papers could have more than one reason for ineligibility. LRTIs - lower respiratory tract infections.
RCT -  randomised controlled trial.
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The eligible papers were published between from 1977 to 2004. All but two of these 
papers (dated 1977 and 1989), were published after 1990. This suggests that the 
inclusion and exclusion criteria that were applied regarding the bacteriology, detail of 
signs and symptoms required and minimum numbers tended to exclude clinical studies 
from pre-1990.
4.6.2.1 Study population
One of the criteria for this systematic review was that a study had to have enrolled a 
minimum of 100 patients. This criterion ignored the fact that some studies had 3 arms. 
The number of patients per arm in the eligible studies ranged from 44 to 1090.
There was considerable inconsistency in the lower age limit that was used in these 
studies; the number of papers (studies) with each lower age limit is shown in Table 4-4.
Table 4-4: Lower age limit in eligible papers
Lower age limit No. of papers
Less than 18 years* 8
18 years 47
35 years 5
40 years 9
45 years 1
‘Adult’ 8
Not specified 5
Total 83
* Lower age limit: 16 years - 1 paper, 15 years - 1 paper, 
13 years - 4 papers, 12 years - 2 papers.
The sample size of the randomised controlled trial was justified in 37 (45%) papers, 
these papers tended to be the more modem papers, dated from 1993-2004. Thirty-four 
of these 37 papers were from the period 1997-2004. The sample size was not 
justified/explained in 46 (55%) papers; these papers were published from 1977-2004, 
however 26 of these papers were from 1977-1996 inclusive.
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4.6.3 Analysis of Systematic Review Objectives
The proportion of bacteriologically-positive patients in each study was identified and the 
variation between the studies examined.
Each of the factors outlined in Section 4.2 (Objective) was examined against the 
proportion of bacteriologically-positive patients in each sub-group within that factor.
4.6.3.1 Rates o f bacteriologically-positive sputum samples
According to the exclusion criteria b) and c) all studies were required to report adequate 
detail of the bacteriological data in the ITT and/or CE population. Twenty studies 
provided bacteriological data on the ITT population only; 34 studies provided 
bacteriological data on the CE population only; and 29 studies gave this information for 
both populations. Therefore data on the ITT population was gained from 49 (20 + 29) 
studies, and on the CE population from 63 (34 + 29) studies.
As the studies varied in the populations in which they reported bacteriology, it was 
impossible to compare the figures for one population across all of the eligible studies. A 
few studies required the sputum sample to be bacteriologically-positive to be included in 
the ITT or CE population. One study required a bacteriologically-positive sample for the 
patient to be eligible for the study and therefore 100% of patients in the ITT population 
were bacteriologically-positive. There were also 19 (23%) studies that required a 
bacteriologically-positive sample for the patient to be eligible for the CE population, and 
in these studies 100% of patients in the CE population were bacteriologically-positive. 
These studies which gave 100% bacteriologically-positive patients in the ITT or CE 
population have been excluded from all the following analyses of the rates of 
bacteriologically-positive patients (sputum samples), as these were selected populations, 
and the rates of bacteriologically-positive patients do not reflect the entry criteria that are 
being examined here. The range of the rates of bacteriologically-positive sputum samples 
in the ITT and CE populations are shown in Table 4-5. The 25th to 75th percentile in the 
ITT population was 28.7% - 64.7%, and was 28.2% - 60.4% in the CE population, 
demonstrating that there was a general wide spread of results and not just a few outliers.
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Table 4-5: Rates of bacteriologically-positive sputum samples
Population No. of Median Range 25th-75th
papers* Percentile
ITT 48 46.1% 13.9% to 96.0% 28.7% to 64.7%
CE 44 41.6% 15.6% to 85.6% 28.2% to 60.4%
* excludes papers that had 100% bacteriologically-positive patients, and those where no value was given.
4.6.3.2 Definition o f chronic bronchitis
The definition of chronic bronchitis of “the daily production of sputum for at least three 
consecutive months over two consecutive years” has generally been accepted as the 
“gold standard” definition of chronic bronchitis for around four decades. Despite this, 
not all clinical trials of chronic bronchitis patients adopted this definition. Of the 83 
papers, 59 (71%) used this standard definition of chronic bronchitis; 23 (28%) papers 
did not define their definition of chronic bronchitis; and just 1 (1%) paper used a 
different definition (history of recurrent productive cough).
Since many of the papers in which the definition of chronic bronchitis was not stated 
may have applied this standard definition, and only one paper specifically used a 
different definition, it is not possible to compare the rates of bacteriologically-positive 
sputum samples among studies that applied the standard definition with those that used a 
different definition. Among the papers that used the standard definition of chronic 
bronchitis, the rates of bacteriologically-positive sputum samples in the ITT populations 
ranged from 16.7% to 87.1% (33 studies; median 45.6%), and in the CE population 
ranged from 15.6% to 85.6% (33 studies; median 42.9%). There was therefore no 
evidence that the standard definition of chronic bronchitis significantly affected the rate 
of bacteriologically-positive patients. In the one paper that used the definition of 
recurrent productive cough, the bacteriologically-positive rate in the ITT population was 
34.0%, the bacteriology of the CE population was not analysed.
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4.6.3.3 Definition o f  an acute exacerbation
The definition of an acute exacerbation was assessed according to the Anthonisen 
classification [Anthonisen et al, 1987]. In 10 (12%) papers, patients were required to 
have a Type I exacerbation to be eligible for the study, and in 14 (17%) papers, patients 
were required to have a either a Type I or II exacerbation to be eligible for the study.
All the other studies had different criteria, although some only included minor 
variations.
The rates of bacteriologically-positive sputum samples in the 10 studies that specified 
only Type I exacerbations, ranged from 13.9% to 66.0% in the ITT population (5 
studies; median 45.6%), and from 26.2% to 67.2% in the CE population (7 studies; 
median 42.7%). In the 14 studies that allowed Type I or Type II exacerbations, the rates 
of bacteriologically-positive sputum samples in the ITT population ranged from 16.7% 
to 44.2% (12 studies; median 27.9%), and in the CE population, 15.6% to 44.2% (9 
studies; median 27.5%).
Among the other 59 studies, the rates of bacteriologically-positive sputum samples in 
the ITT population ranged from 20.0% to 96.0% (31 studies; median 57.6%), and in the 
CE population ranged from 16.0% to 85.6% (28 studies; median 56.5%), as shown in 
Table 4-6. Therefore, although there seemed to be a suggestion that Type I exacerbation 
tended to have higher rates of bacteriologically-positive sputum samples than Type II 
exacerbations, the studies that used other varied criteria appeared to have at least as 
good, if not better, rates of bacteriologically-positive sputum samples than Type I 
exacerbations. It is possible that although the Anthonisen Type I symptoms are a useful 
guide to a bacterial exacerbation; other medical history, disease criteria, and signs and 
symptoms are more significant in predicting a bacterial exacerbation.
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Table 4-6: Rates of bacteriologically-positive patients according to the definition
of an acute exacerbation
Total
papers
ITT population 
Median % Bact-pos 
range (n)
CE population 
Median % Bact-pos 
range (n)
Type I exacerbation 10 45.6% 13.9-66.0% (5) 42.7% 26.2-67.2% (7)
Type I or II exacerbation 14 27.9% 16.7-44.2% (12) 27.5% 15.6-44.2% (9)
Other studies 59 57.6% 20.0-96.0% (31) 56.5% 16.0 - 85.6% (28)
If macroscopically purulent sputum is taken as the major indicator of a bacterial 
exacerbation, 31 (37%) of the 83 studies applied this as a requirement for enrolment to 
the study, the remaining studies did not specify this as an entry requirement, although 
many of the patients would have had purulent sputum, so this is not a precise 
comparison. In the studies that required purulent sputum for entry, the percentage of 
patients in the ITT populations who were bacteriologically-positive (20 of the 31 studies 
gave details on the ITT population) ranged from 13.9% to 81.1%. The studies that did 
not require purulent sputum for entry, showed a similarly wide range of 
bacteriologically-positive ITT patients (19.7% to 87.1%) in 27 of the 52 studies that 
gave details on the ITT population.
4.6.3.4 Microbiological screening o f the sputum sample
A total o f20 (24%) studies had applied criteria for microscopic evaluation of the sputum 
samples (generally >25 WBCs and <10 SECs) that had to be met in order for the patient 
to be eligible for the study. The rates of bacteriologically-positive sputum samples in 
the ITT population in these studies ranged from 54.6% to 96.0% (7 studies; median 
67.3%), and in the CE population ranged from 24.5% to 85.1% (13 studies; median 
57.8%). The rates of bacteriologically-positive sputum samples in the remaining 63 
studies that did not apply microscopic screening of the sputum samples ranged from 
13.9% to 87.1% in the ITT population (41 studies; median 42.5%), and in the CE 
population ranged from 15.6% to 85.6% (31 studies; median 40.4%). These results are 
summarised in Table 4-7.
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Table 4-7: Rates of bacteriologically-positive patients according to
microbiological screening of sputum purulence.
No. of 
papers
WBC*
screen
SEC*
screen
Bact cells 
on Gram- 
stain
% Bact-pos 
ITT (median)
% Bact-pos 
CE (median)
Microbiological screening 
of sputum purulence
20 17 16 8 54.6 - 96.0% 
(67.3%)
24.5 - 85.1% 
(57.8%)
No microbiological 
screening of sputum 
purulence
63 13.9-87.1%
(42.5%)
15.6-85.6%
(40.4%)
WBC: white blood cells; SEC: squamous epithelial cells; * No. of papers using this criterion in the screening.
In the ITT populations, microbiological screening of the sputum appears to increase the 
lowest value of the range of bacteriologically-positive patients. However, this is 
difference is only marginal in the CE populations. The large difference in the lowest 
value of the range between the ITT and CE populations in the studies that applied 
microscopic screening makes this finding uncertain.
In addition, it appeared that in 28 studies (34%) some degree of microscopic screening 
of the sputum was performed to qualify the sputum for culture, this was generally >25 
WBCs and <10 SECs, but sometimes only one of these two criteria was applied.
4.6.3.5 Species o f bacteria that were recognised as pathogens
Across all the studies there was a large variation in the species of bacteria that were 
classed and reported as pathogens. Three papers did not specify any of the organisms 
isolated, leaving 80 papers from which the following results were obtained. Only H. 
influenzae was isolated and reported as a pathogen in every study. S. pneumoniae was 
isolated and reported in 77 (96%) studies and M. catarrhalis was isolated and reported 
in 75 (90%) studies. A few studies seemed to isolate several S. pneumoniae but no M. 
catarrhalis, and a few studies appeared to find the reverse. As both of these pathogens 
are frequently isolated from patients with AECB, this appears to be an unusual finding.
Other pathogens were more difficult to interpret as it was only possible to know if an 
organism had been accepted as a pathogen if it was reported. It was therefore generally 
not possible to know whether a particular organism had not been isolated, or had been
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isolated and was not classified as a pathogen. Staphylococcus aureus was reported in 61 
(76%) studies; H  parainjluemae was reported in 49 (61%) studies; Enterobacteriaceae 
were reported in 45 (56%) studies; P. aeruginosa was reported in 36 (45%) studies; and 
“other”, often unspecified, organisms were reported in 50 studies. Resistant isolates 
were excluded from the results or from the microbiologically-evaluable (ME) population 
(CE population that had a pathogen isolated at baseline) in 12 (15%) studies.
Enterobacteriaceae was a well-reported group of organisms, either by individual species 
(e.g. E. coli, K. pneumoniae etc.) of collectively termed coliforms or enterobacteria. 
Enterobacteriaceae have been recorded as occurring in the lungs of AECB patients, 
particularly those with advanced disease. There is a body of opinion that believes that 
these are almost always colonisers [Hirschmann, 2000], and another that believes that 
they can commonly be the cause of exacerbations [Eller et al, 1998; Miravitlles et al, 
1999]. The rates of bacteriologically-positive sputum samples in the studies that 
included Enterobacteriaceae as pathogens, in the ITT population ranged from 16.7% to 
96.0% (26 studies; median 43.4%), and in the CE population, ranged from 15.6% to 
85.1% (21 studies; median 31.5%). Rates in studies that did not include 
Enterobacteriaceae as pathogens, in the ITT population ranged from 13.9% to 87.1% (21 
studies; median 49.4%), and in the CE population ranged from 16.0% to 85.6% (21 
studies; median 44.8%).
4.6.3.6 Date o f the study
From 1997, studies increased in size quite dramatically, possibly as a result of the 
International Conference on Harmonisation Good Clinical Practice (ICH-GCP). ICH- 
GCP is an international ethical and scientific quality standard for designing, conducting, 
recording and reporting trials that involve human participants. The guidelines were 
developed in order to provide clinical trials with a unified standard across the European 
Union, Japan and the United States and were labelled ICH-GCP at the International 
Conference on Harmonisation, 1996. Almost all studies from 1997 onwards involved 
populations of at least 350 patients. Only 16 of the 54 (30%) studies published in 1997 
or later had less than 350 patients, and 24 (44%) studies had more than 500 patients. 
Prior to 1997, only 12 of the 29 (41%) studies involved populations larger than 200
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patients; and only 7/29 (24%) had 350 or more patients. In addition, 20 of the 22 papers 
that were excluded on the grounds of involving of less than 100 patients were published 
pre-1997.
The rates of bacteriologically-positive sputum samples in the 29 pre-1997 studies, 
ranged from 13.9% to 96.0% in the ITT population (14 studies; median 60.2%), and 
from 16.0% to 85.1% in the CE population (8 studies; median 38.2%). In this time 
period, 13 of the 29 (45%) studies required a pathogen to be isolated for a patient to be 
clinically evaluable, and therefore these studies gave 100% bacteriologically-positive in 
the CE population. In some of these studies, therefore, there was a large difference in 
size between the ITT population and the CE population; the largest difference observed 
was in a study with 802 ITT patients, of which only 182 (23%) patients were clinically 
evaluable. Although not all of these patients would have been clinically non-evaluable 
for the reason of “non-isolation of a pathogen”, this was always the major reason that 
patients were clinically non-evaluable.
The rates of bacteriologically-positive sputum samples in the 54 studies from 1997 
onwards, ranged from 16.7% to 87.1 % in the ITT population (34 studies; median 
45.4%), and from 15.6% to 85.6% in the CE population (36 studies; median 41.6%). In 
this time period, only 6 of the 54 (11%) studies required a pathogen to be isolated for a 
patient to be clinically evaluable, and therefore these studies gave 100% 
bacteriologically-positive in the CE population.
4.6.3.7 Analysis o f the studies with >60% bacteriologically-positive patients
Table 4-8 summarises the 21 studies, dating from 1992 to 2000, which had rates of 
bacteriologically-positive patients of greater than 60%, either from the ITT or CE 
populations. The level of 60 % was chosen because it is significantly above the median 
value of 46.1% ITT and 41.6% CE, and yet is low enough to include at least 20 studies.
These 21 studies were reporting on the activity of a range of antibacterial agents that 
were being developed in the 1990s, many of which were quinolones. Eleven of these 
studies applied the standard definition of chronic bronchitis, while the other 10 studies
Page 50 of 213
did not give a definition of chronic bronchitis. Most studies used a lower age limit of 18 
years, however younger and older lower age limits were also used. In only 2 studies 
were patients required to have a Type I exacerbation according to the Anthonisen 
criteria. There was microscopic screening of sputum purulence prior to entry to the 
study (i.e. only patients with microscopically purulent sputum were allowed to enter the 
study) in 10 of the 21 (48%) studies. This is a higher proportion than for the overall 
database, in which 24% studies specified microscopic screening of the sputum prior to 
entry. Most studies reported a wide range of pathogens, however one study reported 
only 3 species (H. influenzae, S. pneumoniae, and M catarrhalis) [O’Doherty et al, 
1998], and one study reported only 2 species (H. influenzae, and M. catarrhalis) [Perez- 
Gonzalvo et al, 1996].
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4.7 Final Review of the Literature
A review was performed of the literature from March 2004 to July 2008, so that more 
recent randomised, controlled trials of antibacterial agents in AECB could be 
examined and compared with the finding of the original systematic review.
This further review identified 12 papers dating from December 2004 to February 
2007. No eligible study published more recently than February 2007 was identified.
Of these 12 papers [see Section 10.3], one was found to have been included in the 
original systematic review, one was found to be not eligible on the basis of 
insufficient bacteriological data, and one paper was a follow-up paper from a previous 
publication which had been included in the original systematic review. The remaining 
nine papers were reviewed using the same data form as previously.
4.7.1 Results
There were no major differences in these nine papers that would affect the results and 
conclusions of the systematic review.
A couple of trends in the more recent papers were however noted:
• The lower age limit in six of these nine papers (67%) was 30 years or above (1 
x 30yr; 2 x 35yr; 2 x 40yr; and 1 x 45yr). This older age limit in two-thirds of 
studies compares with only 18% of the studies (15/83) in the original review.
• All nine papers (100%) specified Anthonisen criteria for the exacerbation; this 
compares with only 24 studies (29%) in the original review. Four of these 
nine studies (44%) specified a Type I or Type II exacerbation, compared with 
14 studies (17%) in the original review. Five of the nine studies (56%) 
specified Type I exacerbation only, compared with 10 studies (12%) in the 
original review.
• All nine papers (100%) specified that microscopic purulence of each sputum 
sample (defined as >25 leucocytes (or WBCs or PMNs) and <10 squamous 
epithelial cells) was examined. Most specified that only sputum samples that
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met this criterion would be cultured, other were less clear about this point. In 
the original review, descriptions of microscopic screening were often unclear, 
however it appeared that 28 studies (34%) performed some sort of microscopic 
screening of the sputum before culture.
With regard to the main objective of the proportion of bacteriologically-positive 
sputum samples, there was an almost equally wide range of values in these nine 
studies as there was in the original 83 studies. The nine recent studies showed a range 
of bacteriologically-positive sputum samples from 18% to 63% (median 31.2%): this 
compares with a range from 14% to 96% (median 46.1%) in the original review. The 
implication of these findings is that we are not getting any better at identifying 
patients with bacterial exacerbations of chronic bronchitis.
4.8 Summary and Conclusions
This systematic review was set up to document in a consistent manner, the variation in 
the rates of bacteriologically-positive patients in randomised, controlled clinical trials 
of antibacterial agents in patients with AECB. The results of these studies from 1966 
to present, demonstrate some interesting points.
The vast majority of clinical trials published between 1966 and 1989 inclusive, were 
not eligible for this systematic review. The major reasons for this were study 
populations of less than 100 patients, and either no bacteriology, or insufficient detail 
of the bacteriology performed. Consequently 81 of the 83 eligible papers were 
published between 1990 and 2004.
This systematic review has confirmed that in studies of antibacterial agents in 
randomised controlled clinical trials in AECB patients, there is a large variation in the 
proportion of patients that have a bacterial pathogen isolated from their sputum at 
study entry. The signs and symptoms of an acute exacerbation that are used as entry 
criteria vaiy considerably between studies; however, there is no evidence that any 
particular combination of signs and symptoms are linked with a bacterial 
exacerbation, this is likely to be patient specific. The only factor that appeared to
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affect the proportion of patients that had a bacterial pathogen isolated from their 
sputum at study entry (bacteriologically-positive) was the microscopic screening of a 
sputum sample of potential patients, prior to entry into the study. Patients were then 
only allowed to enter the study if their sputum sample “passed” this screening. This 
screening takes time to perform and the patient is not able to enter the study and start 
medication until the results of this screening are available. This adds an extra 
complication to a clinical trial, particularly one conducted in general practice, and it is 
therefore, not surprising that many clinical trials do not use microbiological screening 
of sputum purulence. However, several studies (particularly more recent studies) 
apply this criterion to the evaluability of the sputum sample for culture in accordance 
with FDA guidance [FDA, 1998] In addition, even in studies where microbiological 
screening of sputum purulence has been applied, it does not appear to guarantee a 
high rate of bacteriologically-positive patients. The review of nine more recent papers 
dating from December 2004 to February 2007 suggests that despite a greater adoption 
of Anthonisen Type I (and Type II) exacerbations as entry criteria, and microscopic 
screening of all sputum samples for eligibility for culture, there has been no 
improvement in the proportion of patients enrolled in these studies who have 
respiratory pathogens isolated from their sputum at baseline, and who can therefore be 
classed as having a bacteriologically-proven exacerbation.
This review has confirmed how difficult it is to distinguish between exacerbations 
caused by bacteria and those caused by other agents, and that there has been no 
improvement over the last 40 years, in our ability to identify patients with bacterial 
exacerbations.
Page 55 of 213
5 A MULTICENTRE INVESTIGATION INTO THE BEST 
INDICATOR OF BACTERIAL INFECTION IN PATIENTS 
WITH ACUTE EXACERBATION OF CHRONIC 
BRONCHITIS
5.1 Introduction
The generally accepted description of chronic bronchitis was defined by the American 
Thoracic Society in 1962 [Am Thorac Soc, 1962], although it had been attempted a 
few years earlier by a group in London who had defined it as ‘the production of 
phlegm on most days for at least three months in each year’ [Fletcher et al, 1959]. 
Almost 50 years later, the description of sputum production for at least three months 
of the years and for at least two successive years remains the most frequently used 
definition of this complex disease. As previously described, exacerbations of CB may 
occur due to a number of factors that include exposure to airborne irritants, or as a 
result of infection by bacteria, or viruses. It has been proposed that at least 50% of 
exacerbations are caused by bacteria [Fagon et al, 1990; Miravitlles et al, 1999; Sethi, 
2000,], however many clinical trials of antibacterial drugs in patients with AECB, fail 
to achieve this percentage of patients who have respiratory pathogens cultured from 
their sputum.
Such studies aim to select patients who have an acute bacterial exacerbation, although 
there appears to be no simple and reliable method of distinguishing between 
exacerbations caused by bacteria and those caused by other agents. This lack of 
clarity as to the nature of exacerbations, may contribute to the fact that the criteria 
used for selecting AECB patients for entry into clinical trials of antibacterial drugs are 
not consistent, and the proportion of bacteriologically-positive patients in such clinical 
trials shows considerable variation. The proportion of patients in studies of AECB 
over the last 10 years, who have a bacterial pathogen isolated from a baseline sputum 
sample can vary between 17% [Wilson et al, 2002] and 87% [DeAbate et al, 1999]. 
Although it has been suggested that a sputum sample which contains few epithelial 
cells, abundant neutrophils and a predominant morphological type of bacteria, can 
indicate a bacterial exacerbation [Murray & Washington, 1975; Chodosh, 1991], and 
that applying this criterion for entry into a clinical trial may increase the likelihood of
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enrolling patients with bacterial exacerbations, only a minority of trials have used this 
procedure as part of the entry criteria.
Anthonisen and co-workers [Anthonisen et al, 1987] demonstrated a 20% difference 
in success rates between antibiotic and placebo-treated patients when the patients had 
increased dyspnoea, sputum volume and sputum purulence. Exacerbations with fewer 
symptoms showed less difference between antibiotic and placebo, possibly indicating 
that these were not bacterial exacerbations. It is unfortunate that sputum 
microbiology was not performed in this study as this could have added weight to the 
argument for the use of an antibiotic in these categories of patients. It was concluded 
by Staley and co-workers [Staley et al, 1993] that in view of these results future 
studies with an active control group should be designed to include only patients in 
whom exacerbations are likely to have a bacterial cause. It was claimed that the 
characteristics of increased cough and/or dyspnoea and increased sputum volume and 
purulence are associated with bacterial infection [Periti et al, 1990; Rademaker et al, 
1990], however, many recent studies have produced a disappointing percentage of 
bacteriologically-proven infections, 19% [Zervos et al, 2003], 26% [Wilson et al, 
2004] and 27% [Starakis et al, 2004] even when these criteria were applied. 
Alternatively, in studies where only culture-positive patients are eligible for the 
clinically evaluable (CE) population, then entry criteria attempt to optimise the 
proportion of patients that will have a pathogen isolated from the sputum; 
nevertheless, because patients are almost always enrolled on the basis of clinical signs 
and symptoms and not based on any bacteriological factors (e.g. microscopically- 
purulent sputum, bacterial cells seen on a Gram-stained sputum preparation) around 
50% of the enrolled patients may fail to be eligible for the CE analysis [Shah et al, 
1999; Chodosh et al, 2000]. This makes for very inefficient clinical studies, in which 
many (non-evaluable) patients do not contribute substantially to the efficacy 
conclusions, or in which the conclusions may have been based on a population where 
only a small proportion of patients have proven bacterial exacerbations, and where the 
effects of any one antibacterial agent are diluted by the substantial proportion of 
patients who did not have a bacterial exacerbation and for whom antibacterial therapy 
would have no beneficial effect.
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This clinical study aimed to examine several aspects of the chronic bronchitis patients 
who develop an exacerbation and would be entered into clinical trials of antibacterial 
drugs, to see if patients who have a Type I exacerbation (worsening of sputum 
volume, sputum purulence and dyspnoea), were more likely to have a bacterial 
pathogen than those who had a Type II exacerbation (any two of these signs and 
symptoms). Additional factors were also to be examined to see if a better 
understanding of patients with a bacterial exacerbation could be formed. These 
factors were: microscopic purulence (>25 neutrophils/<10 epithelial cells per low 
power field) and Gram staining of the sputum to identify the presence of bacterial 
cells by their shape and Gram-staining properties (Gram-positive or Gram-negative). 
The study also examined the implications of a 24 hour delay in getting a sputum 
sample to the laboratory, as occurs when a central laboratory is used for culture and 
testing of the samples. Patients often report that they cough up the most purulent 
sputum soon after rising in the morning, therefore the study also looked at the 
isolation rates of potential pathogens in sputum samples produced soon after rising, 
with those produced later in the day. In addition, there had been recent research 
which reported a progression of bacterial species from S. pneumoniae and H. 
influenzae through coliforms (or other Enterobacteriaceae), to P. aeruginosa, as the 
severity of the COPD progressed [Eller et al, 1998; Miravitlles et al, 1999], and the 
time since the previous exacerbation for which an antibiotic was prescribed, compared 
with the bacterial species that were isolated was investigated.
5.2 Objectives
5.2.1 Primary Objective
This prospective study aimed to examine how effective various criteria are in 
indicating bacterial infection in patients with AECB. The criteria to be examined 
were:
a. Anthonisen Type I clinical signs and symptoms (increased sputum purulence; 
increased sputum volume; increased dyspnoea), or Anthonisen Type II clinical 
signs and symptoms (any 2 of the above signs and symptoms).
b. The combination of >25 neutrophils and <10 epithelial cells per x l00 field.
Page 58 of 213
c. The presence of a morphological bacterial cell type in a Gram stained 
preparation of sputum, of greater than 1 cell per oil immersion field.
5.2.2 Secondary Objectives
The study also examined:
1. The implications of a 24 hour delay in getting a sputum sample to the 
laboratory.
2. The isolation rates of potential pathogens in sputum samples produced soon 
after rising, with those produced later in the day.
3. Any association between isolation of a bacterial species and the time since the 
previous exacerbation will be examined.
5.3 Study Design
This was a multicentre, epidemiological study of chronic bronchitis patients 
presenting with signs and symptoms of an acute exacerbation to six GP sites and one 
hospital site in Scotland, and was conducted according to the study protocol dated 5 
February 1999 (Appendix 9.3). The signs and symptoms of infection; the neutrophils 
and epithelial cells in the sputum; and the Gram stain results were compared with the 
results of the sputum culture in order to identify the best indicator of bacterial 
infection.
The original study was set up with four GPs in Edinburgh area, however, as interest in 
the study among Edinburgh GPs was disappointing it was decided to involve a large 
medical centre in Coatbridge and to set up the microbiology laboratory at Monklands 
Hospital in nearby Airdrie as the second central laboratory. In addition, Monklands 
Hospital itself became an investigative site and patients who were being admitted for 
AECB were screened for the study. Over a year later, when recruitment had stopped 
altogether in Edinburgh and Coatbridge, it was decided to involve a few Glasgow GP 
practices that had a proven track record in recruiting AECB patients into clinical
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studies. To service these GP practices, the Southern General Hospital was set up as 
the third central laboratory. These changes were documented in protocol amendment 
1, dated 4 August 2001 (Appendix 9.3).
5.3.1 Entry Criteria
As this was an epidemiological study, no exclusion criteria based on safety factors 
were applicable although investigators were advised that patients with significant 
bronchiectasis should not be enrolled. Patients were not allowed to enter the study 
more than once.
Inclusion criteria
1. Adult patients with evidence of chronic bronchitis as defined by: chronic 
cough and sputum production on most days over a period of 3 months for at 
least 2 consecutive years.
2. Patients with at least two of the following symptoms: increased sputum 
purulence; increased sputum volume; increased dyspnoea.
3. Patients who were able to produce a sputum sample at the visit (alternatively, 
the patient could take a sputum pot away and return a sample the following 
morning, provided that no antibiotic treatment had been started).
4. Patients who had not yet received an antibiotic for this exacerbation.
5. Patients who had consented to the study.
5.3.2 Study Sites, Laboratories and Methodology
The study was performed at six general practice surgeries and at one hospital in 
Scotland (Glasgow, Edinburgh and Coatbridge/Airdrie). Sputum samples were taken 
from the GP surgeries to one of three accredited hospital laboratories in Scotland 
either by a regular van service or by taxi. Each investigator completed a short case
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report form for each patient (Appendix 9.4), recording: date of the visit, basic details 
of demography, smoking history, date of the last chest infection for which an 
antibiotic was given, date and time of production of the sputum sample, and extent of 
pre-infection and current dyspnoea, sputum volume and sputum purulence.
The laboratories also completed a short report form (Appendix 9.4) for each sputum 
sample, reporting: macroscopic appearance of the specimen, microscopic purulence (> 
or <25WBCs and < or >10 squamous epithelial cells per xlOO field) and the presence 
and quantity of morphological bacterial cell types from a Gram-stained preparation; 
interpreted as: +++ = >25 cells; ++ = 10-25 cells; + = <10 cells. Part of the specimen 
was then cultured immediately and any organism grown at >103 colony forming 
units/mL was identified. The species classed as pathogens when found in these 
numbers were: H. influenzae; H  parainfluenzae, S. pneumoniae, M. catarrhalis,
S. aureus, P. aeruginosa, Enterobacteriaceae and any other species that the laboratory 
would normally report from a sputum sample. The remaining part of the specimen 
was left at room temperature for 24 hours and then cultured, so that the results could 
be compared with those of the immediate culture. This procedure of delayed culture 
was designed to simulate transport of a sputum sample to a central laboratory with 
delivery within 24 hours.
Antibacterial therapy was not part of this study and therefore participating 
investigators decided separately whether or not each patient required antibacterial 
treatment, and what follow up was required. This data was not collected as part of the 
study. Investigators were informed of the results of the sputum culture and any 
susceptibility testing that the laboratory routinely performed in order to assist with the 
patient management.
5.3.3 Ethical Aspects
Local ethics committee approval was obtained for all participating sites and the 
submissions and dates of approval are shown in Table 5-1
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Table 5-1: Ethics committee submissions and dates of approvals
Ethics committee submission Date of approval
Protocol
Lothian Heath LREC 01 April 1999
Lanarkshire Health Board LREC 25 November 1999
Protocol plus Amendment
Lothian Heath LREC 13 November 2001
Lanarkshire Health Board LREC 16 October 2001*
Greater Glasgow LREC 19 September 2001
Greater Glasgow LREC (change to stated lab) 17 April 2002
Greater Glasgow LREC (additional sites) 18 September 2002
* submission, approval with investigator
5.3.5.1 Patient information and informed consent
All patients were given a patient information sheet that explained the study. Patients 
were encouraged to discuss any concerns with the doctor. If the patient had any 
doubts about taking part in the study, they were not entered.
All patients who agreed to take part in the study were asked to sign the consent form. 
No patient was allowed to enter the study unless they had signed and dated the 
consent form. A copy of the patient information and the consent form are included in 
the appendices to the study protocol (Appendix 9.3).
5.3.3.2 Confidentiality
All data recorded on the CRF and entered onto the study database was anonymous. 
Patients were assigned a unique patient number when they consented to the study, and 
this was the only identification of the patients' data on the CRF or in the database. If 
any clarification was required between two or more patients, then the dates of birth 
were used.
5.3.3.3 Approval o f the study protocol and amendments
The study protocol was approved by the following people:
Carol Burley project leader
Dr R.G. Masterton project supervisor
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David Shaw statistician
It was agreed that any amendments to the protocol which did not involve patient 
numbers or the statistical plan could be approved by the project leader and the project 
supervisor only. Further statistical advice could be sought from any qualified 
statistician working in pharmaceutical research.
5.3.4 Monitoring
A selection of CRFs was monitored by Carol Burley (CB) as planned, to assess the 
accuracy of the data. Monitoring took place at the majority of sites and covered the 
clinical and microbiological aspects of the data. All monitoring was performed in a 
confidential manner and no record of the patients' names was made. Any errors in the 
data identified at the monitoring visits were corrected in the CRF and (if applicable) 
in the database.
5.3.5 Amendments to the Study Design
One protocol amendment was required during this study; the justifications for this 
amendment are given below and the changes to the protocol are detailed here and in 
the Study Procedures (Section 5.4).
Primary Justification
The original study was planned to only take place in Edinburgh with Lothian general 
practitioners. Because of the lack of response in several centres and the need to get 
the 120 samples completed as quickly as possible, it was decided to extend the study 
to a wider area of Scotland.
Secondary Justifications
It became clear that it would only be possible to monitor a selection of the patient 
notes, rather than all of them. It was then necessary to make this clearer in the 
protocol and in the patient information and consent form.
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The funding for this project, in the form of an educational grant, was clarified as being 
received from Hoechst Marion Roussel (Aventis), as CB was no longer working for 
that company.
The changes of address and telephone number for CB and Dr Masterton were 
detailed.
Confirmation of Scientific and Ethical Content
None of the changes in the protocol amendment were thought to affect the scientific 
content of the study as the laboratories at Monklands Hospital and Southern General 
Hospital, Glasgow agreed to process the sputum samples as laid out in the protocol. 
The changes did not compromise patient treatment or confidentiality in any way.
5.4 Study Procedures
5.4.1 Overview of Data Collection
Data for this study were collected on individual case report forms (CRFs) provided to 
each investigator and to the laboratory. A CRF was completed for each eligible 
patient who consented to take part in the study. Any patient who failed to produce a 
sputum sample before any antibiotic treatment was started was not eligible for the 
project.
Data for this study therefore came from two sources: the investigator completed the 
first section of the CRF (clinical data) at the time of the patient visit, and the 
laboratory completed section two of the CRF (laboratory results).
A copy of the laboratory culture results with routine antibiotic susceptibility results, 
where an organism was isolated, was sent to the investigator by post. The laboratory 
request form to be completed by the investigator for study sputum samples was 
identified by means of an adhesive label. This label was added in order to alert the 
laboratory that the sample should be processed according to the protocol and the 
results recorded on a study CRF.
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5.4.1.1 Clinical data
The following data was collected by the investigator in the CRF provided for each 
patient:
• date of visit
• entry criteria
• confirmation of patient consent
• assignment of unique patient number
• basic patient demography
• date of last exacerbation (for which an antibiotic was prescribed)
•  time and date of sputum sample
• rating of symptoms of dyspnoea, sputum volume and sputum purulence:
-  prior to this infection (pre-infection)
-  currently
5.4.1.2 Laboratory data
All sputum samples were transferred to the local hospital laboratory and processing 
commenced within 6 hours. The instructions for processing, to be applied to all three 
central laboratories are outlined below:
On arrival at the laboratory, samples were logged and any queries about the 
patient number resolved. The sample was split into two aliquots of equal 
purulence, using sterile forceps.
Aliquot 1 had the following tests/examinations performed:
i. Assessment of purulence of the sample by appearance:
Clear, non-viscous 
Grey/white, viscous
non-sputum sample 
mucoid 
mucopurulent 
purulent
Up to 50% yellow-green 
>50% yellow-green
ii. Low power microscopy of cells (total magnification x 100): 
epithelial cells: <10 per field / >10 per field 
neutrophils: >25 per field / <25 per field
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iii. Gram stain and quantitative assessment of bacterial cell types:
No. Bacterial Cells
1-9 per oil immersion field 
10-25 per oil immersion field 
>25 per oil immersion field
Recorded as:
+
+++
iv. Culture of purulent section of sputum for identification of pathogen with a 
semi-quantitative interpretation using a dilution technique (see Appendix V of 
protocol, in Appendix 9.3)
Aliquot 2 was left at room temperature for 24 hours to simulate transport of a 
sputum sample to a central laboratory by overnight courier. After 24 hours a 
purulent section of the sputum was cultured as point iv. above.
All results were recorded in the laboratory CRF.
5.5 Data Handling and Statistical Procedures
5.5.1 Sample Size Justification and Statistical Analysis
All patients entered into this study had either a Type I exacerbation (a worsening of 
sputum volume, sputum purulence and dyspnoea) or a Type II exacerbation (a 
worsening of any two of these symptoms) of chronic bronchitis. The primary 
outcome was to examine whether Type I exacerbations (all 3 symptoms) were 
associated with a higher proportion of bacteriologically-positive (culture-positive) 
patients, than Type II exacerbations (2 symptoms). The assumptions made in order to 
calculate the study sample size were:
CFU/mL 
103 - 104 
10s -.10®  
> 106
Interpretation
Light growth 
Moderate growth 
Heavy growth
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• 50% of patients would have a Type I exacerbation and 50% would have a 
Type II exacerbation.
• 35% of patients with a Type II exacerbation would be culture-positive
It was calculated that a total of 112 patients would provide 85% power of detecting a 
25% increase in patients with a Type I exacerbation (i.e. 60% culture-positive) using a 
Chi-squared test at the 5% level. To allow for a small number of unevaluable patients 
(e.g. sputum samples lost or broken, report forms not completed, etc.) 120 patients 
were recruited.
Data on all patients with a Type I or Type II exacerbation and for whom a clinical and 
laboratory CRF were completed adequately were entered into the analysis. This was 
the only population for analysis. The positive culture rate between the Type I 
exacerbation patient group and the Type II exacerbation patient group was planned to 
be compared using a Chi-squared test at the 5% level. The sensitivity and specificity, 
and positive and negative predictive values were calculated and tabulated for 
comparison.
5.5.2 Changes to the Planned Statistical Tests
On review of the numbers of patients in the result categories of the primary outcome, 
it was decided that that the Chi-squared test was not the most appropriate test for these 
data because of the value of seven (patients) in the Type II exacerbation, culture- 
negative group. Initially, a Chi-squared with Yates’ correction test was performed, 
however it was a later agreed that the Fisher’s exact test would be the most suitable 
test. A Fisher’s exact test was therefore performed on all the primary outcome 
factors. Further discussion on the choice of statistical test and the differences in the 
results between these tests of significance can be found in Section 6, Statistical 
Methods.
During submission for publication in the Journal of Infection, the reviewers requested 
that likelihood ratios were also presented. The results of this statistical test are also 
presented here.
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5.6 Results
Ethics Committee approval for the first set of sites in the Edinburgh area was obtained 
on 1 April 1999. The first patient was consented into the study on 16 November 1999 
and the last patient consented into the study was on 6 February 2003.
5.6.1 Study Population
Overall, 120 patients were enrolled into this study. In 12 patients the investigator 
CRF was not received and in 7 patients the laboratory CRF was not completed, 
leaving 101 patients in which both sets of information were received. Of these 101 
patients, four were enrolled with only one Anthonisen symptom and were not eligible 
for the analysis. A total of 97 patients were therefore included in the analyses. The 
demographics, relevant history, and sputum appearance of the 97 eligible patients are 
presented in Table 5-2.
There were more females than males recruited into the study (57.7% vs 42.3%), 
which seems contrary to the incidence of chronic bronchitis in the general population. 
However, the age range of males and females were very similar, and although any 
adult patient (aged 18 years or above) could enter this study, the youngest patient 
entered was 39 years; the oldest patient enrolled was 90 years old. The older 
character of this population can be seen by the fact that the mean age was close to 65 
years. Overall, there were 48 patients under the age of 65 years, and 49 patients aged 
65 years or over.
As expected, the vast majority of patients were either current smokers or ex-smokers 
(not smoked for >6 months), with only 11.3% of patients reported as non-smokers 
(never smoked). Information on passive smoking at home or at work was not 
collected. The date of the most recent acute infective exacerbation that the patient had 
suffered was also recorded (i.e. the last acute exacerbation for which an antibiotic was 
prescribed). Over half of the patients had suffered an acute exacerbation within the 3 
months prior to the current exacerbation; however, almost 20% of patients had not 
had an exacerbation in the 10 months prior to the current exacerbation. Over two-
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thirds of patients were reported to have a worsening of all three cardinal symptoms 
(sputum purulence, sputum volume, and dyspnoea).
Sputum samples were examined macroscopically by the local laboratory, and 
recorded as purulent, mucopurulent, mucoid, or non-sputum sample. Approximately 
70% of sputum samples were reported to be of purulent or mucopurulent appearance. 
Assessment of microscopic purulence (>25 white blood cells and <10 squamous 
epithelial cells) was also performed by the laboratory. Sputum samples were evenly 
split between purulent (49.5%) and non-purulent (50.5%). The local laboratory was 
also asked to record the morphological cell types and seen on the Gram stain. Over 
90% of sputum samples had bacteria seen on the Gram-stained preparation, and in 
only 7 specimens were no bacteria observed.
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Table 5-2: Patient demographics, history and sputum details (N=97)
Patient status n %
Sex
Male 41 42.3
Female 56 57.7
Smoking History
Current smoker 45 46.4
Ex-smoker 41 42.3
Non-smoker 11 11.3
Last LRTI
<1 mth ago 24 27.9
1-3 mth ago 26 30.2
4-6 mth ago 17 19.8
7-9 mth ago 3 3.4
10-12 mth ago 9 10.5
>12 mth ago 7 8.1
Missing 11
Anthonisen Cardinal Symptoms
All 3 symptoms 68 70.1
Any 2 symptoms 29 29.9
Sputum: macroscopic appearance1
Purulent 31 32.3
Mucopurulent 36 37.5
Mucoid 26 27.1
Non-sputum sample 3 3.1
Missing 1
Sputum: microscopic purulence2
Purulent 48 49.5
Non-purulent 49 50.5
Gram stain morphology
Organisms seen 90 93.1
None seen 7 6.9
Age Mean Range
Males 65.8 39-90
Females 62.9 42-86
All 64.1 39-90
L Assessed by the laboratory.
2 Purulent: >25 white blood cells and <10 squamous epithelial cells; non-purulent: <25 white blood 
cells or >10 squamous epithelial cells.
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5.6.2 Pathogens Isolated from Study Patients
In total, 58/97 (60%) sputum samples grew a pathogenic organism in adequate 
quantity (>10 cfu/mL) when cultured at the local laboratory; the remaining 39 (40%) 
sputum samples grew either insufficient organisms or only normal upper respiratoiy 
tract flora. The species of organisms grown in these 58 patients is shown in 
Table 5-3. A total of 68 organisms were grown from the 58 patients, 48 patients had 
infection with only one organism, and 10 patients were infected with two organisms. 
No patient was found to have more than two pathogenic organisms. H. influenzae 
was the predominant pathogen; present in 30 of the 58 sputum samples and 
accounting for 45% of all pathogens isolated. H. influenzae was the major organism 
among single pathogen infections and in the infections where two pathogens were 
isolated.
S. pneumoniae, M. catarrhalis and coliforms were found in similar numbers overall; 
however, M. catarrhalis and coliforms were mainly found as single pathogens, 
whereas the majority of S. pneumoniae were found in combination with other 
pathogens.
Table 5-3: Pathogens identified in the 58 patients that were culture-positive
Organism combinations isolated Number of occurrences 
(organisms)
%  of patients
H. influenzae 23 (23) 39.7
M. catarrhalis 7 (7) 12.1
S. pneumoniae 4 (4) 6.9
Coliforms 8 (8) 13.8
H. parainfluenzae 1 (1) 1.7
S. aureus 4 (4) 6.9
P. aeruginosa 1 (1) 1.7
H. influenzae + S. pneumoniae 5 (10) 8.6
H. influenzae + M. catarrhalis 1 (2) 1.7
H. influenzae + S. aureus 1 (2) 1.7
M. catarrhalis + S. pneumoniae 1 (2) 1.7
S. aureus + coliform 1 (2) 1.7
S. aureus + E. faecalis* 1 (2) 1.7
Number of patients with 2 pathogens 10
Number of patients (organisms) 58 (68) 100
* Enterococcus faecalis
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5.6.3 Primary Outcome: Analysis of the Indicators of Bacterial Infection
The primary objective of this study was to examine how effective three factors were 
in indicating bacterial infection in patients with AECB. These were:
• The presence of increased sputum purulence, increased sputum volume, and 
increased dyspnoea (Anthonisen Type I exacerbation), compared with the 
presence of any two of these symptoms (Anthonisen Type II exacerbation).
• The combination of >25 neutrophils and <10 epithelial cells per xlOO field 
(microscopic evaluation of purulence).
• The presence of a morphological bacterial cell type in a Gram stained preparation 
of sputum, of greater than 1 cell per oil immersion field.
Macroscopic purulence was also evaluated as a primary outcome measure although 
this was not specified in the protocol. The reason for this deviation was the 
publication of the paper of Stockey et al [2000] on sputum colour as an indicator of 
bacterial infection, which received significance acceptance.
5.6.3.1 Positive sputum culture according to Anthonisen Type I  or Type II  
exacerbations
Table 5-4 shows that of the 68 patients that had all three symptoms present (a Type I 
exacerbation), 36 (53%) had a pathogen isolated from their sputum (culture-positive), 
and 32 (47%) patients were culture negative. Among the patients that had two of the 
three symptoms (Type II exacerbation), 22 (76%) patients were culture-positive and 7 
(24%) patients were culture-negative. The figures would appear to suggest that 
patients are more likely to be culture-positive with only two of these three 
signs/symptoms present than with all three signs/symptoms present, and a Fisher’s 
exact test showed this result to be just significant at the 5% level (p=0.043). Although 
in many respects the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) are irrelevant the values are 62%, 18%, 57%, and 
24% respectively.
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Table 5-4: Culture results of the major indicators of bacterial infection (N=97)
Patient status n Culture-
positive
n(%)
Culture- 
negative 
n (%)
Fisher’s 
exact test
Symptoms
3-symptoms (Type I) 68 36 (52.9%) 32(47.1%) p = 0.043
2-symptoms (Type II) • 29 22 (75.9%) 7 (24.1%)
Macroscopic purulence*
Purulent 67 45 (67.2%) 22 (32.8%) p = 0.045
Non-purulent 29 13 (44.8%) 16 (55.2%)
Microscopic purulence
Purulent 48 35 (72.9%) 13 (27.1%) p = 0.013
Non-purulent 49 23 (46.9%) 26 (53.1%)
Gram stain: bacterial
cells
Seen 90 56 (62.2%) 34 (37.8%) p = 0.113
Not seen 7 2 (28.6%) 5 (71.4%)
* 1 sputum sample was not assessed for macroscopic purulence and was excluded from these 
macroscopic purulence results. The sample was culture-negative
5.6.3.2 Positive sputum culture according to microscopic and macroscopic sputum 
purulence
The macroscopic purulence of the sputum samples was assessed visually by the 
laboratory before any other tests were performed. A total of 67 sputum samples were 
reported as macroscopically purulent, of which 45 (67%) were culture-positive and 22 
(33%) were culture-negative. Twenty-nine samples were not macroscopically 
purulent, and of these 13 (45%) were culture-positive and 16 (55%) were culture- 
negative. One sputum sample was not assessed for macroscopic purulence, and this 
specimen was culture-negative. The Fisher’s exact test showed this result to be 
marginally significant (p = 0.045). The sensitivity of this simple screening was 
reasonably good (78%), but the specificity was poor (45%). The PPV was 67%, and 
the NPV was 55%. These values indicate that this would not be a particularly robust 
test.
Forty-eight sputum samples were found to be microscopically purulent; of these, 35 
(73%) samples were culture-positive and 13 (27%) samples were culture-negative 
(Table 5-4). Of the 49 sputum samples that were non-purulent, 23 (47%) samples
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were culture-positive and 26 (53%) samples were culture-negative. These results 
suggest that microscopically purulent sputum samples are more likely to be culture- 
positive; however among the non-purulent samples, almost half were culture positive. 
The Fisher’s exact test showed this result to be significant (p = 0.013); however the 
sensitivity and specificity, and PPV and NPV were insufficient for this test to be 
particularly useful in a clinical trial setting (sensitivity: 60%; specificity: 67%; PPV 
73%; NPV 53%).
An interesting comparison was that between the microscopic and the macroscopic 
purulence. As can be seen in Table 5-5, microscopic and macroscopic purulence were 
often not in agreement.
Table 5-5: Relationship between microscopic and macroscopic purulence in
culture-positive and culture-negative samples
Culture +ve 
n(%)
Culture -ve 
n (%)
Total
n
Macro-purulent + Micro-purulent 32 (71%) 13 (29%) 45
Macro-purulent not Micro-purulent 13 (59%) 9 (41%) 22
Micro-purulent not Macro-purulent 3(100%) 0 3
Neither 10* (37%) 17 (63%) 27
58 39 97
* These 10 patients’ samples grew 5 H.influenzae; 2 S.pneumoniae; 3 coliforms; and 1 S.aureus
Very few sputum samples were microscopically purulent but not macroscopically 
purulent, and all of the three samples that were, grew a pathogen (culture-positive). 
Excluding this very small group, the most definitive results were macroscopically and 
microscopically purulent, and culture-positive; and not macroscopically or 
microscopically purulent, and culture-negative.
The results of this study, found 45 of 67 (67%) visibly purulent sputum samples grew 
a recognised bacterial pathogen. However, 13 of 29 (45%) visibly non-purulent 
samples grew a bacterial pathogen (Table 5-6). The main three bacteria of AECB (H. 
influenzae, S. pneumoniae and M. catarrhalis), were predominantly isolated from 
visibly purulent sputum samples, nevertheless a significant proportion (mean: 22%) of
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the total were isolated from visibly non-purulent samples. Of the bacteria isolated in 
this study, M. catarrhalis was isolated only from visibly purulent sputum, whereas,
S. aureus was isolated from a greater proportion of visibly non-purulent than purulent 
sputum samples. On the results of this study, visibly (macroscopically) purulent 
sputum does not appear to be a particularly robust feature to distinguish bacterial from 
non-bacterial exacerbations.
Table 5-6: Examination of the pathogens isolated from macroscopically 
purulent and non-purulent sputum samples (N=96)
Bacterial species Purulent sputum 
(N=67) 
n %
Non-purulent sputum 
(N=29) 
n %
Total
H. influenzae 23 34.3 1 24.1 30
S. pneumoniae 8 11.9 2 6.9 10
M. catarrhalis 9 13.4 0 0 9
S. aureus 4 6.0 3 10.3 7
coliforms 6 9.0 3 10.3 9
others 3 4.5 0 0 3
Total pathogens 53 15 68
Total patients with 
a pathogen
45 67.2 13 44.8 58
Total patients with 
no pathogen
22 32.8 16 55.2 38
There were 67 macroscopically (visibly) purulent sputum samples, 29 non-purulent sputum samples 
and 1 sputum sample that was not assessed; this sample did not grow a pathogen.
5.6.3.3 Positive sputum culture according to bacterial cells seen on Gram-stain
Bacterial cells were seen on the Gram stain in the vast majority of sputum samples 
(90/97 samples, 93%). However, pathogens were isolated from only 56 (62%) of these 
90 samples; the remaining 34 (38%) samples were culture-negative i.e. no pathogen 
isolated (Table 5-4). Among the 7 sputum samples in which no bacterial cells were 
seen, 2 (29%) samples were culture-positive and 5 (71%) were culture-negative. A 
Fisher’s exact test shows this result to be not significant (p = 0.113). The two patients 
who had no bacterial cells types seen on the sputum using the non semi-quantitative 
Gram stain, but were culture-positive (Table 5-4), were found to have an organism (H. 
influenzae and S. aureus) that was only present as light growth. This finding might
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suggest that these were part of the orophargeal flora, or were colonisers in the lower 
respiratory tract rather than the cause of the acute exacerbation.
5.6.4 Analysis of the Effect of a 24-hour Delay in Culturing in the Organisms 
Isolated
In some clinical studies, sputum specimens are transported to central laboratories for 
analysis. This often means a delay of around 24 hours before culturing, and the 
specimens are often not refrigerated during transportation. The effect of this delay on 
the accuracy of the culture results was investigated. Table 5-7 shows the results of the 
24 hour culture, compared with the results of the immediate culture. Of the 39 
specimens that were negative on immediate culture, 38 were also negative at 24 hours, 
and the remaining 1 specimen grew a Pseudomonas (species unknown) at 24 hours.
Of the 58 specimens that were culture positive on immediate culture, 54 grew exactly 
the same organism(s) at 24 hours, and in 4 specimens the 24 hour culture was not 
performed.
5.6.5 Analysis of the Difference between Early Morning Sputum Samples 
and those Produced Later in the Day
Patients with CB often report that they produce the most purulent sputum soon after 
rising in the morning. It is therefore often believed that this is the best specimen from 
which to obtain bacteria. This study compared the culture results of specimens 
obtained at or before 9am with those produced later in the day. Table 5-7 presents the 
results of this comparison; the time of day of the specimen was available in 92/97 
patients. Thirty-four (37%) of the 92 specimens in which time of day was known 
were produced at 9am or earlier; of these 22 (65%) were culture-positive, and 12 
(35%) were culture negative. Fifty-eight (63%) specimens were produced after 09:00 
hours, of which 35 (60%) were culture-positive and 23 (40%) were culture-negative.
If the time cut-off is moved to 10am, the proportions of culture-positive and culture- 
negative specimens are almost identical. Only 4 sputum samples were produced at 
8am or earlier, so at this time point it is not feasible to assess with the data.
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Table 5-7: The effect of re-culturing after 24 hours at room temperature, and 
the influence of time of day of sputum sample on culture results.
Culture-positive Culture-negative 
n (%)___________ n (%)
Immediate vs 24 hr culture results
Immediate culture results 58 39
Re-culture results @ 2411T1
Culture-positive at immediate culture2 54 (93%) 0
Culture-negative at immediate culture2 1 (3%)3 38 (97%)
Time of day of sputum sample
< 9:00 am 22 (65%) 12 (35%)
> 9:00 am 35 (60%) 23 (40%)
Time of day not known 1 4
1    1 1 1
4 specimens did not have a 24 hour culture performed.
2 Percentage of the immediate culture result
3 Pseudomonas spp.
5.6.6 Analysis of the Relationship between Frequency of Exacerbations and 
Incidence of Bacterial Infection and the Species Isolated
Forty-two (72%) of the 58 culture-positive specimens were from patients who had 
their last exacerbation within die previous 6 months; only 11 (19%) culture-positive 
patients had their last exacerbation more than 6 months previously, and in 5 culture- 
positive patients the date of the previous exacerbation was not known. Table 5-8 
presents the pathogens that were grown from the sputum samples according to the 
time of the previous exacerbation. Because so few pathogens were grown from 
patients who had their last exacerbation more than 6 months ago, it is not possible to 
discern any trends from these data. H. influenzae was the most frequently isolated 
pathogen in every time period (time since the previous exacerbation); infection with 
more than one pathogen was the second most common infection, and of these H. 
influenzae was involved in the infection in 5/10 patients. In the patients that harboured 
Enterobacteriaceae, all had their last exacerbation within the previous 6 months, 
however with small numbers of patients that had their last exacerbation longer than 6 
months previously, it is not possible to put any great value on this finding.
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Table 5-8: Pathogens isolated from patients according to the time since their
last exacerbation.
No.
patients
Culture-pos
n(%)'
HIN MCA
No. of patients 
SPN Ent Others2 Mixed
culture
< 1 mth 24 13 (54%) 6 - 2 3 - 2
1-3 mth 26 17 (65%) 6 3 1 1 5 1
4-6 mth 17 12 (71%) 6 3 - 2 - 1
7-9 mth 3 1 (33%) - - - - - 1
10-12 mth 9 5 (56%) 2 1 - - 1 1
>12 mth 7 5 (71%) 2 - - - - 3
Not known 11 5 (45%) 1 - 1 2 - 1
Totals 97 58 23 7 4 8
HIN: H. influenzae. MCA: M. catarrhalis. SPN: S. pneumoniae. Ent: Enterobacteriaceae.
1. Percentage of the number of patients in that time period.
2. 1-3 mth: S. aureus — 3; H. parainfluenzae -  1; P. aeruginosa — 1. 10-12 mth: S. aureus — 1.
5.6.7 Examination of a Semi-Quantitative Approach to the Gram Stain
Since none of the planned analyses showed a sufficient difference which might be 
useful in predicting bacterial infection in AECB patients, a closer examination of the 
Gram stain results was undertaken. As presented earlier, 90 of the 97 (93%) patients 
had bacterial cells seen on the Gram stain, which did not prove to be very helpful. 
However, a more quantitative analysis of these results proved to be far more useful.
The results were assessed according to the laboratory Gram stain reports of <10 cells 
(+), 10-25 cells (++) or >25 cells (+++) of each morphological bacterial cell type seen 
per xlOOO field (e.g. Gram-positive cocci). The results of this examination took into 
account the number of morphological bacterial cell types seen, and the highest 
classification (numbers) of cells seen of any of the morphological cell types. The 
categories for this examination were:
a. 1 morphological cell type seen at >25 cells per field gave 8/8 (100%) culture- 
positive specimens
b. 1 morphological cell type seen at 10-25 cells per field gave 14/16 (88%) 
culture-positive specimens
c. >1 morphological cell type seen, at least one type present at >25 cells per field 
gave 17/19 (89%) culture-positive specimens
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d. >1 morphological cell type seen, at least one type present at a maximum of 10- 
25 cells per field gave 4/9 (44%) culture-positive specimens
e. 1 (or more) morphological cell type present, but at <10 cells per field gave 
13/38 (34%) culture-positive specimens.
f. No bacterial cells seen
The first three categories (a. b. and c.) outline culture-positive rates that were 
considerably higher than the overall culture-positive rate of 60%, and of those seen in 
any of the other sub-groups. The last three categories (d. e. and f.) outline culture- 
positive rates that were well below the overall culture-positive rate seen in this study. 
Figure 5-1 presents the results of this semi-quantitative analysis in graphical format.
Figure 5-1: The proportion of patients that were bacteriologically-positive 
against the quantity and number of different bacterial cell types 
seen on the Gram stain.
1 morphological >1 morph type, at 1 morphological >1 morph type, at 1 or more morph No cells seen 
type at +++ least 1 +++ type at ++ least 1 ++ type, + only (n=7)
(n=8) (n=19) (n=16) (n=9) (n=38)
Key: +++ = >25 cells/field; ++ = 10-25 cells/field; + = <10 cells/field.
There appeared to be a clear difference between the Gram stains that produce high 
proportions of bacteriologically-positive patients (black bars) and those that do not 
white bars). When these types of patients were grouped together the distinction could
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be seen more clearly (Table 5-9). In this table ‘semi-quantitative Gram stain: 
bacterial cells -  significant No. seen’, equals the total of the three black bars on the 
graph (categories a.-c.) and the ‘non-significant No. seen’ equals the total of the three 
white bars (categories d.-f.). The major factor here is that very few patients who had a 
significant number of bacterial cells seen on the Gram-stain were culture-negative.
Table 5-9: Culture results of the semi-quantitative approach to the Gram stain
Patient status Culture-positive
n(%)
Culture-negative Fisher’s exact test 
n(%)
Semi-quantitative Gram 
stain: bacterial cells
Significant No. seen 39 (90.7%) 4(9.3%) p = <0.0001
Non-significant. No. seen 19 (35.2%) 35 (64.8%)
58 39
Of the 19 sputum samples that produced a Gram stain that was classed as non­
significant under this semi-quantitative approach and which were culture-positive (see 
Table 5-9), five (26%) samples had only light growth of any organism grown; the 
remaining 14 (74%) sputum samples grew at least one organism that had moderate or 
heavy growth. In comparison, the 39 sputum samples where the Gram stain was 
classed as significant under this semi-quantitative approach and which were culture- 
positive (see Table 5-9), just two (5%) samples had light growth, these organisms 
were S. pneumoniae and Proteus spp.
Applying this method of a quantitative Gram stain whereby a single cell type present 
at >10 cells per (xlOOO) field, or more than one cell type present, but with at least one 
cell type present at >25 cells per field is predictive of a bacterial infection. A Fisher’s 
exact test showed this result to be highly significant (p = <0.0001), with a sensitivity 
of 67%, and a specificity of 90% (positive predictive value: 91%, negative predictive 
value 65%).
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5.7 Summary and Conclusions
This study was set up to examine a number of factors relating to acute exacerbations 
of chronic bronchitis in the context of patient entry criteria for antibacterial clinical 
trials in AECB. The main aim of the study was to seek to identify study entry criteria 
that would optimise the number of enrolled patients with bacteriologically-proven 
exacerbations, and thus the microbiologically-evaluable study populations. The 
achievement of this endpoint was set to enable the most cost-effective management of 
AECB clinical trials. Fifty-eight (60%) of the 97 evaluable patients in this study had 
a culture-positive sputum sample. This percentage of culture-positive samples was 
generally good, and was higher than the median value of 46% found in the systematic 
review.
The primary objective of this study was to investigate the hypothesis that patients with 
Type I exacerbations had a higher percentage of culture-positive sputum samples than 
patients with Type II exacerbations. The study failed to confirm this hypothesis and a 
Fisher’s exact test produced a borderline result which suggested that patients Type II 
exacerbations possibly had a higher chance of having a culture-positive sputum 
sample. This result is discussed fully in the Discussion (Section 8).
From a range of demographic, symptomatic and laboratory investigations, the only 
factor which emerged as highly significant in distinguishing culture-positive from 
culture-negative patients was the semi-quantitative Gram stain analysis. This 
technique may offer a useful method of accurately predicting bacterial infection, in 
around 90% of patients. However, the technique involves considerable laboratory 
expertise and co-operation in achieving a rapid turnaround of results prior to patient 
randomisation and hence may not be suitable for all clinical trial settings.
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6 STATISTICAL METHODS
6.1 Statistical Tests Applied in the Clinical Study
Data produced from a scientific study requires the application of statistical analysis in 
order that the conclusions of the study may be viewed with confidence. The specific 
tests that are selected must be appropriate to the particular type of data that has been 
collected, and the hypothesis that is to be tested.
In this study, the primary and secondary outcomes were categorical data as all the 
factors being examined were assessed as to whether the patient had a pathogen at 
baseline, or not {culture +ve, or culture -ve). The results of each of the primary 
endpoints (see Table 5-4) produced a 2 x 2 frequency table as shown in the example 
below:
Table 6-1: Format of primary endpoint for analysis
Culture +ve Culture -ve Total
Type I exacerbation 36 32 68
Type II exacerbation 22 7 29
Total 58 39 97
When planning this study, it appeared that the most appropriate statistical test for this 
type of data would be a Chi-squared test at the 5% level and this was stated in the 
statistical section of the study protocol [Appendix 9.3].
6.1.1 The Chi-squared Test
The Chi-squared analysis is used to compare two or more frequencies, to investigate 
the probability that their values depart from what would be expected by chance alone 
on the null hypothesis that their frequencies are the same. Interpretation of the Chi- 
squared value is based upon comparing the results seen in the experiment against 
results that could occur due to chance alone and using this to establish the statistical 
significance of the results. For frequency comparisons like those in this study,
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statistical significance shows the probability that the differences between observed 
and expected frequencies are due to chance factors assuming no difference i.e. the null 
hypothesis is true. To determine a critical value that might be termed statistically 
significant, an alpha level must be set. The alpha level is traditionally set at .05 
(although occasionally it may be set at .01).
There are a number of key assumptions in a Chi-squared test and these are: 
o Random sample data.
o A sufficiently large sample size: applying a Chi-squared test to small samples 
risks an unacceptable rate of Type II errors. There is no accepted minimum 
number however a number greater than 50 would generally be seen as 
acceptable.
o Adequate cell sizes: when this assumption is not met for integer data, Yates' 
correction is applied (see Section 6.1.2 on Yates’ correction), 
o Independence: observations must be independent. The same observation can 
only appear in one cell, 
o Non-directional hypotheses: the Chi-squared test tests the hypothesis that two 
variables are related only by chance, 
o Finite values: observations must be grouped in categories.
The major assumption made in the design of this study was that 50% of patients 
entered into the study would have a Type I exacerbation and 50% would have a Type 
II exacerbation. This assumption was not met and the proportions were 
approximately 70% to 30% respectively. This resulted in a small number of patients 
in the Type II exacerbation, culture-negative group. For this reason, a Chi-squared 
test with Yates’ correction was initially performed on the data.
6.1.2 Yates’ Correction
Yates' correction (named after the English statistician Frank Yates who published the 
correction in 1934), is a conservative adjustment to the Chi-squared test when applied 
to tables with one or more cells with frequencies less than five. It is only applied to 2 
x 2 frequency tables (1 degree of freedom). A certain amount of controversy
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surrounds the use of Yates’ Correction and some statisticians apply it to all 2 x 2 
tables since the correction gives a better approximation to the binomial distribution. 
Yates' correction is conservative in the sense that it makes it more difficult to establish 
significance and can tend to overcorrect. This can therefore lead to an overly 
conservative result that wrongly fails to reject the null hypothesis. However, in 
situations with large sample sizes, using the correction will have little effect on the 
value of the test statistic, and hence the p-value obtained.
6.1.3 Comparing the Results of Different Statistical Tests
Later discussions on the most appropriate test for the data resulted in a decision in 
favour of the Fisher’s exact test being performed on these data and this is the test that 
is presented in the study results in Section 5 of this thesis.
A comparison of these three different tests on the primary endpoint is displayed in 
Table 6-2. This shows that the Chi-squared test indicates that the difference in the 
culture-positive rates between patients with a Type I exacerbation and Type II 
exacerbation is statistically significant, whereas when the Yates’ correction is added 
this difference becomes non-significant. The Fisher’s exact test again indicates a 
statistically significant difference (p=0.043), however the result can still be viewed as 
borderline significance.
Table 6-2: Comparison of Chi-squared test, Chi-squared test with Yates’
correction, and Fisher’s exact test on the primary endpoint
Culture
+ve
Culture
-ve
Chi-squared 
(X2) test
X2 test with 
Yates’ 
correction
Fisher’s 
exact test
Type I exacerbation 36 32 4.44
p=0.035
3.54
p=0.059 p=0.043(sig.)Type II exacerbation 22 7 (sig.) (n.s.)
As previously mentioned the level of significance (alpha) is traditionally set at 0.05, 
however, this is only a generally accepted standard that allows 5% error. Any result 
must be assessed against the possibility that this could be a chance occurrence. If a 
more rigorous level of significance of 0.01 was imposed for all the primary endpoints
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of this study (see Table 5-4), none of the results would be significant. However the 
semi-quantitative Gram stain would remain highly significant.
6.2 Diagnostic Statistical Analyses
When confronted with a patient who complains of a particular set of symptoms, a 
doctor needs to make a diagnosis. The doctor will rely on the combination of signs 
and symptoms, and quite possibly one or more laboratory tests. In some cases, a 
diagnosis will depend almost solely on the result of a laboratory test. The results of a 
laboratory test may seem very straightforward e.g. pregnant or not-pregnant.
However, the majority of these tests do not have clear cut results -  even in a 
pregnancy test false negatives are not unknown. For most laboratory tests the results 
provide only a probability of the patient having or not having the disease being tested 
for. The consequence of this is that the doctor may have to decide how definitive this 
result is in his whole picture of the patient’s medical condition and whether further 
tests or procedures are necessary in order to make a firm diagnosis.
This study employed microbiology tests in addition to signs and symptoms in an 
attempt to predict bacterial infection in patients with chronic bronchitis who presented 
with an acute exacerbation. As previously explained, acute exacerbations of chronic 
bronchitis may be caused by infection with bacteria or viruses, or a reaction to an 
allergen such as pollution, smoke, or dust. The ability to distinguish reliably between 
these aetiologies would be extremely useful as it would mean that antibiotics could be 
targeted at the patients who have a bacterial aetiology and will benefit from antibiotic 
therapy. In this study, the aim was to be able to identify patients who had a high 
chance of having a bacterial cause of their AECB. In this way a clinical trial of 
antibacterial drugs would have a high proportion of patients who had pathogenic 
bacteria grown from their sputum, and would therefore be eligible for the 
microbiological analysis populations.
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6.2.1 Application of Diagnostic Statistical Tests
Laboratory tests are aimed at identifying the truth about whether a patient has a 
particular disease or not. In a broad sense this could be likened to a jury trying to 
establish the truth about whether an accused person is innocent or guilty. A jury may 
correctly find the accused guilty, or correctly find him innocent; alternatively, they 
may find him guilty when he is innocent, or find him innocent when he is guilty. In a 
laboratory test, these jury verdicts relate to correctly identifying disease or non­
disease; or diagnosing disease when the patient does not have the disease, or 
diagnosing that the patient is clear of the disease when they actually have it. 
Diagnostic statistical tests can apply numbers to the laboratory results in order to 
provide the likelihood of this result heing the correct result. There are a number of 
diagnostic statistical tests that can be applied and each one gives a specific piece of 
information about the laboratory result. Usually several diagnostic statistical tests will 
be performed to give a full picture of the relevance of a single laboratory test.
6.2.2 Sensitivity and Specificity
Sensitivity and specificity give the proportions of patients who are correctly identified 
as having, or not having the disease in question. Sensitivity is the measure of the 
percentage of patients with the condition in question who have a positive test result. 
Specificity is the measure of the percentage of patients without the disease who have a 
negative test result. That is:
• Sensitivity = how good the test is at detecting disease
• Specificity = how good the test is at identifying normal
Sensitivity and specificity are the most widely used statistics used to describe a 
diagnostic test. However, because it is not generally known whether or not the patient 
has the disease (which is why the test is being done), sensitivity and specificity do not 
provide the complete information that is required to interpret the test results.
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6.2.3 Positive and Negative Predictive Values
Positive and negative predictive values take the sensitivity and specificity and apply 
them in another way to in order to suggest the value of a positive or negative test 
result. The positive predictive value (PPV) of a test is the probability that the patient 
has the disease when restricted to those patients who test positive. The negative 
predictive value (NPV) of a test is the probability that the patient will not have the 
disease when restricted to all patients who test negative.
• PPV = how often a patient with a positive test has the disease
• NPV = how often a patient with a negative test does not have the disease.
The positive predictive value and negative predictive value should not be applied to a 
sample where the prevalence of the disease was artificially controlled. For example, 
the PPV or NPV is meaningless in a study where healthy and diseased patients were 
specifically enrolled in a one to one ratio.
6.3 The Effect of Prevalence
Prevalence describes how common a disease is in the general population at any point 
in time e.g. 3% of UK adults have diabetes mellitus. The prevalence of a disease or 
abnormality is therefore an important factor in interpreting the results of a diagnostic 
test. Sensitivity and specificity remain unaffected by the prevalence, but PPV and 
NPV are significantly affected. When the true prevalence of the disease or 
abnormality being tested for is unknown, it makes the calculation of PPV and NPV 
unreliable.
If a disease has a prevalence of 10% in a given population, and a particular laboratory 
test for the disease has a sensitivity and a specificity each of 95%, the positive 
predictive value of the test can be calculated using Bayes’ theorem.
The two mutually exclusive possibilities are that the person has disease or is normal. 
The ‘prior probability’ of having disease is 10% (0.1) and of being normal is 90% 
(0.9). If a person has the disease, the probability of having a positive test result is
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0.95. If a person is normal, the probability of having a positive test result is 0.05. 
These probabilities are obtained from the sensitivity and specificity values given 
above. If the sensitivity is 95%, then the false negative rate is 5%; and if the 
specificity is 95%, then the false positive rate is 5%. The joint probabilities are the 
products of multiplying the prior probability and the probability of a positive test 
result. The posterior (or final) probability for each of the two mutually exclusive 
states is obtained by dividing the joint probability value by the sum of the two joint 
probability values.
Prior probability
Probability of a 
positive test result
Joint probability
Posterior probability
Disease
0.1
0.95
0.1 x0.95 = a 
a/(a+b) =0.68
Normal
0.9
0.05
0.9 x 0.05 = b 
b/(a+b) =0.32
In this case, with a disease prevalence of 10%, a person with a positive test result has 
a 68% probability of having disease, and a 32% probability of being normal. 
However, in a population in which the disease prevalence is 0.1% (0.001), the 
calculations are as follows:
Prior probability
Probability of a 
positive test result
Joint probability
Posterior probability
Disease
0.001
0.95
0.001 x 0.95 = a 
a/(a+b) =0.019
Normal
0.999
0.05
0.999 x 0.05 = b 
b/(a+b) =0.981
PPV = sensitivity x prevalence
sensitivity x prevalence + (1 -  specificity) x (1 -  prevalence)
NPV= _____________ specificity x (1 -  prevalence)____________
(1 - sensitivity) x prevalence + specificity x (1 -  prevalence)
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In this situation, the interpretation has changed appreciably; a person with a positive 
test result has only a 1.9% probability of having disease and a 98.1% probability of 
being normal.
The prevalence of a disease in the population, therefore, has an important influence on 
the positive predictive value of a laboratory test. With increasing disease prevalence, 
the more likely it becomes that a person with a positive test result has the disease, and 
the less likely it becomes that a positive result is a false positive.
6.4 Application of Diagnostic Testing in this Study
6.4.1 Patients with AECB
The overall prevalence of chronic bronchitis is difficult to assess as different studies 
have found different rates depending on the country, the age of the population studied 
and other factors [Cerveri et al, 2001; Huchon et al, 2002; von Hertzen et al, 2000]. 
However this study was not aimed at identifying chronic bronchitis, it was about 
identifying bacterial exacerbations in patients with chronic bronchitis. This adds two 
more factors into the equation: chronic bronchitis patients who have an exacerbation, 
and an exacerbation that is caused by a bacterial infection.
Patients who have chronic bronchitis can be identified by their history cough and 
sputum production (daily production of sputum for 3 consecutive months over 2 
successive years). Also, an acute exacerbation is relatively easy to identify and is 
normally defined as a worsening of at least two of the following three symptoms: 
worsening cough, worsening sputum volume, and worsening sputum purulence. The 
problem arises in identifying the cause of the acute exacerbation, as this can be due to 
viral infection, bacterial infection, or pollution/noxious chemicals. Bacterial infection 
has been estimated to account for approximately 50% of acute exacerbations [Sethi, 
2000]. This prevalence of bacterial infection in acute exacerbations of chronic 
bronchitis makes the high sensitivity of the semi-quantitative analysis of a Gram 
stained sputum specimen more relevant. A patient with a positive result on the semi- 
quantitative analysis of the Gram-stained sputum specimen (sensitivity = 0.67,
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specificity = 0.9 in this study) would have an 87% chance (PPV) of having an acute 
bacterial exacerbation of chronic bronchitis, based on a prevalence of acute bacterial 
exacerbations of 50%, applying the formula given earlier in this section. The negative 
predictive value would be 73%.
6.5 Summary and Conclusions
Selection of the most appropriate statistical test to be applied in a research project is 
important. In this clinical study, the statistical test that was first proposed for the 
primary outcome was based on the assumption that there would be no number lower 
than 17 in the 2 x 2 frequency table. There were far fewer patients with Type II 
exacerbations than expected and the lowest number in the actual 2 x 2  table was 
seven. Although opinions vary, a Yates’ corrected Chi-squared appeared to be 
suitable, and this suggested that there was no difference between Type I and Type II 
exacerbations with regard to the proportion of patients who would produce a culture- 
positive sputum sample. Further discussion indicated that the Fisher’s exact test 
would be the optimum test for this data. The Fisher’s exact test suggested that the 
difference in culture-positive rates between Type I and Type II exacerbations was 
significant, but remained borderline. It is recognised that Yates’ correction tends to 
overcorrect (and in this case resulted in a significant result) and therefore it is not 
surprising that the Fisher’s exact test changed the borderline non-significant result 
into significance. Overall, the main conclusion has to be that the results are 
borderline. The results could reflect a real difference, but then again, they might not. 
Furthermore, it is possible that the difference being observed (Type I or Type II 
exacerbation) is not the difference that is causing the difference in culture-positive 
rates; this could be something totally different or a combination of factors that happen 
to have come together in a higher proportion of patients with a Type II exacerbation 
than those with a Type I exacerbation.
The patients who were eligible for the study were not a random sample of the 
population, they were patients with a documented history of chronic bronchitis, and 
they had presented to the doctor with signs and symptoms of an acute exacerbation. 
The only question regarding these patients was whether this acute exacerbation was
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caused by a bacterial infection or not. However, this is exactly the population that 
should be tested and not a random sample of the population. Therefore, the 
proportion of acute exacerbations of chronic bronchitis that have a bacterial aetiology, 
reported as being around 50% [Sethi, 2000] is a realistic prevalence to apply to the 
results obtained in this clinical trial.
Calculation of the positive and negative predictive values to these results applying the 
rate of prevalence of 0.5 (50%) gave a positive predictive value of 0.87 (87%), and a 
negative predictive value of 0.73 (73%). These vary from the PPV and NPV given in 
Section 5.6.7 because of the rate of prevalence applied. In the clinical study, the PPV 
and NPV were calculated on the basis of the results obtained in the study. However in 
the study, the prevalence i.e. the rate of culture-positive patients, was 60% (Section 
5.6.2). Using the study prevalence of 60%, the PPV was 0.91 and the NPV was 0.65; 
whereas, using the documented prevalence of 50%, the PPV was lower at 0.87 but the 
NPV was higher at 0.73. Whichever prevalence is applied, this technique of semi- 
quantitative analysis of a Gram stained sputum samples for bacterial cell types 
appears to have a good PPV and an acceptable NPV.
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7 FUTURE RESEARCH IN IDENTIFYING BACTERIAL 
EXACERBATIONS OF CHRONIC BRONCHITIS
This study has not given a definitive answer to the initial question posed and further 
research is warranted in this important area. Distinguishing bacterial infection from 
viral infection or from non-infectious causes in exacerbations of chronic bronchitis 
has not been a key area of research in the last 10 years. Although the term chronic 
bronchitis has appeared in the literature relatively rarely since the turn of the century, 
research remains active in COPD. During the early part of the clinical study in this 
thesis, Professor Stockley’s team in Birmingham were examining the association of 
certain characteristics of purulent sputum and bacterial exacerbations. This is a very 
simple test that can match the colour of the expectorated sputum to the chances of the 
exacerbation being bacterial in nature [Stockley et al, 2000]. The majority of the 
current research in COPD is centred on the inflammatory process in COPD and the 
inflammatory markers, through which the progression of the disease may be 
monitored; however, the role of some of this work could prove useful in identifying 
bacterial infection if it is found that the presence (or abundance) of certain 
inflammatory markers are associated with bacterial infection. White et al [2003], 
identified that resolution of bronchial inflammation following AECB is related to 
bacterial eradication, and patients in whom bacteria continue to be cultured in their 
sputum have partial resolution of inflammation which may reflect continued 
stimulation by the remaining bacteria. This link between inflammation and bacteria 
should provide a marker for bacterial exacerbations, but to date no clear and reliable 
biomarker has come to light. Nevertheless, there are some promising candidates for 
predicting bacterial infection, and all of these require further research.
7.1 Sputum colour
As explained in the Introduction, purulent sputum has long been associated with 
bacterial infection. Stockley et al suggested that it should be possible to separate the 
presence of bacteria as commensals in the airway from those causing an infection 
[Stockley et al, 2000], they proposed that an active infection would be accompanied
\
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by activation of secondary host defenses, which include increased neutrophil 
recruitment to the airways. This neutrophil influx should result in a change in 
secretions from mucoid to purulent (because the enzyme myeloperoxidase in the 
neutrophils is greenish in colour). This process would then reverse once the bacterial 
load had been reduced or eliminated following antibiotic therapy. The results showed 
a positive association between green or yellow-green sputum and bacterial infection. 
This is a quick and simple indicator of bacterial infection, as it can be applied using a 
colour chart along with a sputum sample. Nevertheless, this approach is not perfect; 
the sensitivity was good at 94.4%, but the specificity was only 77%. This level of 
specificity means that almost a quarter of patients who do not have green sputum will 
have significant numbers of bacteria in their sputum.
In another study [Allegra et al, 2005], not only was purulent sputum colour associated 
with bacterial infection, but additionally deeper colours of sputum were associated 
with increased yield of Gram-negatives including P. aeruginosa and 
Enterobacteriaceae. The results of the bacterial species cultured from mucoid and 
purulent sputum, and from patients with an FEVj of 35-50% and those with an FEVi 
of <35% of predicted is interesting, although hardly conclusive. Increasing sputum 
purulence colour from whiteish, through yellowish, greenish, and brownish, showed a 
percentage of no significant bacterial growth (<106 cfu/mL) of 22%, 2%, 8%, and 
24%, suggesting that patients with the least purulent and the most purulent sputum 
samples had the lowest frequency of bacterial infection. In the study of Allegra et al 
the sensitivity and specificity were not given, however it could be assumed that the 
specificity of purulent-coloured sputum samples would not be high, because of the 
relatively high level of no significant bacterial growth (24%) in patients with the 
highest level of sputum purulence (brownish).
The results of my clinical study (Section 5) indicated that although more respiratory 
pathogens were isolated from visibly purulent sputum than non-purulent sputum (53 
pathogens from 67 specimens versus 15 pathogens from 29 specimens). The 
sensitivity was adequate at 78%, however the specificity (45%) was not particularly 
good as 13 of the 29 visibly non-purulent sputum samples grew a respiratory 
pathogen.
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The complication of identifying bacterial infection is that in patients with moderate to 
severe chronic bronchitis there is often colonisation of the lungs, so that there are 
bacteria permanently present in the lungs. Consequently, an effective indicator of 
bacterial infection has to be able to distinguish between colonisation and active 
bacterial infection. In addition, the effect of a viral infection on sputum colour 
remains unclear. Therefore whether this is an effective indicator of bacterial infection 
or just infection, has not been proven conclusively. This concept is therefore 
deserving of further research and validation.
The level of C-reactive protein (CRP) was also examined in the study of Stockley et 
al, 2000. It was found that CRP was higher overall in patients with purulent sputum 
than those with non-purulent sputum and therefore appeared to be linked with 
bacterial exacerbations. CRP is often used in hospital as an indicator of infection, 
particularly in pneumonia where there is a more profound systemic response. 
However, other authors have found CRP to be an unreliable measure of bacterial 
infection in AECB [Dev et al, 1998].
7.2 Changes in FEVj/FVC
The values of FEVj and FVC as a measure of lung function are regularly assessed in 
chronic bronchitis patients. A sudden deterioration in FEVi and/or FVC is a sign of 
an exacerbation; however not necessarily a bacterial or even infectious exacerbation. 
Therefore, such a sudden deterioration in FEVi and FVC cannot, in isolation, indicate 
a bacterial exacerbation. However, in combination with other changes in a patient’s 
condition such as a change to the production of purulent sputum, it can help to support 
a diagnosis of a bacterial exacerbation. Van der Valk et al concluded from their study 
that patients presenting with an exacerbation who have a negative result of a sputum 
Gram stain, do not have a clinically relevant decrease in lung function, and who have 
experienced less than 2 exacerbations of COPD in the previous year do not require 
antibiotic treatment [van der Valk et al, 2004].
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7.3 Leucocyte Esterase in Sputum
Leucocyte esterase (LE) is most familiar as one of the tests on a urine dipstick and 
will indicate urinary infection. This test shows the presence of polymorphonuclear 
neutrophils (PMNs) in urine through the detection of LE enzyme activity. Perhaps 
because of its simplicity and speed of result, the LE test has been evaluated in ascitic 
fluid [Butani et al, 2004] and effusion fluid in otitis media [Lebovics et al, 1993]. In 
relation to infections of the lung, the test has been assessed in the diagnosis of 
infectious pleural effusions [Azoulay et al, 2000], in spontaneous bacterial empyema 
[Castellote et al, 2005], and in bronchoalveolar lavage fluid as a potential screening 
for ventilator-associated pneumonia [Jacobs et al, 2000]. These studies have reported 
variable levels of reliability of the LE test.
A study published in 2004 reported results of a study to test the usefulness of the 
reagent strip for examining sputum samples, not to identify infection, but to determine 
sputum quality; to differentiate between specimens from the lower respiratory tract 
(LRT) and those from the upper respiratory tract [Gal-Oz et al, 2004]. The results of 
this study found that the specific gravity test was a sensitive test for the evaluation of 
sputum quality. Surprisingly, the LE test was found to be ineffective for the purpose 
of evaluating sputum. The authors suggested that enzymes such as amylase, 
glycoproteins, mucins, immunoglobulins, lyzozymes, and other proteins that are 
found in saliva may cross-react with die LE reagent.
7.4 Procalcitonin
Procalcitonin is a small (13 kilodaltons) protein that is normally undetectable in 
plasma. Procalcitonin increases markedly in bacterial infections, especially those 
associated with sepsis; however, it does not appear to be increased by inflammation 
that is autoimmune or due solely to viral infection [Martinez, 2007].
In 2003, Polzin and colleagues examined the value of procalcitonin as an indicator of 
bacterial infection in respiratory tract infections including hospital-acquired 
pneumonia, community-acquired pneumonia and acute exacerbation of chronic
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bronchitis. Significantly elevated procalcitonin levels were found in patients with 
LRT infections compared with the control group, but these levels were below the 
recommended cut-off level of 0.5 ng/mL. Therefore, in regard to the currently 
recommended cut-off level, procalcitonin was not found to be a useful parameter in 
the diagnosis of LRT infections [Polzin et al, 2003].
In a recent publication, Stolz et al report their study of procalcitonin-guided antibiotic 
therapy in exacerbations of COPD [Stolz et al, 2007]. The results showed that using 
procalcitonin levels to guide the requirement for antibiotics (cut-off >0.25 ng/mL), 
reduced the exposure of patients to antibiotics. They also found that over the 
following 6 months there was no increased antimicrobial usage. However, they found 
that there was no correlation between procalcitonin levels and sputum bacteriology, 
but as no molecular genotyping was performed, they could not determine whether a 
high procalcitonin was associated with new bacterial strains. Similarly, it was found 
that procalcitonin was not effective in identifying bacterial from non-bacterial 
infection in acute otitis media [Echols et al, 2008].
7.5 Serum Amyloid A
The most recent biomarker to be investigated in acute exacerbations of COPD is 
serum amyloid A (SAA). SAA is an acute phase protein secreted from the liver, 
which is induced by inflammatory mediators including interleukin-6 (IL-6), 
interleukin-1 p (IL-lp), and tumour-necrosis factor-a (TNF-a). An investigation by 
Bozinovski et al set out to assess SAA as a biomarker for acute exacerbations of 
COPD [Bozinovski et al, 2008]. They found that SAA was associated with infection, 
but it could not effectively distinguish between bacterial and viral infections. The 
group also examined the other inflammatory markers C-reactive protein (CRP), IL-6, 
and procalcitonin, but found IL-6 and procalcitonin to be uninformative. The study 
concluded that SAA was more sensitive than CRP alone or in combination with 
dyspnoea.
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7.6 A Proposal for Future Research
All of the above biomarkers of infection attempt to identify the patient’s immune 
response to the bacterial challenge. However, an individual’s response to infection is 
not always predictable. A lowered immune response can be caused by other medical 
conditions, drugs such as steroids, and advanced age; this results in markers such as 
these not responding to indicate infection. It is well recognised for example that 
elderly patients who develop pneumonia sometimes do not have a fever and do not 
display a rise in white cell count or CRP.
As identified previously, in AECB and AECOPD the situation is complicated by the 
fact that many patients have bacteria colonising their lungs. Because of this, it is 
often difficult to know the significance of bacteria that are found in a sputum sample; 
these could be the bacteria of an active bacterial infection, or they could be a sample 
of the colonising bacteria and the exacerbation is actually viral in origin. It has also 
been noted that a viral infection that causes an exacerbation might lead to a secondary 
bacterial infection. Overall, the picture is extremely complicated and often very 
difficult to interpret in individual cases.
The clinical study detailed in Section 5, concludes that a semi-quantitative Gram stain 
is the best indicator of bacterial infection. This method relies on higher numbers of 
bacteria present on the Gram stain indicating infection. Higher numbers of bacteria 
present, particularly of one species, is certainly suggestive of abacterial infection and 
this seems to be the best indicator of a bacterial exacerbation that we currently have.
A major hurdle seems to be how to distinguish between colonising bacteria and those 
that are causing an infection. It may be that the bacteria themselves could give away 
their activity and that this is where the breakthrough might come in identifying 
bacterial exacerbations. Colonising bacteria are relatively sessile, their numbers are 
kept steady, the rate of reproduction is low, and overall the bacterial cell metabolism 
is comparatively slow. In comparison, bacteria causing an infection are in active 
growth phase, their numbers will be increasing, the rate of reproduction is high, and 
they will have a rapid metabolism. If a test can be found that will accurately identify 
rapidly growing bacteria, this would be the best indicator of active infection. One
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possible chemical that could be used to assess bacterial metabolism is bacterial ATP. 
There are existing tests to detect bacterial ATP; however, a methodology would have 
to be determined which could separate colonising (sessile) bacteria from those causing 
an infection. There are likely to be other bacterial products of metabolism which 
could also be used to identify rapidly growing pathogenic bacteria.
7.7 Summary and Conclusions
The link between sputum colour, FEVi, and bacterial infection is a complex one. 
Purulent sputum, as indicated by sputum colour, appears to be a simple and 
reasonably effective indicator of bacterial infection, and more work in this area is 
warranted in order to quantify more accurately, the sensitivity and specificity of this 
indicator in large numbers of patients in a multicentre study. It is however, 
noteworthy that in both the Stockley et al and the Allegra et al studies [Stockley et al, 
2000; Allegra et al, 2005], a proportion of patients with mucoid sputum had 
significant growth of such pathogens as H. influenzae and M. catarrhalis, and 
therefore it appears that caution should be used in applying this technique too strictly. 
In the clinical study described in this thesis, the association between sputum colour 
(visibly purulent or not) and bacteriologically-positive sputum samples was present, 
but was relatively weak, and other indicators were more strongly associated with 
bacteriologically-positive sputum.
Further research in this area should examine sputum colour in a large, multicentre 
population of chronic bronchitis or COPD patients, with a full statistical calculation of 
the number of patients required to statistically prove the value to be measured. This 
research should start with stable chronic bronchitis patients and then follow them 
through an exacerbation and back to the stable condition. Sputum samples would be 
collected in the initial stable state, a few times during an exacerbation, and then again 
on at least two occasions when the patient has recovered from the exacerbation and is 
in the stable state again. Research into measures of lung function such as FEVi and 
FVC may be useful when combined with other biomarkers, but there is currently little 
benefit in further research into this area alone in respect of identifying indicators of 
bacterial exacerbations of chronic bronchitis.
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The study of Gal-Oz et al [2004] into LE is interesting [Gal-Oz et al, 2004], as this 
was the marker that I was originally planning to examine, following the original 
research into signs and symptoms and Gram stain results. Section 3.3.1 details the 
reasons why this line of research was abandoned. My reasons for abandoning this 
planned research were based on practical grounds of GPs handling sputum samples in 
an uncontrolled environment, another problem was seen to be the identification of the 
best way to test thick sputum and whether it might need to be homogenised with some 
normal saline before testing. The paper of Gal-Oz suggests that had I continued with 
this research into the evaluation of LE test on sputum samples, it would not have 
provided helpful results. Further research of LE activity in raw sputum using reagent 
strips would appear to be fruitless.
Procalcitonin appears to have potential as a biomarker for bacterial infection, but there 
is still no conclusive evidence that this has good sensitivity and specificity. In 
addition, it is not certain what level of procalcitonin provides a high chance (>95%) 
that the exacerbation has a bacterial cause. This may be because of a wide variation 
between patients in the response of procalcitonin to bacterial infection. Research into 
SAA is still at an early stage. SAA appears to be associated with infection, but this 
may be viral only, bacterial only, or viral and bacterial. Bozinovski et al [2008] 
comment that it is currently not possible to detect SAA in sputum reliably, although 
the group will be attempting to develop methods to achieve this. An interesting result 
from this study was that procalcitonin was not found to be informative, possibly 
because procalcitonin levels might better reflect pneumonia than acute exacerbations 
of GOPD. Another possibility is that procalcitonin levels soar in sepsis, pneumonia 
often involves sepsis but acute exacerbations of COPD do not. Although SAA may 
prove to be useful in predicting the severity of an exacerbation and suggesting 
whether there is an infectious cause or not. In isolation, it currently does not appear to 
hold potential for indicating bacterial infection; however, there may be potential for 
SAA measured in sputum in combination with one or more other markers.
The results of my clinical project suggest that further research into a semi-quantitative 
Gram-stain approach, possibly in combination with macroscopic and/or microscopic
Page 99 of 213
purulence could be warranted. A population of patients who have an acute 
exacerbation of chronic bronchitis, even if they satisfy the Anthonisen Type I criteria 
are a varied group with regard to, in their non-exacerbation state: FEVi and FVC, 
volume of sputum produced, colour of sputum produced, degree of colonisation, 
organisms with which they are colonised, concomitant diseases etc. It is quite 
possible that each of these factors may affect how the semi-quantitative Gram-stain, 
and macroscopic and microscopic purulence should be interpreted. The ideal would 
be to know each CB patient’s baseline levels so that significant changes in status, 
particularly in the bacterial load or in the bacterial species (or strains) present, could 
be identified and then treated.
In conclusion, sputum colour as an indicator of bacterial infection has gathered much 
support since the paper of Stockley and colleagues [Stockley et al, 2000]. Sputum 
colour is certainly a quick, simple and non-invasive method of assessing the 
likelihood of bacterial infection and could be applied easily to clinical trials of 
antibacterial drugs. From the work of Stockley et al [2000], the sensitivity and 
specificity of sputum colour suggest that a positive sputum colour (purulent sputum) 
will indicate bacterial involvement; however, a negative sputum colour (mucoid 
sputum), does not totally rule out bacterial involvement. My own results on the 
macroscopic appearance of sputum showed similar results. Unless a better 
understanding of individuals’ baseline status is possible, it seems likely that no single 
biomarker in isolation will be able to identify the aetiology of an exacerbation of 
chronic bronchitis.
The future may lie in developing a simple combination of tests that will confirm that a 
patient is starting to have an acute exacerbation and indicate the causative agent. The 
method of testing may also be innovative involving testing saliva or exhaled breath. 
Alternatively, it may be possible to track each patient’s disease status in detail so that 
the changes in a specific patient, which indicate a bacterial infection in the lungs, but 
which would not suggest a bacterial infection in another patient, can be identified. 
Furthermore, if markers of bacterial metabolism can be quantified to separate 
colonising bacteria from pathogenic bacteria, and if this marker (or markers) could be 
incorporated into a simple, non-invasive test, this could be of great importance not
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only in the area of AECB and AECOPD, but also in several other diseases where the 
presence of bacteria alone is not enough to be able to diagnose infection. Diseases 
such as cystic fibrosis and bronchiectasis would certainly come into this category, but 
so too might certain skin and soft tissue infections.
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8 DISCUSSION AND OVERALL CONCLUSIONS
8.1 Acute Exacerbations of Chronic Bronchitis
As previously detailed, chronic bronchitis is a disease of mucus hypersecretion caused 
by an inflammatory response to an irritant or allergen. The predominant trigger in 
chronic bronchitis is cigarette smoke, however other industrial chemicals and 
pollutants can initiate and maintain this inflammatory response. The airways 
inflammation is thought mainly to be due to neutrophil recruitment and release of 
elastase in response to the trigger factors such as cigarette smoke [Riise et al, 1995]. 
Chronic bronchitis itself is a slowly progressive disease, however, the acute 
exacerbations that occur at intervals in chronic bronchitic patients tend to accelerate 
the progression of this disease [Donaldson et al, 2002; Spencer & Jones, 2003; Hurst 
et al, 2005; Martinez et al, 2006]. Studies of protected specimen brush technique in 
patients with stable chronic bronchitis (patients not undergoing an acute exacerbation) 
showed that a quarter of patients had bacteria (predominantly H. influenzae) 
colonising their lungs even when they were not suffering an exacerbation [Monzo et 
al, 1995]. Murphy and Sethi proposed the hypothesis of a ‘vicious cycle’ of bacterial 
colonisation leading to weakened host defences in the respiratory tract, which 
predisposes to bacterial infection which further weaken the host defences [Murphy & 
Sethi, 1992]. This theory had already been put forward for progression of 
bronchiectasis [Cole, 1989; Cole & Wilson, 1989] and it seemed that it could be 
relevant also in COPD (and chronic bronchitis).
Another comparison that might be made is with patients who have cystic fibrosis 
(CF). In this condition, the sufferers have bacteria colonising their lungs almost from 
birth, with the species of bacteria changing as the patient gets older. The change over 
time of bacterial species in CF bears many similarities to COPD, from Gram-positive 
species such as S. pneumoniae and S. aureus to the Gram-negative organisms H. 
influenzae and coliforms, eventually to P. aeruginosa, Stenotrophomonas maltophilia 
and Burkholdaria cepacia. In CF patients, adverse changes in sputum purulence and 
dyspnoea are assumed to be a bacterial infection, and the patient is treated with a 
course of antibiotics. In the diseases of bronchiectasis, COPD, and CF advances
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made in one of this trio of lung diseases should be investigated in the other two 
diseases.
The issue of bacterial colonisation of the LRT in patients with moderate to severe 
CB/COPD leads us to the major problem surrounding identification of an acute 
exacerbation caused by bacterial infection -  if a significant proportion of patients with 
chronic bronchitis permanently have bacteria in their respiratory tract, does isolation 
of bacteria in the sputum have any significance during an acute exacerbation? The 
answer to this question may lie in the number of colony forming units (cfu) per 
millilitre (mL) that are grown, or more simply a minimum number of bacterial cells of 
the same morphological type that can be seen in a Gram-stained sputum specimen, as 
examined in the clinical study in this report.
Wedzicha’s group in London [Seemungal et al, 2001; Wedzicha, 2004] studied the 
prevalence of respiratory viruses in acute exacerbations of COPD and in the stable 
state, and found that patients with moderate to severe COPD can have viruses present 
in their lungs during the stable state. However, this was not compared with the 
presence of bacteria in the stable state in these patients; nevertheless, it is likely that at 
least some of these patients were also colonised with bacteria. It has been reported 
that, when properly defined, 80% of AECB are likely to be infectious in origin, 
approximately 50% bacterial, and 30% viral (with or without a superimposed bacterial 
infection) [Sethi, 2000]. However other studies have shown that almost two-thirds of 
exacerbations of COPD follow on from a symptomatic cold and that respiratory 
viruses may therefore be responsible for in excess of 50% of exacerbations 
[Seemungal et al, 2001]. These overlapping percentages could suggest more than a 
simple bacterial or viral infection in a significant number of patients with AECB or 
AECOPD.
Many exacerbations of CB/COPD (particularly in patients with underlying moderate 
to severe disease), could therefore be of a more complex aetiology than has been 
previously suggested. It seems likely that in some patients a severe exacerbation may 
be a combination of viral and bacterial infection. From the evidence that patients with 
moderate to severe COPD can have viruses present in their lungs during the stable
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state, it is probable that these patients are colonised with one or more species of virus 
[Seemungal et al, 2001], and it is likely that many of these patients are also colonised 
with bacteria. Although most studies have focussed on either bacterial infections or 
viral infections in exacerbations of CB or COPD, a recent study which tested for 
bacteria and viruses in sputum samples found that a quarter of all patients with an 
acute exacerbation appeared to be co-infected [Papi et al, 2006]. The implications of 
these findings may be wide-reaching and could require a review of the management of 
CB and COPD patients. The role of atypical pathogens, such as Mycoplasma 
pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in exacerbations 
of CB or COPD however, is unclear [MacNee, 2008].
It is therefore possible that any disruption to the equilibrium in the LRT could allow 
both a viral and bacterial infection either in parallel, possibly in different areas of the 
LRT, or sequentially. Such exacerbations would be severe, would invoke a profound 
inflammatory response, and could be difficult to treat. This type of co-existing 
bacterial and viral infection could account for some of the clinical failures of 
antibiotic therapy, when the isolated species of bacteria shows susceptibility to the 
antibiotic. The full picture in such patients might be that the bacterial infection was 
successfully treated but the viral infection was still present and still causing clinical 
signs and symptoms of infection.
8.2 Review of the Objectives of this Research
This research project was inspired by my personal dismay in the late 1990s, that many 
clinical trials of antibiotics in patients with acute exacerbation of chronic bronchitis 
have so few bacteriologically-proven infections (patients who have a pathogen 
isolated at baseline). It seemed to me that this was unacceptable on several levels:
• As the primary efficacy outcome is almost always clinical response at the test 
of cure (TOC) visit, if less than half of the patients had a proven bacterial 
exacerbation, then it is possible that in more than half of the patients who were 
clinical cures at TOC, the cure is unrelated to the antibiotic therapy.
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• If the above occurs, then any benefit that one antibiotic has over another will 
be impossible to demonstrate by clinical response (but might be possible by 
examining bacterial eradication rates); in every clinical population for analysis 
the patients with non-bacterial exacerbations would be diluting the difference 
in effect between the two (or more) treatment arms. It is therefore possible to 
see how even a comparison of an antibiotic against a placebo could show very 
little difference between the clinical response rates in the two treatment 
groups.
• In terms of the clinical trial and in the wider general prescribing, many 
patients with an acute exacerbation of CB will receive antibiotics who will not 
benefit from them and might possibly be harmed by receiving them. These 
patients could suffer side effects from the antibiotic or could later discover that 
their treatment had lead to the development of an antibiotic-resistant strain of 
bacteria in their lungs, or they could develop Clostridium <##?cz/e-associated 
diarrhoea, particularly if  they had been treated in hospital.
• An antibiotic has the power to kill bacteria and that is what it should be tested 
for. This is relatively easy in a petri dish, but somewhat more difficult in the 
human body. As previously discussed, chronic bronchitis is a complex 
inflammatory disease and the periodic acute exacerbations are similarly 
complex. Therefore, the only fair test of an antibiotic is in a patient who has a 
bacterial infection. An antibiotic is not an anti-inflammatory, anti-viral, 
bronchodilator, decongestant, mucolytic, or antitussive and so it cannot be 
assessed in patients who have a non-bacterial cause of their AECB.
In order to demonstrate the effect on clinical success rates, of only 30% of clinical 
trial patients having a bacterial exacerbation of CB (or COPD), we can consider the 
following example:
In a 500 patient study of two antibiotics, one antibiotic (Drug A) has a success rate of 
95% in acute bacterial exacerbations of chronic bronchitis (ABECB), and the other 
(Drug B) has a success rate of 85%. If all the patients have ABECB, then the 
difference between the two antibiotic treatments should be approximately 10%.
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However, the effect on the clinical success rates if only 30% of patients in the study 
have a bacterial exacerbation is dramatic and is shown in Figure 8-1.
Figure 8-1: Diagram of the effect of only 30% patients having a bacterial 
exacerbation on a 10% difference between antibiotics
Drug A
250 patients
75 Bact +ve 
^95% success
Clin Success: 71 pat. 
Clin Failure: 4 pat.
175 Bact-ve
i small proportion of failures
Clin Success: 173 pat. 
Clin Failure: 2 pat.
DrugB
250 patients
75 Bact +ve 
85% success
I'
Clin Success: 64 pat. 
Clin Failure: 11 pat.
175 Bact-ve
i small proportion of failures
Clin Success: 173 pat. 
Clin Failure: 2 pat.
Overall Clin Success: 244 (97.6%) Overall Clin Success: 237 (94.8%)
Overall Clin Failure: 6 (2.4%) Overall Clin Failure: 13 (5.2%)
In this scenario, a theoretical 10% difference in success rate was reduced to 2.8%. 
Consequently, any study designed to demonstrate 10% superiority, or even 5% 
superiority, would be doomed to fail. The reason for this is that the 70% of patients 
who do not have a bacterial infection have exactly the same chance of clinical success 
regardless of the drug to which they are randomised.
In this way, it is not surprising that in comparative studies of two antibacterial 
therapies in AECB or AECOPD, little difference in clinical success rates between 
drugs is observed, and equivalence of the two drugs is all that can be achieved. In 
addition, the standard time to perform the assessment that is used for the primary 
results (the Test of Cure [TOC] visit) is approximately 2 weeks after the end of 
therapy, or 3-4 weeks after the onset of the exacerbation; this happens to coincide 
with the time that an exacerbation caused by viruses or environmental triggers might 
be expected to resolve spontaneously. It is for this reason that the majority of patients 
with non-bacterial exacerbations will have an outcome of cure at the TOC visit. This 
factor almost certainly complicates the results of clinical trials of antibiotics in 
patients with AECB.
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This project was therefore designed to explore aspects of AECB that could be used to 
increase the proportion of patients in clinical trials of antibiotics in AECB that have a 
bacterial pathogen isolated at baseline from a sputum sample. The study of 
Anthonisen and co-workers [Anthonisen et al, 1987] is recognised as landmark study 
in trials of AECB/COPD patients [Miravitlles & Torres, 2004]. However, the 
Anthonisen study did not include microbiology and therefore the suggestion that Type 
I (and to a lesser extent Type II) exacerbations are bacterial in aetiology was not fully 
evidence-based. I could not identify any publications that had subsequently compared 
the proportion of patients with a Type I exacerbation that had culture-positive sputum 
samples with those who had a Type II exacerbation in order to investigate whether 
there was a difference. I therefore wondered whether this simple test of patient signs 
and symptoms could help to improve the proportion in clinical trials of antibiotics that 
had a bacterial pathogen isolated from their baseline sputum sample.
A multicentre, placebo-controlled study in acute exacerbations of COPD, which was 
conducted in Italy, found that a five-day course of antibiotic gave a significantly 
lower percentage of clinical failures (13.6% versus 49.7%) than five days of placebo 
[Allegra et al, 1991]. Like Anthonisen’s study, this clinical trial did not report 
microbiology, which could have supported the findings and therefore strengthened the 
robustness of these results. In addition, patients did not have to have purulent sputum 
to register as an exacerbation for which an antibiotic might be given. Nevertheless, 
this study provides additional evidence of the benefit that antibiotic therapy can 
provide.
More recent clinical trials in AECB/AECOPD normally screen the baseline sputum 
sample for microscopic purulence (>25 PMNs and <10 SECs per low power field) as 
recommended by the FDA [FDA, 1998]. The results of this screen are used either to 
exclude patients whose sputum samples did not meet these criteria, or just to exclude 
the sputum samples from bacterial culture on the basis of poor quality, ensuring that 
these patients will not be microbiologically-evaluable. A few studies screened a 
Gram-stained preparation of sputum for the presence of bacterial cells. I decided also 
to look at these microscopic screening techniques to investigate whether one or both
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could significantly improve the proportion of patients who had a baseline pathogen, 
and would therefore be microbiologically-evaluable, allowing a true assessment and 
comparison of two or more antibiotics’ activities.
8.3 Clinical Trials of Antibacterial Drugs over the Last 50 Years
In the past 50 years, antibiotics have been critical in the fight against many diseases 
and infections. Their discovery was one of the leading causes for the marked rise in 
average life expectancy in the 20th century and their significance to public health is 
immense. The introduction of penicillin into general clinical practice in 1944 meant 
that previously deadly illnesses such as scarlet fever, and Strep throat became curable. 
Today, we depend heavily on antibiotics, although with the rise of antibiotic 
resistance we are having to reassess our perhaps over zealous use of these drugs. In 
England in 2007, in excess of 39 million prescriptions were written for antibiotics, at 
a value of over £173 million [Dept of Health website, 2008]. At an average cost per 
prescription of £4.43 they are among the lowest cost drugs in use and considerably 
less than the current prescription charge of £7.10. However, the most frequent users 
of antibiotics are children and the elderly, who are exempt from prescription charges.
8.3.1 The Systematic Review of Clinical Trials of Antibiotics in AECB Since 
1966
In the systematic review, the majority of studies used 18 years as the lower age limit 
for the clinical trial, despite the fact that true chronic bronchitis is relatively rare in 
people under 35 years of age; as evidenced by a retrospective study of over 100 
patients admitted to hospital for AECOPD where the lowest patient age was 38 years 
[Smith et al, 1999]. Therefore a lower age of 35 years would be more in keeping with 
the disease. The use of 18 years as a lower age limit is likely to reflect the indication 
that the sponsor company has for a licensed antibiotic, or wishes to achieve. The risk 
of applying a lower age limit of 18 years in these clinical trials is that some doctors 
who are less familiar with the condition or who wish to enter as many patients into the 
clinical trial as possible, may in error enrol young adults who have a combination of 
asthma and allergic rhinitis rather than a true acute exacerbation of chronic bronchitis.
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Overall the rates of bacteriologically-positive patients varied between 13.9% and 
96.0%: an enormous variation. The 25th to 75th percentile in the ITT populations was 
28.7% - 64.7%, which is still a wide range, thus demonstrating that the spread of 
bacteriologically-positive rates is not accounted for by a few outliers at each end of 
the range.
It was surprising that despite a recognised definition of chronic bronchitis since 1962, 
28% of the papers did not specify that this definition had been applied in the entry 
criteria and one paper specifically used a variation on the standard definition. When it 
comes to the definition of an acute exacerbation, arguably the most recognised 
definition and classification is that described by Anthonisen et al [1987] and around 
which this project was based. According to Anthonisen’s data, Type I and II (but 
predominantly Type I) exacerbations are generally considered to benefit from 
antibiotic therapy; whereas, Type III exacerbations are accepted as not benefiting 
from antibiotic therapy. This review found that in the clinical trials that used 
Anthonisen’s definition of Type I and Type II exacerbations, the rates of 
bacteriologically-positive patients were higher in patients with a Type I exacerbation 
than those with a Type II exacerbation. This difference in the proportion of 
bacteriologically-positive patients between Type I and Type II exacerbations 
supported the objectives of the clinical study that formed the main part of this project. 
However, those studies that used various other combinations of signs and symptoms 
at baseline, had rates of bacteriologically-positive patients that were at least as high if 
not higher those in Type I exacerbations. Overall, this suggests that signs and 
symptoms are a complex issue and are not a good guide to bacterial infection.
Twenty studies screened the sputum samples of potential patients for WBCs, SECs 
(and a bacterial cell type) on a Gram stained specimen, and only those patients whose 
samples met the entry criteria were allowed to enter the study. This criterion appeared 
to produce a higher rate of bacteriologically-positive patients, compared with the 
studies where this was not done. However, the data were not conclusive.
The 80 studies that reported individual pathogens, varied considerably in the species 
of bacteria that were isolated and reported as pathogens. H. influenzae, S. pneumoniae
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and M. catarrhalis were reported by virtually all the studies; however species such as
H. parainfluenzae, S. aureus, P. aeruginosa and the Enterobacteriaceae were reported 
in only a proportion of studies. In most cases, when a species was absent from the 
reporting, it was difficult to determine whether the reason was that the species had not 
been isolated from any patient (as they are found less commonly than H. influenzae, S. 
pneumoniae and M. catarrhalis), or whether the species had been isolated, but was 
not accepted as a pathogen. What was evident from the results was that it was not a 
simple case that the more species that were included as pathogens, the higher the rate 
of bacteriologically-positive patients; the main reason for this is that these species are 
isolated in only a few patients.
A specific examination of the studies that had rates of bacteriologically-positive 
patients of greater than 60% in the ITT or CE population, showed that the only factor 
that appeared to have an impact on the bacteriologically-positive rate was 
microbiological screening of sputum purulence (possibly with the presence of 
bacterial cells), as there were twice as many studies (as a percentage) that had applied 
this screening as an entry criteria, in this group of studies than in the whole dataset.
8.4 Review of the Clinical Study
8.4.1 Objectives of the Clinical Study and the Difficulties, Solutions and 
Limitations
The clinical study was designed to investigate three potential indicators (primary 
objective) of a bacterial exacerbation in patients presenting to their GP or at hospital 
admission with AECB.
• The primary indicator to be evaluated (and the one upon which the sample size 
was calculated) was whether patients with a Type I exacerbation of CB (all 
three cardinal signs/symptoms) had statistically higher probability of having a 
bacterial pathogen isolated from their sputum than patients with a Type II 
exacerbation (two of the three signs/symptoms present).
The other two primary objective indicators investigated were:
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• Microscopic purulence of the sputum at baseline i.e. whether the sputum had 
>25 PMNs and <10 SECs (microscopically purulent), or not
• The presence of bacterial cells on a Gram-stained preparation of sputum at 
baseline.
In addition, other factors that might affect the presence of baseline pathogens in the 
sputum were examined including: the numbers of months since the previous 
exacerbation for which an antibiotic was given and the relationship between this and 
the species or bacteria grown; the time of day that the sputum sample was produced; 
and delaying culture of part of the sputum sample for 24 hours at room temperature.
Unlike more recent studies of acute exacerbations of COPD, this study did not 
measure lung function of the patients. The measurement of FEVi and FVC has most 
value when a series of measurements can be taken from each patient, ideally a) stable 
state, b) during an acute exacerbation, c) just after the acute exacerbation, d) a few 
weeks later in the stable state again. In this way the baseline value (the first stable 
state) can be recorded for each patient and it is against this that all later measurements 
will be evaluated. The sequence of deterioration of lung function during the acute 
exacerbation, followed by improvement of the lung function again after the 
exacerbation can be assessed. One of the major factors is whether lung function 
returns to the baseline value, or whether each time the patient has an acute 
exacerbation a further small proportion of lung function is lost. The measurement of 
FEVi and FVC was considered in the design stage of the study, but as all the data to 
be recorded by the investigators was to be collected at one visit (when the patient first 
presented with signs and symptoms of an acute exacerbation), it was thought that a 
single set of measurements from each patient would not have a great deal of value. It 
was therefore decided not to collect lung function data.
The study started with four GP surgeries in Edinburgh, however because of a lack of 
interest in this study in the initial period of recruitment of investigators (it was 
originally planned to have at least six investigative sites in Edinburgh), the study was 
extended to Coatbridge to a large Medical Centre. Monklands Hospital, which was 
originally involved as the laboratory for the Coatbridge GP practice then also became
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an investigative site, recruiting patients from its admissions of patients with AECB. 
Over a year later, because of poor recruitment figures in Edinburgh and Coatbridge, a 
further four general practices in Glasgow that had a good record of recruiting AECB 
patients for clinical trials joined the study. By extending the study to Glasgow, it was 
eventually possible to meet the recruitment target of 120 patients. However, these 
120 patients only yielded 97 evaluable patients instead of the intended 112 patients. 
These reduced numbers of evaluable patients will have affected the power of the 
study, but only in a minor way. Nevertheless, as the power of the study was set at 
85% any reduction could be of concern. Extending the study outside Edinburgh 
meant that other laboratories were required to conduct the sputum culture from sites in 
Coatbridge and Glasgow. The outcome was that the study had three central 
laboratories instead of the original plan for a single central laboratory. Although the 
laboratories all agreed to adhere to the methodology for sputum culture given in the 
protocol, it was later found out that the methodology of Airdrie and Glasgow hospitals 
was almost identical, but this was different to that of the Edinburgh laboratory and the 
methodology given in the protocol. The laboratories at Airdrie and Glasgow 
performed the cultures according to their standard procedures and not to the protocol. 
There were two key differences in technique/interpretation, these were; a) sputum 
samples were not homogenised before culture, but a piece of the most purulent section 
of sputum was removed and cultured; and b) the numbers of organisms used to rank 
the Gram-stain preparation varied from that used in Edinburgh. As there were only 
four eligible patients enrolled in Edinburgh, and only three of them had cells on the 
Gram stain, the interpretation used in the analysis of the Gram stain results from these 
three patients was that of Airdrie and Glasgow hospital laboratories. The differences 
between the two laboratories in the numbers of organisms required in each growth 
group (+, ++, and +++) are shown in Table 8-1.
Table 8-1: Differences in the interpretation of Gram stain quantitative
assessment between the 3 central laboratories
Gram stain quantitative 
assessment
No. of cells per oil immersion field 
Edinburgh lab Airdrie/Glasgow lab
+ 1 1-9
++ 2-10 10-25
+++ >10 >25
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The use of three central laboratories lead to a lack of standardisation in this study and 
that was not ideal. Nevertheless, the results were made as consistent as possible in the 
circumstances, and it is believed that the overall results are robust.
8.4.2 Discussion of the Clinical Study Results
The primary outcome of this study suggested that patients with Type II exacerbations 
were more likely to have bacterial involvement than those in patients with Type I 
exacerbations. However, this difference was borderline and given the reduced 
number of patients in the evaluable population (97 instead of 112) and the fact that the 
distribution of Type I and Type II exacerbations was very unequal 7:3 instead of an 
expected 1:1 distribution, this result may have occurred purely by chance. This 
difference between Type I and Type II exacerbations is counterintuitive and contrary 
to previous studies where there has been a suggestion that patients with Type I 
exacerbations are more likely to have a bacterial cause than patients with a 
combination of Type I and Type II exacerbations. As stated, although the statistical 
design of the study was based on there being a 1:1 ratio of patients with Anthonisen 
Type I and Type II exacerbations, the actual ratio was approximately 7:3. This 
imbalance may have reflected investigator and/or patient bias in confirming that all 
three symptoms had worsened, leading to a more varied collection of patients in the 
Type I group than the Type II group and consequently, the more accurate reporting of 
just two symptoms. However, the severity of dyspnoea, sputum volume and sputum 
purulence in the pre-exacerbation state in these patients did not indicate that patients 
with a Type II exacerbation had more severe chronic bronchitis in the stable state than 
those who were reported to have a Type I exacerbation, which could have explained 
this difference in bacterial exacerbations. In hindsight, stratifying for Type I and 
Type II exacerbations would have improved the design of the study. This would have 
guaranteed an even distribution of Type I and Type II exacerbations which would 
have allowed a better statistical analysis. If this type of study is repeated, 
stratification is recommended.
The secondary outcome of microscopic purulence (>25 WBCs and <10 squamous 
epithelial cells), showed significance, though the sensitivity and specificity meant that
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the test is probably not useful in a clinical or research study setting. Geckler and 
colleagues found a correlation of 94% between potential pathogens grown from 
sputum samples containing <10 squamous epithelial cells and >25 white blood cells 
per low power (xlOO) field and paired transtracheal aspirates [Geckler et al, 1977]. 
However, the study presented in this thesis worked within conventional clinical 
practice where the position is less clear cut. Although the test of >25 WBCs and <10 
epithelial cells has been used in many studies to distinguish between bacterially and 
non-bacterially infected sputum specimens, the findings in this study challenge the 
rigid application of this test. The usefulness of this investigation was questioned in 
another clinical trial in AECB, and based on the culture results it was decided 
retrospectively not to apply it [Wilson et al, 1999].
There was virtually no difference between the results of the immediate sputum culture 
and the culture of the same specimen following 24 hours at room temperature. This 
lack of any significant difference in the culture results was surprising. The question 
of whether a delay in culturing sputum samples leads to a difference in the culture 
results was investigated by Gould et al [1996]. Gould et al, stored the sputum 
samples for 48 hours at 4°C and found a discrepancy of 5-25% between early and late 
testing; however, the three laboratories taking part in this study accounted for much of 
this difference. It was concluded by the authors that methodology rather than storage 
time was responsible for most of the variation. There is therefore no great 
discrepancy between the results of Gould et al and the results of the study presented in 
this thesis.
There was similarly no difference between the proportion of culture-positive sputum 
samples that were produced early in the day (<09:00 hours) with those produced after 
this time; however, the major factor here may not be the precise time of the day, but 
that it is the first sputum sample produced after waking up in the morning, and this 
information was not known. Many of the sputum samples that were produced at or 
before 09:00 hours may not have been the first sputum sample of the day, and this 
could have affected the results.
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In this study, the date of the most recent exacerbation for which an antibiotic was 
prescribed was collected, rather than the number of exacerbations that the patients had 
suffered in the previous 12 months; a parameter which is more usually collected in 
clinical trials. Collecting the date of the most recent exacerbation may have been a 
less reliable measure of the severity of their disease, but it was a simple and objective 
value for the investigators to record. It is recognised that CB patients may not visit 
their GP for every exacerbation. GPs will have a record of each exacerbation for 
which a surgery (or home) visit was made or for which there was a direct hospital 
admission but some exacerbations may go unrecorded. However, asking the patient 
how many exacerbations they have had in the previous 12 months may be 
unsubstantiated and possibly under or over-estimated. A total of 26 patients had the 
previous exacerbation less than one month before the current presentation, and it is 
therefore questionable whether the current exacerbation was indeed a new episode, or 
whether it was a relapse of the previous exacerbation; it was in this group of patients 
that one of the lowest culture-positive rates was seen. Overall, there were no 
particularly significant trends seen in the species of pathogen isolated in the different 
time periods since the previous exacerbation; however, the numbers of patients in 
several of the time periods were small and this makes any assessment unreliable. 
Nevertheless, the finding that Enterobacteriaceae were only isolated from patients 
who had had an exacerbation within the previous 6 months is consistent with the 
theory that Enterobacteriaceae are mainly found in the lungs of patients with poor 
lung function, and therefore patients who have more frequent exacerbations [Eller et 
al, 1998; Sayinerctn/, 1999].
Medici and colleagues [Medici et al, 1988] found that in a comparison of Gram stain 
and culture, microscopic examination of the Gram stain was found to be superior to 
culture, with around 50% of organisms microscopically identified as pneumococci 
failing to grow. This is an interesting observation, but offers little information about 
the pathogenicity of these organisms. It is not surprising to find bacteria in the LRT 
of these patients. The question is therefore, are they causing the exacerbation? The 
results of Medici and colleagues do not provide such information.
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It was when the pattern of the Gram stain results was examined that a distinct 
relationship between the number of bacterial cells seen on the Gram stain and the 
subsequent culture results was observed. This observation was then formalised into a 
full analysis. Accepting all the reservations of a post-hoc analysis, the semi- 
quantitative analysis of the Gram stain results provided the best indicator of bacterial 
infection. A single bacterial cell type present at >10 cells per field (x 1000), or more 
than one bacterial cell type present with at least one cell type at >25 cells per field was 
seen in over 90% of the culture-positive specimens. The benefit of quantitative Gram 
stain analysis has been described previously [Chodosh et al, 1991]. Chodosh 
suggested that chronic bronchitis patients in stable state (between exacerbations) have 
few bacteria on a Gram stain. However, during a bacterial exacerbation, Chodosh 
demonstrated that thresholds can be applied which, when exceeded in a sputum 
sample, indicate that the exacerbation is of bacterial origin. The criteria given were 
>12 Haemophilus-like organisms, >8 pneumococcus-like organisms, or >18 
Moraxella-HkQ organisms per oil-immersion field. Hie technique applied in this study 
however, is simpler than that of Chodosh because the same numbers are used for all 
relevant cell types. Furthermore, the technique of Chodosh requires extensive 
microbiology experience and is very user specific. The classification of the numbers 
of cell types seen in this study was based on standard laboratory practice and for the 
purpose of identifying acute bacterial exacerbations of CB may not be optimal. 
Nevertheless, in this study the semi-quantitative investigation appeared to provide the 
possibility of a potential classification method for predicting bacterial infection in 
AECB patients. The results of this clinical study were published first in summary as a 
poster presentation [Burley, 2003], and then as an original research paper [Burley et 
al, 2007 and Appendix 9.5].
It has been established that frequent exacerbations in patients with chronic bronchitis 
or COPD increases the decline in lung function and also quality of life [Donaldson et 
al, 2002; Spencer& Jones, 2003; Hurst et al, 2005; Martinez et al, 2006]. In addition, 
the frequency of exacerbations is related to the underlying severity of COPD [Hurst & 
Wedzicha, 2007]. Consequently, any medical intervention, antibiotic therapy or other 
intervention, which can decrease the frequency of exacerbations, will be of significant 
long-term benefit to these patients. One of the first steps along this path will be to be
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able to identify correctly those patients who have an acute exacerbation caused by 
bacteria. It is hoped that this research may contribute in a small way to this goal.
8.4.3 Comparison with Other Research
The ATS definition of chronic bronchitis has stood the test of time; nevertheless, the 
condition goes beyond this definition in terms of the inflammation and in more severe 
cases, colonization of the airways. The ‘vicious circle’ hypothesis proposed by 
Murphy and Sethi in 1992 gave a revised view of chronic lung disease and how the 
presence of bacteria results in an alteration in the host defences in the respiratory tract, 
which in turn predispose to further infection [Murphy & Sethi, 1992]. This 
hypothesis lends support to the argument that antibiotics are useful in the treatment of 
exacerbation thought to be bacterial in nature as their use will return the bacterial load 
to a low level, and therefore minimise the damage to host respiratory defences. 
Stockley and co-workers established that the colour of the sputum can help to predict 
whether or not an exacerbation is caused predominantly by bacteria [Stockley et al, 
2000]. This is simple technique, which is detailed in Section 7.1, could easily be used 
in the community, without the need for an immediate laboratory examination of the 
sputum sample. Assessing purulent sputum by colour against the culture-positive 
results gave a positive predictive value of 83.9%, which is good, but lower than the 
PPV of 90.7% that was achieved using the semi-quantitative Gram stain analysis 
recommended in the clinical study presented in this thesis.
Van der Valk et al investigated predictors of bacterial involvement in exacerbations of 
COPD. They examined patients’ lung function and found that a combination of a 
positive Gram stain result associated with a decrease in the FEVi (>12%, and of 
>200mL), and 2 or more exacerbations in the preceding year best predicted a bacterial 
exacerbation (positive predictive value 67%; negative predictive value 100%) [van 
der Valk et al, 2004]. These positive and negative predictive values are almost the 
reverse of those from the study presented in this thesis (which had a high PPV and a 
lower NPV), and which used only a semi-quantitative Gram stain result. The purpose 
of being able to predict bacterial involvement was different in these two studies. In 
van der Valk’s study the aim was to assist the appropriate use of antibiotics, and in
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this regard a high negative predictive value was essential. In the current study the 
intention was to be able to distinguish as accurately as possible those patients that 
were highly likely to have a bacterial exacerbation so that within a clinical trial 
population there would be a high proportion of bacteriologically-proven infections 
and a high proportion of patients in the microbiologically-evaluable population.
The objective in clinical trials of antibiotics in patients with AECB is to have a high 
proportion of culture-positive patients to enable a more relevant comparison of two 
(or more) antibacterial drugs. In terms of PPV and NPV, a high PPV is most 
important as this indicates that few of the patients enrolled into the study on the basis 
of the test result will be culture-negative (few false positives). A number of patients 
may be excluded from the study on the basis of the test who later turn out to be 
culture-positive (false negatives), but this is of less importance to the final robustness 
of the clinical trial. In clinical practice however the situation is reversed, a high rate 
of false-negatives will create a problem as these are patients who need an antibiotic, 
but on the basis of the test may be refused this treatment. Instead, treating a small 
proportion of patients unnecessarily with antibiotics (the false positives) is likely to be 
the more acceptable option.
Bacterial colonisation of the LRT brings into question all assumptions that bacteria 
grown from expectorated sputum are pathogenic. However, it is difficult to argue that 
none of these culture-positive patients is suffering a bacterial exacerbation. So what 
is the truth? It has been reported that a common cold precedes the majority of 
exacerbations of COPD [Wedzicha, 2004], but are all of these exacerbations 
exclusively viral in nature? There is now good evidence that many exacerbations are 
triggered by respiratory viruses, and the following viruses have been identified with 
acute exacerbations: cold viruses, influenza and parainfluenza viruses, and respiratory 
syncytial virus (RSV) [Sethi, 2000]. In a proportion of these patients it also seems 
possible that the viral infection allows the colonising bacteria, or a newly arrived 
strain of existing bacteria to flourish and develop into a secondary infection. It is 
possible that a high yield (>107 cfu/mL) of a bacterial species from a sputum sample 
is currently our best indicator of active infection, until a more precise marker of 
bacterial infection is found. In this way a semi-quantitative Gram stain makes sense
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in being able to suggest possible active bacterial infection, before the culture of the 
sputum sample is performed.
8.5 Overall Conclusions
1. Chronic bronchitis is a complex disease and the terminology for the condition 
has changed over the last 40-50 years. This is reflected in the number of 
different terms that had to be used in the systematic review in order to identify 
the disease in the years since 1966.
2. Over the last 50 years, the design and statistical rigour of clinical trials of 
antibiotics in AECB has improved significantly.
3. The proportion of patients with AECB who have a respiratory pathogen isolated 
from their sputum in significant numbers shows wide variation (14% to 96% in 
the systematic review). However, there was no clear association between the 
proportion of bacteriologically-proven AECB and signs/symptoms, or sputum 
sample quality.
4. The Anthonisen et al [1987] classification of exacerbations may be useful in 
guiding antibiotic therapy; however this study provided no evidence that there 
was a higher proportion of bacteriologically-positive patients among those who 
had Type I exacerbations than patients who had Type II exacerbations. The 
results were counter-intuitive and the Fisher’s exact test gave a borderline 
result. This outcome was possibly the result of the very uneven distribution of 
Type I and Type II patients in this study (approx. 7:3 instead of 1:1).
5. Applying a semi-quantitative screen of a Gram-stained preparation of sputum 
gave the best indication of bacterial infection. In total, 91% of samples that had 
at least 10 bacterial cells per oil immersion field (x 400 magnification) as the 
only bacterial morphological cell type present, or at least 25 cells per field with 
multiple bacterial morphological cells types present, grew a recognised
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pathogen. The test had a sensitivity of 67% and a specificity of 90%; a positive 
predictive value of 91%, and a negative predictive value of 65%.
6. In large multinational clinical trials the shipment of sputum samples to a local 
accredited laboratory and the rapid processing of the sample and reporting back 
to the general practitioner may not be possible. Consequently, this procedure 
may have some limitations for community-based studies.
7. Current research in the area of AECB is identifying several potential 
biomarkers of inflammation and infection. Currently none of these have 
conclusively demonstrated efficacy in identifying acute bacterial exacerbations 
of CB from non-bacterial exacerbations.
8. Research to understand more clearly the whole disease area is still required, and 
patients in whom antibiotics will be of benefit in exacerbations requires further 
clarification. Nevertheless, new antibiotics will continue to be developed and 
these must be evaluated rigorously in patients with acute exacerbations of 
CB/COPD. Therefore, any simple technique that can be applied in clinical 
trials of these antibiotics in acute exacerbations of CB/COPD, which can 
reliably and consistently provide a high proportion of patients who have 
culture-positive sputum samples at baseline may have clinical benefits (in terms 
of more appropriate prescribing of antibiotics), as well as making clinical trials 
easier and more scientifically robust.
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9 APPENDICES
9.1 Proposed Further Research Project: Draft Protocol
9.2 Systematic Review: Protocol (including Data Collection Form)
9.3 Clinical Study: Protocol and Amendment
9.4 Clinical Study: Data Collection Forms
9.5 Clinical Study: Publication in Journal of Infection, Sep. 2007
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APPENDIX 9.1 
Proposed Further Research Project: Draft Protocol
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1. INTRODUCTION AND STUDY RATIONALE
Chronic bronchitis was defined by the American Thoracic Society in 1962 as ‘the daily 
production of sputum for at least three consecutive months over two consecutive years,(1) 
and over 40 years later, this description remains the best definition that we have of this 
disease. Clinical trials of antibacterial drugs in patients with acute exacerbations of chronic 
bronchitis (AECB), aim to select patients who have an acute bacterial exacerbation. 
Exacerbations of chronic bronchitis may occur due to a number of factors that include 
exposure to airborne irritants, or as a result of infection by bacteria, or viruses. There is no 
reliable method of distinguishing between exacerbations caused by bacteria and those 
caused by other agents. The criteria that are used for selecting AECB patients for entry 
into clinical trials of antibacterial drugs are not consistent, and the proportion of 
bacteriologically positive patients shows considerable variation. The proportion of patients 
in studies of AECB, who have a bacterial pathogen isolated from a sputum sample can 
vary between 25% (2) and 73% (3). Although a Gram stain of the sputum may be helpful if it 
shows abundant neutrophils and a predominant morphological type of organism, few 
clinical trials use this procedure as part of the entry criteria, possibly because it presents 
logistical problems and a delay in being able to enrol and treat the patients.
Anthonisen and co-workers(4) demonstrated a 20% difference in success rates between 
antibiotic and placebo-treated patients when they had the three ‘cardinal symptoms’ of 
increased dyspnoea, sputum volume and sputum purulence (Type I exacerbation). 
Exacerbations with fewer symptoms showed less difference between antibiotic and 
placebo, possibly indicating that many of these were not bacterial exacerbations, it is 
unfortunate that sputum microbiology was not performed in this study as this could have 
added weight to the argument for the use of an antibiotic. It was concluded by Staley et 
a f5) however, that in view of these results future studies with an active control group should 
be designed to include only patients in whom exacerbations are likely to have a bacterial 
cause. The characteristics of increased cough and/or dyspnoea and increased sputum 
volume and purulence have been demonstrated to be associated with bacterial 
infection(6,7), but still the majority of studies produce a disappointing percentage of 
bacteriologically proven infections e.g. 44% {8), 39% {9), 27% (10), 34%(11).
The correlation of potential pathogens grown from sputum samples and paired 
transtracheal aspirates has been shown to be 94% in sputum samples with <10 squamous 
epithelial ceils and >25 white blood cells per low power (x100) field(12). Gram staining has 
been reported to confirm the presence of bacteria characterized by their morphology.
Using an oil immersion field (x1000) >8 pneumococcus-like, >12 haemophilus-like, or >18 
moraxella-like organisms are likely to indicate acute bacterial exacerbation; stable patients 
have few bacteria per high power field(13). In a previous comparison of the usefulness of 
the categories of: Anthonisen type II exacerbation (2/3 symptoms), Anthonisen type I 
exacerbation (all 3 symptoms), >25 neutrophils/<10 epithelial cells per low power field 
and a Gram stain of the sputum as indicators of bacterial infection, it was found that 
screening the sputum samples for purulence and bacterial cell types, significantly 
increased the proportion of patients in which a pathogen was grown(14). This study 
therefore demonstrated the benefit of applying a screening procedure to sputum samples 
prior to enrolling patients into a clinical study however, in large, multinational, Phase III 
clinical trials this screening is logistically difficult, adds a significant expense to the study, 
delays the entry of patients into the study and consequently delays the start of antibacterial 
therapy, which may create ethical concerns. Ideally what is needed is a simple method of 
identifying bacterial infection that could be applied by the general practitioners, and would 
give a high degree of sensitivity and specificity, similar to that achieved by Gram stain 
screening the sputum.
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This study aims to examine two simple methods of testing sputum samples from patients 
with AECB for bacterial infection, and compare them with the number of bacteriologically- 
positive patients using just the standard inclusion criterion of two or all three of 
Anthonisen’s cardinal symptoms. The two methods to be tested are:
i. sputum colour, matched against a colour chart based on the work of Stockley et a l (15)
ii. presence of leucocyte esterase in the sputum, using reagent strips; this technique has 
been used successfuly in other infection types(16,17) and may be useful in AECB.
These two methods applied separately or in combination may offer a convenient, simple, 
inexpensive and reliable method for GPs to assess the likelihood of bacterial infection in 
patients presenting with AECB that could be applied to the inclusion criteria of clinical 
studies of antibacterial agents, potentially offering a simple and effective means of 
ensuring a significantly higher proportion of bacteriologically-evaluable patients.
2. OBJECTIVES
2.1 Primary objective
•  To compare the sensitivity and specificity of a) sputum colour and b) leucocyte
esterase (tested on expectorated sputum with a urine dipstick) as assessed by the GP, 
with Anthonisen (type I and II) symptoms as indicators of bacterial infection in patients 
with acute exacerbation of chronic bronchitis.
2.2 Secondary objectives
a) To compare the accuracy and specificity of sputum colour assessed by the GP with the 
presence of predominant organism on a Gram-stained sputum preparation, as 
indicators of bacterial infection in patients with an acute exacerbation of chronic 
bronchitis.
b) To compare the accuracy and specificity of leucocyte esterase (tested on expectorated 
sputum with a urine dipstick) assessed by the GP with the presence of predominant 
organism on a Gram-stained sputum preparation as indicators of bacterial infection in 
patients with an acute exacerbation of chronic bronchitis.
c) To examine the effect of combining sputum colour and presence of leucocyte esterase 
as an indicator of bacterial infection in these patients, and how this compares with 
Anthonisen (type I and II) symptoms and with the presence of predominant organism 
on a Gram-stained sputum preparation.
d) To compare the assessment of sputum colour and leucocyte esterase performed by 
the laboratory with that of the G P to assess the reproducibility of these methods.
e) To examine the effect of using each of these four methods (symptoms, sputum colour, 
leucocyte esterase and predominant organism on Gram stain) as the main inclusion 
criterion in clinical trials of antibacterial agents in the patients with an acute 
exacerbation of chronic bronchitis, in terms of the proportion of bacteriologically- 
evaluable subjects and the additional costs that would be incurred.
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3. STUDY DESIGN
This study is a prospective, multicentre, non-interventional study of documented chronic 
bronchitic patients presenting to a general practitioner with signs and symptoms of an 
acute exacerbation.
4. STUDY DURATION AND DATES
The study is planned to commence in <MONTH YEAR> and finish <MONTH YEAR>. In 
order to recruit the required number of subjects, a second winter season may be required, 
in which case the study will finish during the winter season 2004/05 when the <100 
subjects> (rough calculation) have been enrolled.
5. SELECTION OF SUBJECTS
5.1 Number of subjects
It has been calculated that XXX subjects will be required to identify a 20% improvement in 
the number of subjects with a proven bacterial infection between either sputum colour and 
Anthonison type I and II symptoms or a positive leucocyte esterase test and Anthonison 
type I and II symptoms (see section 7.1 for details o f the sample size justification).
No centre will recruit more than <32 subjects>.
5.2 Entry criteria
Inclusion criteria
>  Adult patients aged 35 years and above with evidence of chronic bronchitis as defined 
as: chronic cough and sputum production on most days over a period of 3 successive 
months for at least 2 consecutive years.
>  Patients with a t least two of the following symptoms: increased sputum purulence; 
increased sputum volume; increased dyspnoea.
>  Patients who are able to produce a sputum sample at the visit (alternatively, the patient 
may take a sputum pot away and return a sample the following morning, provided that 
no antibiotic treatment has been started).
>  Patients who have consented to the study.
Exclusion criteria
>  Patients who have significant bronchiectasis (>100mL sputum daily).
>  Patients who have cystic fibrosis.
>  Patients who have already received antibiotic treatment for this episode.
>  Patients who have received an antibiotic for any reason in the previous 7 days.
>  Patients who have previously entered this study.
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6. STUDY PROCEDURES
6.1 Overview of data collection
Data for this study will be collected on individual case report forms (CRFs) provided to 
each investigator and to the laboratory. A  CRF will be completed for each eligible patient 
who consents to take part in the study. Any patient who fails to produce a sputum sample 
before antibiotic treatment is started will not be eligible for the project, and will be replaced.
Data for this study will come from two sources. The investigator will complete the first 
section of the CRF (clinical data) at the time of the patient visit. The laboratory will 
complete section two of the CRF (laboratory results). A  copy of the laboratory results with 
routine antibiotic susceptibility results, where an organism is isolated, will be sent to the 
investigators by post. The laboratory request forms will be identified as sputum samples 
for this research project by means of an adhesive label.
6.2 Clinical data
The following data will be collected by the investigator in the CRF provided for each 
patient:
>  date of visit
>  entry criteria
>  confirmation of patient consent
>  assignment of unique patient number
>  basic patient demography
>  relevant medical history checklist
>  number of exacerbations in the previous 12 months for which an antibiotic was 
prescribed
>  time and date of sputum sample
>  rating of symptoms of dyspnoea, sputum volume and sputum purulence:
a) prior to this infection (pre-infection)
b) currently
>  ranking of the sputum colour according to the supplied colour chart
>  test for the presence of leucocyte esterase in the sputum sample using the dipsticks 
provided
6.3 Laboratory data
All sputum samples will be transferred to the agreed local microbiology laboratory by the 
routine collection service or in special circumstances by a taxi service which will be setup 
as necessary. All samples will be identified by a study specific adhesive label, which will 
identify the study subject number.
On arrival at the microbiology laboratory, samples will be logged and any queries about the 
subject number resolved.
The sputum sample will have the following tests/examinations performed:
1. Assessment of purulence of the sample by appearance:
Clear, non-viscous non-sputum sample
Grey/white, viscous mucoid
Up to 50% yellow-green mucopurulent
>50% yellow-green purulent
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2. Ranking of the sputum colour according to the supplied colour chart
3. Test for the presence of leucocyte esterase in the sputum sample
4. Low power microscopy of cells (total magnification x100):
epithelial cells: <10 per field /  >10 per field 
neutrophils: >25 per field /  <25 per field
5. Gram stain and quantitative assessment of bacterial cell types:
<10 per oil immersion field +
10-25 per oil immersion field ++
>25 per oil immersion field +++
6. Culture of purulent section of sputum for identification of pathogen with a semi- 
quantitative interpretation using a dilution technique (see Appendix V )
CFU/mL Interpretationo
I
toO
Light growth
10&- 1 0 e Moderate growth
>106 Heavy growth
All results will be recorded in the laboratory CRF.
7. D A T A  H A N D L IN G  A N D  S T A T IS T IC A L  P R O C E D U R E S
7.1 Sam ple size justification
Data from a previous study has shown that a maximum of 60% of subjects with two or three 
symptoms of an acute exacerbation (Anthonisen type I & II exacerbations) will have a 
proven bacterial infection (?pathogen grown at >105 CFU/mL) however, many clinical trials 
produce a much lower proportion of subjects with proven bacterial infection. In order to 
have a 90% chance (power) of demonstrating an increase of 20% or greater in the 
proportion of subjects with a proven bacterial infection in subjects with a positive sputum 
colour (from the colour chart) or with a positive leucocyte esterase test (using the dipsticks 
provided), a total of XXX subjects will be required.
Assuming that 10% of subjects will be non-evaluable (non-eligibility or missing test results) 
7 77  subjects will be recruited and a one-sided (5%) chi-squared test will be applied to each 
of the two primary analyses.
7.2 Data management
All data collected in the CRFs will be entered into a computer database for analysis. All 
data entered onto this database will be anonymous. Subject data will be identified only by 
the subject number, with the date of birth as a qualifier.
7.3 Study populations
Data from all subjects who consented and were given a subject number will be entered 
into the database. All subject data that has all the major fields completed will be entered 
into the analysis population. This will be the only population for analysis.
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Major protocol violations 
Investigator CRF
♦ non-fulfilment of any of the entry criteria
♦ missing or incomplete ratings of symptoms of dyspnoea, sputum volume and 
sputum purulence pre-infection and currently
♦ missing ranking of the sputum colour according to the supplied colour chart
♦ missing result of the test for the presence of leucocyte esterase in the sputum 
sample
Laboratory CRF
♦ missing or incomplete microscopy of cells (WBCs and epithelial cells)
♦ missing or incomplete Gram stain and quantitative assessment of bacterial cell 
types
♦ missing or incomplete culture of sputum sample
7.4 Statistical methods
The positive culture rate between the 2-symptom group and the 3-symptom group will be 
compared with a one-sided chi-squared test at the 5% level.
The sensitivity and specificity will be calculated under all prediction schemes and tabulated 
for comparison.
7.5 Interim analyses
No interim analysis is planned for this study.
8. ETHICAL ASPECTS
8.1 Subject information and informed consent
All patients will be given a patient information sheet (see Appendix HI) that explains the 
study. Patients will be encouraged to discuss any concerns with the doctor. If the patient 
has any doubts about taking part in the study, they will not entered.
All patients who agree to take part in the study will be asked to sign the consent form (see 
Appendix IV ). No patient may enter the study unless they have freely signed and dated 
the consent form.
8.2 Confidentiality
All data recorded on the CRF and entered onto the study database will be anonymous. 
Patients will be assigned a unique patient number when they consent to the study, and this 
will be the only identification of the patients' data on the CRF or in the database.
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8.3 Approval of the study protocol and amendments
The study protocol and any amendments will be reviewed and approved by the following 
people:
Carol Burley PhD student
<To be assigned> project supervisor
9. MONITORING
A selection of the investigator and laboratory CRFs will be monitored by Carol Burley (CB) 
to ensure the completeness and accuracy of the data, and access to the patients' GP 
medical notes will be required. All monitoring will be performed in a confidential manner 
and no record of the patients' names will be made.
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Protocol Approval Form
PhD/AECB-ll/03
A  prospective, multicentre comparison o f sputum colour and leucocyte esterase  
against standard symptoms, as an indicator o f bacterial infection in patients with  
acute exacerbation o f chronic bronchitis.
This study protocol was subject to critical review and has been approved by the signatories 
below.
The information it contains is consistent with the moral, ethical and scientific principles 
governing clinical research as set out in the Declaration of Helsinki and Good Clinical 
Practice guidelines.
PhD student
Carol Burley Date
Project Supervisor
Dr Date
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Investigator Protocol Agreement
A prospective, multicentre comparison of sputum colour and leucocyte esterase 
against standard symptoms, as an indicator of bacterial infection in patients with 
acute exacerbation of chronic bronchitis.
Declaration of Investigator
I have been adequately informed about the study PhD/AECB-ll/03. I have read this study 
protocol and agree that it contains all the information required to conduct the study. I 
agree to conduct the study as set out in this protocol.
I agree to provide a signed and dated copy of my curriculum vitae before the study starts. 
Investigator
Print Name
Signed Date
Co-investigator (if applicable)
Print Name Position
Signed Date
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Patient Information Sheet
A  study to compare simple indicators o f bacterial infection in patients with acute
exacerbation o f chronic bronchitis.
Your doctor is taking part in a small research study to test two simple ways of telling if 
patients, like yourself, have a chest infection caused by bacteria (germs) and compare these 
against the symptoms that you are suffering. W e are asking whether you would agree to help 
with this research.
Approximately XXX patients with symptoms of a chest infection will take part in this study. 
Worsenings (exacerbations) of chronic bronchitis are sometimes caused by bacteria, in which 
case an antibiotic might be helpful, or they might be caused for other reasons (e.g. pollution, 
viruses), in which case an antibiotic would not help at all. The problem is that it is difficult to 
tell what is causing each worsening. This study will examine and compare two simple 
methods 1) comparing the colour of your sputum against a colour chart, 2) testing your 
sputum with a test stick that is often used to test urine samples for bacterial infection. This 
study involves no experimental (trial) medicine.
If you agree to take part, a few notes will be made about the nature of your current and 
previous chest infections and about some other medical problems you may have (such as 
heart problems) and you will be asked to produce a good sputum sample for analysis - that is 
all. You will not have to make any other visits to your GP or have any other samples taken as 
part of this study.
Your doctor will give you regular medication for your chest infection if it is necessary. The 
results of the laboratory tests on your sputum sample will be sent to your GP within 5 days. 
You will be able to find out the results of these tests by contacting your surgery after this time.
All records kept for this project will be anonymous. You will be identified by a number and 
only your doctor will know who this number refers to. If the results of this project are 
published, your identity will remain confidential.
The information written down in the study report form may be checked against your medical 
notes, to confirm the completeness and accuracy of the data. This is standard practice in 
such research work and all monitoring will be performed in a confidential manner by the post­
graduate researcher.
You are under no obligation to take part in this study. You may choose not to take part 
without having to give a reason. Your treatment and the attitude of your doctor towards you 
will not be affected if you decide not to take part Please feel free to ask your doctor any 
questions you may have about this study.
Thank you for reading this sheet.
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Patient Consent Form
A study to compare simple indicators of bacterial infection in patients with acute
exacerbation of chronic bronchitis.
1. I agree to take part in this study comparing indicators of bacterial
infection in patients with acute exacerbation of chronic bronchitis. | |
2. I have been given a patient information sheet and have received an 
explanation of the nature and purpose of the study and what I am 
expected to do.
3. I confirm that I have informed the doctor of any antibiotics that I 
have received for this chest infection, from other doctors.
4. I understand that I am under no obligation to take part in this project 
and that my treatment and the attitude of the doctor towards me will 
not be affected if I decide not to take part.
5. I understand that I will not be referred to by name in any report or 
publication concerning this project.
6. I understand that the project leader of this study will wish to inspect 
my medical records to verify the information collected. By signing 
this document I give my permission for this review of my records.
NAME OF PATIENT: 
SIGNATURE OF PATIENT: 
DATE OF SIGNATURE:
□
□
□
□
□
I confirm that I have explained the nature and purpose of the project to the above named 
patient, and that he/she freely consented to participate.
NAME OF INVESTIGATOR: ..............................................................
SIGNATURE OF INVESTIGATOR:............................................................
DATE OF SIGNATURE: ..............................................................
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APPENDIX 9.2 
Systematic Review: Protocol (including Data Collection Form)
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PROTOCOL
SR/0401
A Systematic Review of Clinical Trials of Antibiotics in Patients 
with Acute Exacerbations of Chronic Bronchitis, to Examine 
the Variation in the Proportion of Bacteriologically-positive 
Subjects and any Association with the Entry Criteria.
PhD Project of:
Postgraduate Medical School, 
University of Surrey 
Stirling House 
Surrey Research Park 
Guildford 
Surrey. GU2 7DJ
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Postgraduate Medical School,
03 March 2005
Tel:
E-mail:
Supervisor:
Tel:
E-mail:
Date:
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1. INTRODUCTION
Virtually all clinical trials of antibacterials drugs in patients with acute exacerbation of 
chronic bronchitis (AECB) use the definition of chronic bronchitis that was published by 
the American Thoracic Society in 1962 as Ih e  daily production of sputum for at least 
three consecutive months over two consecutive years’ [1]. Exacerbations of chronic 
bronchitis may occur due to exposure to airborne irritants, or as a result of infection by 
bacteria or viruses. Unfortunately, there is no reliable method of distinguishing 
between exacerbations caused by bacteria and those caused by other agents. The 
criteria that are used for selecting AECB patients for entry into clinical trials of 
antibacterial drugs are not consistent, and the proportion of bacteriologically-positive 
patients shows considerable variation.
Anthonisen and co-workers {2] demonstrated a 20% difference in success rates 
between antibiotic and placebo-treated patients when they had increased dyspnoea, 
sputum volume and sputum purulence (Type I exacerbation). Exacerbations with 
fewer symptoms showed less difference between antibiotic and placebo, possibly 
indicating that these were not bacterial exacerbations. The characteristics of increased 
cough and/or dyspnoea and increased sputum volume and purulence have been 
demonstrated to be associated with bacterial infection [3,4]; nevertheless, the majority 
of studies produce a disappointing percentage of bacteriologically-proven infections, 
sometimes below 20% [5, 6, 7]. Given the significant variation in the percentage of 
patients from whom a bacterial pathogen is isolated in clinical trials, and yet the 
standard definitions of chronic bronchitis, and to a lesser extent the definition of an 
acute exacerbation, it seems strange that such a wide variation should exist. A  
systematic review of randomised, controlled, clinical trials of antibacterial agents 
(antibiotics) in the treatment of patients with an acute exacerbation of chronic 
bronchitis will be undertaken in order to attempt to understand the reasons why such 
variations in the proportions of bacteriologically-proven infections should exist, and 
potentially to propose some entry criteria to improve the proportion of subjects from 
whom a pathogen may be isolated.
2. OBJECTIVE
To examine the differences in the rates of bacteriologically-positive sputum samples 
(i.e. sputum samples at study entry from which a recognised pathogen was isolated) in 
clinical trials of antibacterial drugs in patients with acute exacerbation of chronic 
bronchitis, and to investigate whether there is any association between the percentage 
of bacteriologically-positive subjects and the following factors:
-  definition of chronic bronchitis
-  definition of an acute exacerbation
-  microbiological screening of the sputum sample for white blood cells and 
squamous epithelial cells, +/- bacterial cells seen on Gram stain (this can either 
be done as an entry criterion, or as a criterion for culture of the sputum or for 
the patient/pathogen to be eligible for the microbiologically-evaluable 
population)
-  species of bacteria that were recognised as pathogens
-  date of the study
Following analysis of the data, other associations or factors may be investigated and 
presented. These will be presented as non-planned analyses.
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3. SELECTION OF PAPERS
3.1 Databases to be Used
The databases that will be used for this study will be:
a) Ovid Medline
b) Cochrane Library
3.2 Search Terms Used 
Medline
A) Disease definition 
o bronchitis,
o lung diseases, obstructive, 
o bronchitis, chronic 
o pulmonary disease, chronic obstructive 
o pulmonary emphysema 
o acute exacerbation of chronic bronchitis
B) Antibiotic therapy definition
o anti-infective agents (administration & dosage, therapeutic use)
A) and B)
Limit to: Human, Adult, English language, Randomised controlled clinical trial.
Cochrane Library
o Acute exacerbation chronic bronchitis
3.3 Entry Criteria for Papers 
inclusion criteria
Papers that will be eligible for this systematic review will meet the following criteria:
•  Clinical trials of one or more antibacterial agent in the treatment of patients with 
an acute exacerbation of chronic bronchitis.
•  Randomised, controlled, clinical trials.
•  Published in English.
Exclusion criteria
The following types of papers will be excluded from the analysis:
•  Letters.
•  Clinical trials that did not perform or report any bacteriology.
•  Papers that did not give sufficient detail of the study design and or the 
bacteriology.
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•  Papers reporting interim data.
•  Clinical trials that only examined one pathogen in AECB.
•  Papers that report on a subset of a larger study (in such cases efforts will be
made to identify the publication of the full study).
•  Clinical trials that enrolled less than 100 patients.
4. INFORMATION TO BE COLLECTED
4.1 Overview of Data Collection
Each suitable paper (or potentially suitable paper) will be obtained either from my own 
collection of papers and journals; from online access; from the library at the Royal 
Society of Medicine; or by ordering the paper from the British Library. Each paper will 
be read and the data from each suitable paper will be collected on individual data 
collection forms (see Appendix I). At the end of data collection, the data from these 
forms will be transferred to an Excel spreadsheet for analysis.
4.2 Data to be Extracted from the Papers
Each paper identified will be given a unique reference number and the following data 
will be collected from each eligible paper
>  Reference number.
>  1st Author.
>  Journal.
>  Year; volume; and start page of paper.
>  Study drug.
>  Comparators).
>  Whether the standard definition of chronic bronchitis was applied in the study 
(the daily production of sputum production fora  minimum of 3 consecutive 
months of the year over at least 2 successive years).
>  Minimum and maximum age of subjects.
>  The signs and symptoms of an acute exacerbation that are required for entry.
>  Whether there is any screening of the sputum prior to subject enrolment.
>  Whether there are any requirements that have to be met on the quality of the 
sputum e.g. WBCs; SECs.
>  Whether there was any statistical justification for the sample size.
If so, whether the a) enrolment target, b) evaluable subject target was reached.
>  The number of subjects that were enrolled 
Number of subjects in the ITT population
Number of subjects in the clinically evaluable (CE) population.
>  Number of pathogens in the ITT population
Number of bacteriologically-positive subjects in the ITT population 
Proportion of bacteriologically-positive subjects in the ITT population.
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>  Number of pathogens in the CE population
Number of bacteriologically-positive subjects in the CE population 
Proportion of bacteriologically-positive subjects in the CE population.
>  Clinical success rates in the ITT population 
Clinical success rates in the CE population.
>  The organisms that are recorded as pathogens
Whether organisms that are resistant to the study drugs are excluded.
There will also be the opportunity to comment on any unusual aspects of the design in 
each study.
5. DATA MANAGEMENT, ANALYSIS AND REPORTING
5.1 Database
An Excel spreadsheet will be created to reflect the data collection form so that the 
information collected on the data collection forms can easily be transferred to the Excel 
spreadsheet.
5.2 Analysis of Data
The differences in the rates of bacteriologically-positive sputum samples (i.e. sputum 
samples at study entry from which a recognised pathogen was isolated) in clinical trials 
of antibacterial drugs in patients with acute exacerbation of chronic bronchitis will be 
examined in both the ITT and CE populations and reported as a median and range.
Any association between the percentage of bacteriologically-positive subjects and the 
following factors will be analysed and reported:
-  definition of chronic bronchitis (ATS definition or alternative)
-  definition of an acute exacerbation (Anthonisen Type I and Type II 
exacerbations or alternative)
-  presence or absence of microbiological screening of the sputum sample for 
white blood cells and squamous epithelial cells, +/- bacterial cells seen on 
Gram stain done as an entry criterion, or as a criterion for culture of the sputum 
or for the patient/pathogen to be eligible for the microbiologically-evaluable 
population.
-  the species of bacteria that were recognised as pathogens
-  date of the study (based on the year that the paper was published).
Following completion of the above analyses, other associations or factors may be 
investigated and presented. These will be presented as non-planned analyses.
5.3 Systematic Review Report
Once the analysis has been completed, a  systematic review report will be prepared, 
which will form part of the final thesis. It is anticipated that the results from this review 
will determine the direction of the subsequent stages of this research project.
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APPENDIX I
Study Details
R e fN o .:D -n n n 1st Author:..................................................
Journal:.......................................... Year/Vol/pg:..............................................
Study drug:......................................... Comparators):..........................................
Population & Entry Criteria
Population: Std AECB? Yes PJ No P] Age range: from f i n
if No, specify:..................................................................  to PJP1 OR no upper limit PJ
Symptoms reqd for entry
Purul sputum: req.PJ opt.PJ; Dyspnoea: req.PJ opt.PI: t  Sputum vol: req.PJ opt.PJ;
Cough: req.n opt.P]; Wheezing/rales: req.f~l opt.PJ; Fever: req.PJ opt.n: FEVi: req.l~~l opt.PI 
Any 1 of optional P] Any 2 of optional PJ Any 3 of optional PJ Not specified P] Req. only n  
Anything different to above: ........................................................................................................
Sputum criteria for study entry Yes □  No □  N/K □
If Yes, WBCs>25: PJ SECs<10: PJ predominant cell types on Gram stain: PI
Sputum criteria for culture/to be included BacL Population Yes □  No □  N/K □
If Yes, WBCs>25: Pj SECs<10: PJ predominant cell types on Gram stain: f l
Study Numbers
Total patients entered: | II ||~ l| 1 Statjustif of No.? Yes 11 NopJ N/K 1 1
Recruit, target met? Yes PJ No PI N/K P] Clin eval. target met? Yes 1 1 No 1 1 N/K PJ
No. in ITT: □ □ □ No. in PP: □ □ □
Bacteriological population
ITT - No. of paths: □ □ □  ITT - No. of Bact+ pats: □ □ □  ITT - % of Bact+ pats:
PP - No. of paths: P1PO PP - No. of Bact+ pats: P O D  PP - % of Bact+ pats:
ITT - Clinical Success (study drug vs comparator): PJPJ.P]% vs PJP].P]% vs | jPJ-CZJ%
PP - Clinical Success (study drug vs comparator): PIPj.PI% vs P3P].Pj% vsPJPj.P3%
Path: SPN PI HIN □  MCA □  HPA □  SAU □  PAE P] E’bact □  others □  spp N/K P] R-orgs excl. □
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APPENDIX 9.3 
Clinical Study: Protocol and Amendment
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STUDY PROTOCOL
MSc/CB/98/01
A local multicentre investigation into the best indicator o f bacterial 
infection in patients with acute exacerbation of chronic bronchitis.
Investigator: Multicentre GP Study, Edinburgh
Principal Investigator Dr I. McKay
Rose Garden Medical Centre 
4 Mill Lane, Leith 
Edinburgh. EH6 6TL
Laboratory : Department of Microbiology 
Western General Hospital 
Edinburgh 
EH 42XU
MSc Project of: Carol Burley (Project Leader) 
d o  HPRU, University of Surrey 
Milford Hospital 
Godalming 
Surrey. GU7 1UT
Tel: 01895 837622
Supervisor: Dr R.G. Masterton
Department of Microbiology 
Western General Hospital 
Edinburgh EH4 2XU
Tel: 0131 537 1925
Date: 05 February 1999
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LIST OF INVESTIGATORS
Only Lothian practices will be taking part in this study and the specific practices are 
listed below:
Dr I. McKay (Principal Investigator)
Rose Garden Medical Centre 
4 Mill Lane,
Leith
Edinburgh. EH6 6TL
Dr D.G. Maxwell 
Leith Walk Surgery 
60 Leith Walk 
Edinburgh. EH6 5HB
Dr N. Hewitt
The Long House Surgery 
73, East Trinity Road 
Edinburgh. EH5 3EL
Dr J. Shaw 
The Surgery 
8a Bridge Street 
Musselburgh 
Midlothian. EH21 6BL
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1. INTRODUCTION AND STUDY RATIONALE
Chronic bronchitis was defined by the American Thoracic Society in 1962 as ‘the daily 
production of sputum for at least three consecutive months over two consecutive 
years,(1) and almost 40 years later, this description remains the best definition that we 
have of this disease. Clinical trials of antibacterial drugs in patients with acute 
exacerbations of chronic bronchitis (AECB), aim to select patients who have an acute 
bacterial exacerbation. Exacerbations of chronic bronchitis may occur due to a 
number of factors that include exposure to airborne irritants, or as a result of infection 
by bacteria, or viruses. There is no reliable method of distinguishing between 
exacerbations caused by bacteria and those caused by other agents. The criteria that 
are used for selecting AECB patients for entry into clinical trials of antibacterial drugs 
are not consistent, and the proportion of bacteriologicaily positive patients shows 
considerable variation. The proportion of patients in studies of AECB, who have a 
bacterial pathogen isolated from a sputum sample can vary between 27% (2) and 
73% (3). Although a Gram stain of the sputum may be helpful if it shows abundant 
neutrophils and a predominant morphological type of organism, few clinical trials use 
this procedure as part of the entry criteria.
Anthonisen and co-workers(4) demonstrated a 20%  difference in success rates 
between antibiotic and placebo-treated patients when they had increased dyspnoea, 
sputum volume and sputum purulence (Type I exacerbation). Exacerbations with 
fewer symptoms showed less difference between antibiotic and placebo, possibly 
indicating that these were not bacterial exacerbations. It is unfortunate that sputum 
microbiology was not performed in this study as this could have added weight to the 
argument for the use of an antibiotic. It was concluded by Staley et a f5) however, that 
in view of these results future studies with an active control group should be designed 
to include only patients in whom exacerbations are likely to have a bacterial cause.
The characteristics of increased cough and/or dyspnoea and increased sputum 
volume and purulence have been demonstrated to be associated with bacterial 
infection(6,7), but still the majority of studies produce a disappointing percentage of 
bacteriologicaily proven infections, approx. 42% (8) 39%<9)and 48% <10).
The correlation of potential pathogens grown from sputum samples and paired 
transtracheal aspirates has been shown to be 94% in sputum samples with <10  
squamous epithelial cells and >25 white blood cells per low power (x10Q) field(11).
Gram staining has been reported to confirm the presence of bacteria characterized by 
their morphology. Using an oil immersion field (x1000) >8 pneumococcus-like, >12 
haemophilus-like, or >18 moraxella-like organisms are likely to indicate acute bacterial 
exacerbation; stable patients have few bacteria per high power field(12). Medici et a /(13) 
found that in a comparison of Gram stain and culture, microscopic examination of the 
Gram stain was found to be superior to culture, with around 50% of organisms 
microscopically identified as pneumococci failing to grow.
The issue of delay in processing sputum samples has been investigated by Gould et al 
{14), although they stored sputum samples for 48 hours at 4°C. They found only a 5 -  
25% discrepancy between early and late testing. However, the three different 
laboratories taking part accounted for much of this difference. It would appear from 
these results that methodology rather than storage time was responsible for the 
variation in viability of the organisms.
This study aims to examine the usefulness of the categories of: Anthonisen type II 
symptoms, Anthonisen type I symptoms, >25 neutrophils/<1G epithelial cells per low 
power field and a Gram stain of the sputum as indicators of bacterial infection. The 
study will also examine the implications of a 24 hour delay in getting a sputum sample
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Ito the laboratory, as occurs when a central laboratory is used for culture and testing of 
the samples. Patients often report that they cough up the most purulent sputum soon 
after rising in the morning. The study will also look at the isolation rates of potential 
pathogens in sputum samples produced soon after rising, with those produced later in 
the day.
2. OBJECTIVES
2.1 Primary objective
•  To identify the best indicator of bacterial infection, in patients with acute 
exacerbation of chronic bronchitis. The indicators that will be studied will be:
1) Anthonisen type II clinical signs and symptoms (at least 2 out of the following 
signs/symptoms: increased sputum purulence; increased sputum volume; 
increased dyspnoea)
2) Anthonisen type I clinical signs and symptoms (all 3 of the above signs/symptoms)
3) The combination of >25 neutrophils and <10 epithelial cells per x100 field
4) The presence of a morphological type of organism in a Gram stain of greater than 
1 cell per oil immersion field.
2.2 Secondary objectives
f) To compare the pathogens isolated from the sputum samples within 6 hours (same 
day) and 24 hours (next day), and assess the implications of this to clinical trials 
using a central laboratory.
g) To compare the proportion of bacteriologicaily positive sputum samples collected 
at 9:00am or earlier, with those collected later in the day.
h) To examine the link between isolation of a bacterial species and the time since the 
previous exacerbation.
3. STUDY DESIGN
This is a local, multicentre, non-drug study of chronic bronchitis patients presenting 
with signs and symptoms of an acute exacerbation to 3 -6  GPs in the Edinburgh, 
Lothian area. The signs/symptoms of infection, the neutrophils/epithelial cells in the 
sputum and the Gram stain results will be compared with the results of the sputum 
culture in order to identify the best indicator of bacterial infection.
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4. STUDY DURATION AND DATES
The study is planned to commence in February 1999 and finish by December 1999.
The start and finish dates are dependent upon local research ethics committee 
approval and the rate of patient recruitment, and may therefore vary from those given 
above. The study will finish when the 120 patients have been recruited.
5. SELECTION OF SUBJECTS
5.1 Num ber o f subjects
It is estimated that 120 patients will be required to identify the best indicator of 
bacterial infection in patients with acute exacerbation of chronic bronchitis (see section
7.1 for details of the sample size justification). A  minimum of 12 and a maximum of 48 
patients will be recruited by each of the 3 to 6 investigators taking part in the project.
5.2 Entry criteria
As this is a study that involves no study treatment, no exclusion criteria based on
safety factors are applicable. Patients may not enter the study more than once.
Inclusion criteria
>  Adult patients with evidence of chronic bronchitis as defined by: chronic cough and 
sputum production on most days over a period of 3 months for at least 2 
consecutive years.
>  Patients with a t least two of the following symptoms: increased sputum purulence; 
increased sputum volume; increased dyspnoea.
>  Patients who are able to produce a sputum sample at the visit (alternatively, the 
patient may take a sputum pot away and return a sample the following morning, 
provided that no antibiotic treatment has been started).
>  Patients who have not yet received an antibiotic for this exacerbation.
>  Patients who have consented to the study.
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6. STUDY PROCEDURES
6.1 Overview of data collection
Data for this study will be collected on individual case report forms (CRFs) provided to 
each investigator and to the laboratory. A CRF will be completed for each eligible 
patient who consents to take part in the study. Any patient who fails to produce a 
sputum sample before antibiotic treatment is started will not be eligible for the project, 
and will be replaced.
Data for this study will come from two sources. The investigator will complete the first 
section of the CRF (clinical data) at the time of the patient visit. The laboratory will 
complete section two of the CRF (laboratory results). A  copy of the laboratory results 
with routine antibiotic susceptibility results, where an organism is isolated, will be sent 
to the investigators by post. The laboratory request forms will be identified as sputum 
samples for this research project by means of an adhesive label.
6.2 Clinical data
The following data will be collected by the investigator in the CRF provided for each 
patient:
>  date of visit
>  entry criteria
>  confirmation of patient consent
>  assignment of unique patient number
>  basic patient demography
>  date of last exacerbation
>  time and date of sputum sample
>  rating of symptoms of dyspnoea, sputum volume and sputum purulence:
a) prior to this infection (pre-infection)
b) currently
6.3 Laboratory data
All sputum samples will be transferred to the Department of Clinical Microbiology at the 
Western General Hospital, Edinburgh and processing commenced within 6 hours.
This will be achieved by the routine collection service.
On arrival at the Department of Clinical Microbiology, samples will be logged and any 
queries about the patient number resolved. The sample will be split into two aliquots 
of equal purulence, using sterile forceps.
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Aliquot 1 will have the following tests/examinations performed:
7. Assessment of purulence of the sample by appearance:
Clear, non-viscous non-sputum sample
Grey/white, viscous mucoid
Up to 50% yellow- 
green
mucopurulent
>50% yellow-green purulent
8. Low power microscopy of cells (total magnification x100):
epithelial cells: <10 per field /  >10 per field 
neutrophils: >25 per field /  <25 per field
9. Gram stain and quantitative assessment of bacterial cell types:
1 per oil immersion field +
2-10 per oil immersion 
field
++
>10 per oil immersion 
field
+++
10. Culture of purulent section of sputum for identification of pathogen with a semi- 
quantitative interpretation using a dilution technique (see Appendix V )
CFU/m L Interpretation
0 0
9 1 _9h o Light growth
105- 1 0 “ Moderate growth
>106 Heavy growth
Aliquot 2 will be left at room temperature for 24 hours to simulate transport of a sputum 
sample to a central laboratory by overnight courier. After 24 hours a purulent section 
of the sputum will be cultured as point 4. above.
All results will be noted in the laboratory CRF.
7. DATA HANDLING AND STATISTICAL PROCEDURES
7.1 Sample size justification
All patients are required to have two out of the three major symptoms of acute 
exacerbation of chronic bronchitis to enter the study, however, some patients will only 
have two symptoms, whereas the remainder of patients will have all three symptoms. 
Assuming 50% of patients will have two symptoms only, with the remaining 50%  
having three symptoms, and a 2-symptom positive culture rate of 35%, a total of 112 
patients will provide 85% power of detecting a 25% increase in the 3-symptom group 
(60% positive culture rate) using a one-sided (5%) chi-squared test. To allow for a 
small number of unevaluable samples, 120 patients will be recruited.
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7.2 Data management
All data collected in the CRFs will be entered onto a computer database.
7.3 Study populations
Data on all patients where a sputum sample was received and cultured by the 
laboratory will be entered into the analysis. This will be the only population for 
analysis. Any patient who successfully produced a sputum sample, but for reasons of 
breakage or non-receipt by the laboratory, no sputum sample results are available, will 
not be entered into the analysis, but will be listed separately in any report or 
publication. Patients who are unable to produce a sputum sample are not eligible to 
enter the study.
7.4 Statistical methods
The positive culture rate between the 2-symptom group and the 3-symptom group will 
be compared with a one-sided chi-squared test at the 5% level.
The sensitivity and specificity will be calculated under all prediction schemes and 
tabulated for comparison.
7.5 Interim analyses
No interim analysis is planned for this study.
8. ETHICAL ASPECTS
8.1 Subject information and informed consent
All patients will be given a patient information sheet (see Appendix in ) that explains 
the study. Patients will be encouraged to discuss any concerns with the doctor. If the 
patient has any doubts about taking part in the study, they will not entered.
All patients who agree to take part in the study will be asked to sign the consent form 
(see Appendix IV ). No patient may enter the study unless they have signed and dated 
the consent form.
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8.2 Confidentiality
All data recorded on the CRF and entered onto the study database will be anonymous. 
Patients will be assigned a unique patient number when they consent to the study, and this 
will be the only identification of the patients' data on the CRF or in the database.
8.3 Approval of the study protocol and amendments
The study protocol and any amendments will be approved by the following people:
Carol Burley project leader
Dr R.G. Masterton project supervisor 
David Shaw statistician
9. MONITORING
All CRFs will be monitored by Carol Burley (CB) to ensure the completeness and accuracy 
of the data and access to the patients' medical notes will be required. All monitoring will 
be performed in a confidential manner and no record of the patients' names will be made. 
All monitoring visits will be made from Buckinghamshire where CB is based. Travel costs 
will be paid for by CB’s employers, who are covering the costs of the MSc course, and will 
cover the laboratory costs.
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Page 159 of 213
Protocol Approval Form
A local multicentre investigation into the best indicator of bacterial infection in
patients with acute exacerbation of chronic bronchitis.
This study protocol was subject to critical review and has been approved by the 
signatories below.
The information it contains is consistent with the moral, ethical and scientific principles 
governing clinical research as set out in the Declaration of Helsinki and Good Clinical 
Practice guidelines.
Project Leader
Carol Burley Date
Project Supervisor
Dr R.G. Masterton Date
Biometrician
David Shaw Date
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Investigator Protocol A greem ent
A local multicentre investigation into the best indicator of bacterial infection in
patients with acute exacerbation of chronic bronchitis.
Declaration of Investigator
I have been adequately informed about the study MSc/CB/98/01. I have read this 
study protocol and agree that it contains all the information required to conduct the 
study. I agree to conduct the study as set out in this protocol.
I agree to provide a signed and dated copy of my curriculum vitae before the study 
starts.
Investigator
Print Name
Signed Date
Co-investigator (if applicable)
Print Name Position
Signed Date
Patient Information Sheet
A local multicentre investigation into the best indicator of bacterial infection in
patients with acute exacerbation of chronic bronchitis.
Your doctor is taking part in a small research study to examine the best way to tell if 
patients, like yourself, have a chest infection caused by bacteria (germs). W e are 
asking whether you would agree to help with this research. Approximately 120 patients 
in the Edinburgh area will take part in this study.
This study involves no experimental (trial) medicine.
If you agree to take part, a few notes will be made about the nature of your chest 
infection and you will be asked to produce a good sputum sample for analysis - that is 
all. You will not have to make any other visits to your GP or have any other samples 
taken as part of this study.
Your doctor will give you regular medication for your chest infection if it is necessary. 
The results of the laboratory tests on your sputum sample will be sent to your GP  
within 5 days. You will be able to find out the results of these tests by contacting your 
surgery after this time.
All records kept for this project will be anonymous. You will be identified by a number 
and only your doctor will know who this number refers to. If the results of this project 
are published, your identity will remain confidential.
Some of the information written down in the study report form will be checked against 
your medical notes, to confirm the completeness and accuracy of the data. This is 
standard practice in such research work and all monitoring will be performed in a 
confidential manner by the organiser of the study.
You are under no obligation to take part in this study. You may choose not to take part 
without having to give a reason. Your treatment and the attitude of your doctor 
towards you will not be affected if you decide not to take part.
Please feel free to ask your doctor any questions you may have about this study.
Thank you for reading this sheet.
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Patient Consent Form
A local multicentre investigation into the best indicator of bacterial infection in
patients with acute exacerbation of chronic bronchitis.
1. I agree to take part in this study into the best indicator of bacterial infection in 
patients with acute exacerbation of chronic bronchitis.
2. I have been given a patient information sheet and have received an explanation of 
the nature and purpose of the project, and what I am expected to do.
3. I confirm that I have informed the doctor of any antibiotics that I have received for 
this chest infection, from other doctors.
4. I understand that I am under no obligation to take part in this project and that my 
treatment and the attitude of the doctor towards me will not be affected if I decide not 
to take part.
5. I understand that I will not be referred to by name in any report or publication 
concerning this project.
6. I understand that the project leader of this study will wish to inspect my medical 
records to verify the information collected. By signing this document I give my 
permission for this review of my records.
NAME OF PATIENT: 
SIGNATURE OF PATIENT: 
DATE OF SIGNATURE:
I confirm that I have explained the nature and purpose of the project to the above 
named patient, and that he/she freely consented to participate.
NAME OF INVESTIGATOR: ...........................................................
SIGNATURE OF INVESTIGATOR:.........................................................
DATE OF SIGNATURE: ...........................................................
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Laboratory Techniques
SPUTUM CULTURE METHOD
The above respiratory secretion specimens must be processed in the Category 3 
laboratory using the safety cabinet and wearing protective gloves and clothing.
METHOD
1. Record the appearance of the specimen.
2. Make a heat-fixed smear and stain with Gram's stain and examine for the presence 
of pus cells, epithelial cells and organisms. Record the results according to the 
protocol definitions.
3. Using a sterile pastette add an equal volume of sputolysin to the aliquot of the 
sputum sample selected for processing.
4. Vortex the sample until it is liquefied.
5. Add 0.1 ml of the liquefied sputum (actually now 1:2) to 9.9ml of saline giving a 
1.200 dilution.
6. Then add 0.1 ml of this preparation to another 9.9ml of saline giving a 1:2000 
dilution.
7. Inoculate each plate as follows with 0.1 ml of the appropriate sputum dilution (mark 
plates accordingly) and spread over the entire surface of the plate using a 
spreader.
BA BA + Optochin disc Chocolate/Bacitraci
neat liquefied 
sputum 
(actually 1:2 
dilution)
1:200 dilution 1:200 dilution 1:200 dilution
1:2000 dilution 1:2000 dilution 1:2000 dilution
8. Incubate the media as follows:-
Media Atmosph Temp Duration
BA co2 37°C 24hrs
BA + Optochin An02 37°C 24hrs
Chocolate/Bacitra C02 37°C 24hrs
If there is no growth after 24hrs, re-incubate for a further 24hrs.
9. Count the number of colonies of pathogenic organisms and calculate the number 
of colony forming units/ml of sputum.
10. Identify suspected pathogens according to the standard laboratory methods.
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PROTOCOL AMENDMENT NO.1
A local m ulticentre investigation into the  b e s t indicator o f bacterial
infection in patien ts with acu te  exacerbation of chronic bronchitis
MSc/CB/98/01
Date of Amendment: 04 August 2001
Date of original protocol: 0 5  February 1999
Dates of previous am endm ents: N /A
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1. JUSTIFICATION FOR AMENDMENT
Primary Justification
The original study was planned to only take place in Edinburgh with Lothian general 
practitioners. Because of the lack of response in several centres, and the need to get 
the120 samples completed by Spring 2002, it has been agreed to extend the study. 
Centres will now include Monklands Hospital, Airdrie, one GP practice in Coatbridge, 
and two GP practices in the area of Glasgow Royal Infirmary.
This means that a number of references to the study taking place only in the 
Edinburgh area will need to be changed.
Secondary Justifications
As a student it will only be possible to monitor a small selection of the patient notes 
and this has been made clearer in the protocol and in the patient information and 
consent form.
The funding for this project has been clarified as being received from Hoechst Marion 
Roussel as the student is no longer employed by this company, however the 
educational grant remains and will be accounted for as part of the dissertation.
The change of address and telephone number of the student and supervisor have 
been detailed.
Confirmation of Scientific and Ethical Content
All the changes to the Final Protocol dated 5th February 1999 are detailed in this 
protocol amendment.
None of these changes will affect the scientific content of the study as the laboratories 
at Monklands Hospital and Glasgow Royal infirmary have agreed to process the 
sputum samples as laid out in the protocol. The changes will not compromise patient 
treatment or confidentiality in any way.
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2. INDIVIDUAL CHANGES
Unless otherwise specified, the page numbers and section numbers given refer to the 
original protocol.
Page 1. Title 
The title:
A local multicentre investigation into the best indicator of bacterial infection in patients 
with acute exacerbation of chronic bronchitis
Will be amended to read:
A multicentre investigation into the best indicator of bacterial infection in patients 
with acute exacerbation of chronic bronchitis
Page 1. Principal Investigator and Laboratory 
The text:
Investigator: Multicentre GP Study, Edinburgh
Will be changed to read:
Investigator. Multicentre Study
And the designations:
Principal Investigator D r I. McKay
Rose Garden Medical Centre 
4 Mill Lane, Leith 
Edinburgh. EH6 6TL
Laboratory: Department o f Microbiology
Western General Hospital
Edinburgh
EH4 2XU
will be deleted and detailed on page 2 under List of Investigators and Laboratories:
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Page 1, Student and Supervisor
The text:
MSc Project of:
Tel:
Supervisor:
Tel:
Carol Burley (Project Leader) 
c/o HPRU, University of Surrey 
Milford Hospital 
Godalming 
Surrey. GU7 1UT
01895 837622
Dr R.G. Masterton 
Department of Microbiology 
Western General Hospital 
Edinburgh EH4 2XU
0131 537 1925
W ill be corrected to read: 
MSc Project of:
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
Tel:
Supervisor: Dr R.G. Masterton
Deputy Medical Director & Director of Clinical Developments 
The Royal Infirmary of Edinburgh 
Lauriston Place 
Edinburgh EH3 9YW
Tel: 0131 536 3014
Page 2, List of Investigators
The sentence:
Only Lothian practices will be taking part in this study and the specific practices are 
listed below:
Dr I. McKay (Principal Investigator)
Rose Garden Medical Centre 
4 Mill Lane,
Leith
Edinburgh. EH6 6TL
DrD.G. Maxwell 
Leith Walk Surgery
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60 Leith Walk 
Edinburgh. EH6 5HB
Dr N. Hewitt
The Long House Surgery 
73, East Trinity Road 
Edinburgh. EH5 3EL
DrJ. Shaw  
The Surgery 
8a Bridge Street 
Musselburgh 
Midlothian. EH21 6BL
will be changed to read:
LIST OF INVESTIGATORS AND LABORATORIES
Practices in Edinburgh, Glasgow and Coatbridge/Airdrie will be taking part in this 
study. The specific practices and hospital laboratories are listed below:
Edinburgh
Investigators: Dr I. McKay
Rose Garden Medical Centre
4  Mill Lane
Leith
Edinburgh. EH6 6TL
Laboratory:
Glasgow
Investigators:
and at:
Laboratory:
Dr N. Hewitt
The Long House Surgery 
73, East Trinity Road 
Edinburgh. EH5 3EL
Dept of Microbiology 
Western General Hospital 
Edinburgh. EH4 2XU
Dr G. McKaig 
Shettleston Health Centre 
420 Old Shettleston Road 
Glasgow. G32 7JZ
Baillieston Health Centre 
20 Muirside Road 
Glasgow. G69 7AD
Dept of Bacteriology 
Glasgow Royal Infirmary 
Glasgow. G4 0SF
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Coatbridge/Airdrie
Investigators: Dr M. Curie
Coatbridge Health Centre 
1 Centre Park Court 
Coatbridge. ML5 3AP
Dr A. Leanord 
Consultant Microbiologist 
Monklands Hospital 
Airdrie. ML6 0JS
Laboratory: Dept of Microbiology
Monklands Hospital 
Airdrie. ML6 0JS
Page 6. Section 3 Study Design 
The sentence:
This is a local, multicentre, non-drug study of chronic bronchitis patients presenting 
with signs and symptoms o f an acute exacerbation to 3-6 GPs in the Edinburgh,
Lothian area.
Will be changed to read:
This is a multicentre, non-drug study of chronic bronchitis patients presenting with 
signs and symptoms of an acute exacerbation to six G P and Hospital centres in 
Scotland.
Page 7, Section 4 Study Duration and Dates 
The sentence:
The study is planned to commence in February 1999 and finish by December 1999. 
Will be changed to read:
The study started in October 1999 and is expected to finish by March 2002.
Page 8. Section 6.3 Laboratory data 
The following sentence in paragraph 1:
All sputum samples will be transferred to the Department of Clinical Microbiology at the 
Western General Hospital, Edinburgh and processing commenced within 6 hours.
Page 170 of213
Will be changed to read:
All sputum samples will be transferred to the local hospital laboratory and processing 
commenced within 6 hours.
The following sentence in paragraph 2:
On arrival at the Department of Clinical Microbiology, samples will be logged and any 
queries about the patient number resolved.
Will be changed to read:
On arrival at the laboratory, samples will be logged and any queries about the patient 
number resolved.
Page 11. Section 8.3 Approval of the study protocol and amendments 
Section 8.3:
The study protocol and any amendments will be approved by the following people:
Carol Burley project leader
D r R.G. Masterton project supervisor 
David Shaw statistician
Will be changed to read:
The study protocol will be approved by the following people:
Caro! Burley project leader
Dr R.G. Masterton project supervisor
David Shaw statistician
Any amendments to the protocol which do not involve the patient numbers or the 
statistical plan will be approved by the project leader and the project supervisor only. 
Further statistical advice may be sought from any qualified statistician working in 
pharmaceutical research.
Page 11. Section 9 Monitoring 
The paragraph:
All CRFs will be monitored by Carol Burley (CB) to ensure the completeness and 
accuracy of the data and access to the patients' medical notes will be required. All 
monitoring will be performed in a confidential manner and no record of the patients' 
names will be made.
All monitoring visits will be made from Buckinghamshire where CB is based. Travel 
costs will be paid for by CB’s employers, who are covering the costs of the MSc 
course, and will cover the laboratory costs.
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/Will be changed to read:
A selection of the CRFs will be monitored by Carol Burley to check the completeness 
and accuracy of the data. Access to the medical notes of the selected patients will be 
required. All monitoring will be performed in a confidential manner and no record of 
the patients' names will be made.
Monitoring visits will be made from Buckinghamshire where CB is based. A  small fee 
will be paid to investigators for their time and to the laboratory to cover their costs. 
These monies will be paid from an educational grant for this project from Hoechst 
Marion Roussel.
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Page 16, Appendix III: Patient Information S heet and  C onsent Form
Patient Information Sheet
A local multicentre investigation into the best indicator of bacterial infection in 
patients with acute exacerbation of chronic bronchitis.
Your doctor is taking part in a small research study to examine the best way to tell if 
patients, like yourself, have a chest infection caused by bacteria (germs). We are 
asking whether you would agree to help with this research. Approximately 120 patients 
in the Edinburgh area will take part in this study.
This study involves no experimental (trial) medicine.
If  you agree to take part, a few notes will be made about the nature of your chest 
in fection and you will be asked to produce a good sputum sample for analysis -  that is 
all. You will not have to make any other visits to your GP or have any other samples 
taken as part of this study.
Your doctor will give you regular medication for your chest infection if it is necessary. 
The results o f the laboratory tests on your sputum sample will be sent to your GP  
within 5 days. You will be able to find out the results o f these tests by contacting your 
surgery after this time.
All records kept for this project will be anonymous. You will be identified by a number 
and only your doctor will know who this number refers to. If  the results o f this project 
are published, your identity will remain confidential.
Some of the information written down in the study report form will be checked against 
your medical notes, to confirm the completeness and accuracy of the data. This is 
standard practice in such research work and all monitoring will be performed in a 
confidential manner by the organiser o f the study.
You are under no obligation to take part in this study. You may choose not to take part 
without having to give a reason. Your treatment and the attitude o f your doctor 
towards you will not be affected if you decide not to take part.
Please feel free to ask your doctor any questions you may have about this study.
Thank you for reading this sheet.
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Patient Consent Form
A local multicentre investigation into the best indicator of bacterial infection in
patients with acute exacerbation of chronic bronchitis.
1. I agree to take part in this study into the best indicator o f bacterial infection in 
patients with acute exacerbation of chronic bronchitis.
2. I have been given a patient infonnation sheet and have received an explanation of 
the nature and purpose of the project, and what I am expected to do.
3. I confirm that I have informed the doctor o f any antibiotics that I have received for 
this chest infection, from other doctors.
4. I understand that I  am under no obligation to take part in this project and that my 
treatment and the attitude of the doctor towards me will not be affected if I decide not 
to take part.
5. I understand that I will not be referred to by name in any report or publication 
concerning this project.
6. I understand that the project leader o f this study will wish to inspect my medical 
records to verify the information collected. By signing this document I give my 
permission for this review of my records.
NAME O F PATIENT: 
SIGNATURE O F PATIENT: 
DATE OF SIGNATURE:
I confirm that I have explained the nature and purpose of the project to the above 
named patient, and that he/she freely consented to participate.
NAME OF INVESTIGATOR: ..............................................................
SIGNATURE OF INVESTIGATOR:............................................................
DATE O F SIGNATURE: ..............................................................
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Will be changed  to read:
( T O  B E  P R I N T E D  O N  H E A D E D  P A P E R )
Patient Information Sheet
A multicentre investigation into the best indicator of bacterial infection in 
patients with acute exacerbation of chronic bronchitis.
Your doctor is taking part in a small research study to examine the best way to tell if 
patients, like yourself, have a chest infection caused by bacteria (germs). The aim of 
this project is to help to improve the design of future antibiotic clinical trials in chest 
infections. W e are asking whether you would agree to help with this research. 
Approximately 120 patients in Glasgow, North Lanarkshire and Edinburgh area will 
take part in this study.
This study involves no experimental (trial) medicine.
If you agree to take part, a few notes will be made about the nature of your chest 
infection and you will be asked to produce a good sputum sample for analysis - that is 
all. You will not have to make any other visits or have any other samples taken as part 
of this study.
Your doctor will give you regular medication for your chest infection if it is necessary. 
If you are attending your GP surgery, the results of the laboratory tests on your sputum 
sample will be sent to your GP within 5 days. You will be able to find out the results of 
these tests by contacting your surgery after this time.
All records kept for this project will be anonymous. You will be identified by a number 
and only your doctor will know who this number refers to. Some of the information 
written down in the study report form may be checked against your medical notes, to 
confirm the completeness and accuracy of the data. This is standard practice in 
research work and all such data checking will be performed in a confidential manner.
This research is being organised and monitored by a post-graduate student and will 
form part of a MSc degree. If the results of this project are published, your identity will 
remain confidential.
You are under no obligation to take part in this study. You may choose not to take part 
without having to give a reason. Your treatment and the attitude of your doctor 
towards you will not be affected if you decide not to take part.
Please feel free to ask your doctor any questions you may have about this study.
Thank you for reading this sheet.
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( T O  B E  P R I N T E D  O N  H E A D E D  P A P E R )
Patient Consent Form
A multicentre investigation into the best indicator of bacterial infection in 
patients with acute exacerbation of chronic bronchitis.
1. I agree to take part in this study into the best indicator of bacterial infection in 
patients with acute exacerbation of chronic bronchitis.
2. I have been given a patient information sheet and have received an explanation of 
the nature and purpose of the project, and what I am expected to do. I have also had 
the opportunity to ask questions.
3. I confirm that I have informed the doctor of any antibiotics that I have received for 
this chest infection, from other doctors.
4. I understand that I am under no obligation to take part in this project and that my 
treatment and the attitude of the doctor towards me will not be affected if I decide not 
to take part.
5. I understand that I will not be referred to by name in any report or publication 
concerning this project.
6. I understand that the organiser of this study may wish to inspect my medical 
records to verify the information collected. By signing this document I give my 
permission for this review of my records.
NAME OF PATIENT: 
SIGNATURE OF PATIENT: 
DATE OF SIGNATURE:
I confirm that I have explained the nature and purpose of the project to the above 
named patient, and that he/she freely consented to participate.
NAME OF INVESTIGATOR: ..............................................................
SIGNATURE OF INVESTIGATOR:............................................................
DATE OF SIGNATURE: ..............................................................
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3. SIGNATURES 
I agree to the changes listed above:
Project Leader
Date:____________  Signature: _______________
Carol Burley
Project Supervisor
Date:____________  Signature: ________________
Dr R.G. Masterton
Investigator
Date:____________ Signature:________________
Name (block letters):
APPENDIX 9.4 
Clinical Study: Data Collection Forms
Investigator Case Report Form
MSc/CB/98/01
A local multicentre investigation into the best indicator of bacterial infection 
in patients with acute exacerbation of chronic bronchitis.
MSc Project of:
MATERIAL REDACTED AT 
REQUEST OF UNIVERSITY
University Address:
Dept of Pharmaceutics! Medicine 
HPRU, University of Surrey 
Egerton Road 
Guildford
Surrey. GU2 5XP
Tel:
Fax:
Supervisor: Dr R.G. Masterton 
Medical Director
Ayrshire & Arran Acute Hospitals Trust
Crosshouse Hospital
Kilmarnock
Ayrshire
KA2 QBE
Tel: 01563 577004
Local Laboratory: Dept of Bacteriology 
Southern General Hospital 
Glasgow
Please fax completed forms (excluding this page) to Carol Burley at: 
or post to above home address keeping a copy for your file.
Please remember to complete patient number on each page -  thank you.
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Project: MSc/CB/98/01 
NEW PATIENT ENTRY
Form No.: 01
ENTRY CRITERIA
Date of Visit:
Day Month Year
All Entry Criteria must be answered ‘Yes’ for patient to be eligible
1. Patient has history of chronic bronchitis i Q  No Yes
2. Patient has at least 2 symptoms of an exacerbation 
from: increased sputum purulence
increased sputum volume 
increased dyspnoea
3. Patient is able to produce a sputum sample
4. Patient has NOT taken an antibiotic for 
this episode
5. Patient has consented to the study
Q  No J G  Yes
i Q  No J G  Yes
> □  No Yes
i Q  No 2G  Yes
Patient No:
I confirm that this patient has consented to take part in this study and has signed and 
dated the consent form provided.
Signed Date
Page 1
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MSc/CB/98/01 Patient No
Form No.: 02
PATIENT SUMMARY
1. Patient Initials
2. Date of Birth:
3. Gender:
4. Patient is a:
Day Month Year
□  Male Female
i d  Smoker
2d  Ex-smoker (> 6  mth) 
3d Non-smoker
Day Month Year
5. Date of last chest infection for which an antibiotic 
was given:
6 . Time and date patient produced the sputum sample:
Hrs Mins Day Month Year
/
24 hr clock
Page 2
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MSc/CB/98/01 Patient No: CZI'
Form No.: 03
PATIENT SIGNS / SYMPTOMS
7. Dyspnoea:
8 . Sputum Volume 
in 24 hrs:
9. Sputum 
Purulence:
a) Pre-infection
iQ  none
2O  only on unusual exertion 
3Q  during normal activity 
4O  at rest
1Q  no sputum
2Q  up to 1 tablesp. (<15ml)
U  1-4 tablesp. (15-60ml)
4Q  >4 tablesp. (>60ml)
O  no sputum
2O  grey/white (mucoid)
3G  up to 50% yellow/green 
(mucopurulent)
4Q  >50%  yellow/green (purulent)
b) Currently
O  no change 
2Q  worse
O  no change 
2O  worse
i G  no change 
2G  worse
DECLARATION OF THE INVESTIGATOR
I confirm that, to the best of my knowledge, the information in this case report form is 
complete and accurate.
Signature of Investigator Date
Page 3
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Laboratory Case Report Form
MSc/CB/98/01 
A local multicentre investigation into the best indicator of bacterial infection 
in patients with acute exacerbation of chronic bronchitis.
Patient Initials: 
Patient Date of Birth: 
Patient No.:
Day Month Year
Hrs Mins
Time & Date of Receipt of Sample:
Day Month Year
24 hr clock
MSc Project of:
Tel:
Fax:
Carol Burley 
4, Franklin Court 
Furlong Close 
Bourne End 
Bucks SL8 5AT
01628 851351 
01628 819187
University Address:
Dept of Pharmaceutical Medicine 
HPRU, University of Surrey 
Egerton Road 
Guildford
Sunev. gU2 t>AP
Supervisor: Dr R.G. Masterton
Ayrshire & Arran Acute Hospitals Trust
Tel: 01563 577004
Please fax completed forms to Carol Burley at: 01628 819187 
or post to above home address keeping a copy for your file. 
Please remember to complete patient number on each page -  thank you.
Page 1
Page 183 of213
MSc/CB/98/01 Patient No:
Form No.: 04
SPUTUM SAMPLE RESULTS
1. Appearance of sputum sample: o Q  non-sputum sample
lG mucoid 
2 G  mucopurulent 
3 G  purulent
2. Cells: Epithelial cells 1Q  < 10j--1 £ L l OI ■■"L
Neutrophils l U  > 25 2*J <25
3. Gram  stain -  cell o G  none □ + □ ++ □ +++
types seen: l G  Gram-negative bacilli □ + Q  ++ 0  +++
2Q  Gram-negative cocci □ + □ ++ Q  +++
3Q  Gram-positive cocci □ + □  ++ O  +++
4G  Gram-positive bacilli □ + □ ++ □ +++
Growth
4. Culture — immediate Light Moderate Heavy
Organism(s) isolated: o G  none
1G  H. influenzae □ □ □
2G  H. parainfluenzae □ □ □
3G  M. catarrhalis □ □ □
4 G  S. pneumoniae □ □ □
s G  S. aureus □ □ □
6 G  coliform(s) □ □ □
olease soecifv:
7 G  other □ □ □
Dlease soecifv:
Page 2
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MSc/CB/98/01 Patient No:
Form No.: 05
SPUTUM CULTURE RESULTS @ 24 hr.
5. Culture -  @ 24 hr. Light
Growth
Moderate Heavy
Organism(s) isolated:
o Q  none 
iO  H. influenzae □ a □
2G H. parainfluenzae □ a □
3G M. catarrhalis □ □ □
4G S. pneumoniae □ a a
5Q S. aureus □ □ □
e Q  coliform(s) □ □ a
Dlease sDecifv: 
7Q  other □ □ □
Dlease SDecifv:
DECLARATION OF THE LABORATORY
I confirm that, to the best of my knowledge, the information in this case  report form is 
complete and accurate.
Name (Please print) Position
Signature Date
Page 3
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/APPENDIX 9.5 
Clinical Study: Publication in Journal of Infection, Sep. 2007
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